Nanosuspensions and amorphous solid dispersions of hydrophobing agents and methods of use thereof
Deposition of hydrophobic agent nanosuspensions or amorphous solid dispersions through high-frequency droplet dispensers solves the application challenges of traditional dosage forms in low-dose and personalized medicine, improves the bioavailability of drugs and the consistency of dosage forms, and reduces the use of drugs. Development complexity and cost.
Patent Information
- Application Number
- CN202380028030.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2023-03-17
- Publication Date
- 2024-11-08
AI Technical Summary
The application of traditional solid dosage forms in low-dose and personalized medicine has challenges in consistency and uniformity, the crystalline forms of insoluble drugs affect bioavailability and stability, and the development of amorphous solid dispersions is costly and complex.
Deposit droplets of nanosuspension or amorphous solid dispersion containing hydrophobic agents onto the substrate using a high-frequency droplet dispenser, controlling the viscosity and deposition structures through thermal or piezoelectric processes, and inhibiting hydrophobicity using polymers and viscosity regulators The agent crystallizes, forming a predictable form of treatment.
It realizes precise preparation of dosage forms in personalized medical care, improves drug absorption and bioavailability, reduces development costs and complexity, and ensures consistency and uniformity of dosage forms.
Smart Images

Figure CN118922177A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Patent Application Nos. 63 / 321,516 and 63 / 321,519, filed on March 18, 2022, which are incorporated herein by reference in their entirety. Technical Field
[0003] In certain aspects, the present disclosure relates to a nanosuspension comprising a plurality of nanoparticles suspended in an aqueous carrier, the plurality of nanoparticles comprising a hydrophobic agent, the nanosuspension having a desired viscosity. In other aspects, the present disclosure relates to an amorphous solid dispersion (ASD) comprising a pharmaceutical agent that is susceptible to crystallization. Also provided are related methods (such as methods for identifying ASD-forming solutions, and methods for preparation, e.g., methods for preparing dosage forms comprising a hydrophobic agent and / or a pharmaceutical agent that is susceptible to crystallization), compositions (e.g., used in preparation methods and compositions produced therefrom), devices, and systems. Background Art
[0004] Traditionally, the development of drugs has generally taken a "one size fits all" approach in terms of dosage and image, most commonly with a standard tablet size as an example. This requires the development of suitable batch manufacturing methods and supply chains with appropriate quality control to deliver drugs to target patient populations at specific doses. However, the increasing understanding of disease pathology and its relationship to genetics and the increasing amount of statistical data available for each patient have led to significant interest in personalized medicine approaches. In addition, the rise of highly effective drug molecules has emphasized the precise control of small amounts of drug delivery. In addition, the pharmaceutical industry is challenged by an increasing number of poorly soluble drug candidates. This can lead to significant problems in obtaining adequate absorption and bioavailability, the risk of exposure variation, and difficulty maintaining a safe therapeutic index. Current manufacturing methods for solid dosage forms (such as tablets) face significant challenges in consistency and content uniformity at low doses, which is particularly important for highly effective drugs and for pediatric indications. Therefore, the ability to manufacture precise dosage forms as needed (which can be tailored to individual patients while handling small amounts of drugs) is of significant value.
[0005] The crystalline form of a medicament (such as a hydrophobic therapeutic drug) may unexpectedly affect properties, such as bioavailability, dissolution rate, solubility and stability. This may cause significant problems in the following aspects: obtaining sufficient absorption and bioavailability, the risk of exposure variation and being difficult to maintain a safe therapeutic index. The discovery and use of the non-crystalline solid form of such medicaments (for example, as an amorphous solid dispersion) can achieve more predictable and effective therapeutic uses. Amorphous solid dispersions are a combination of a medicament and a polymer ratio that are easy to form a crystalline form, wherein the medicament is maintained as a non-crystalline form. Amorphous solid dispersions provide medicaments in the form of high solubility and continuous supersaturation. The identification and development of amorphous solid dispersions are challenging, costly and require a large amount of raw materials. In the context of drug development, such demand has hindered the progress and identification of available pharmaceutical dosage forms, especially when only a small amount of drug compounds are available. Summary of the invention
[0006] The present disclosure relates to a method for preparing a dosage form comprising a hydrophobic agent. The method includes using a high-frequency droplet dispenser to deposit multiple droplets of a preparation comprising a hydrophobic agent onto a substrate to form a dosage form. In some aspects, the viscosity of the preparation is less than 3 cP.
[0007] In some embodiments, the high-frequency droplet dispenser uses a thermal process to deposit the plurality of droplets. In some embodiments, the high-frequency droplet dispenser uses a piezoelectric process to deposit the plurality of droplets. In some embodiments, the high-frequency droplet dispenser includes about 100 to about 1000 individual nozzles. In some embodiments, each nozzle includes a hole having a diameter of about 20 μm to about 120 μm. In some embodiments, the high-frequency droplet dispenser is a high-frequency sub-nanoliter droplet dispenser. In some embodiments, the high-frequency sub-nanoliter droplet dispenser dispenses droplets at more than 3 kHz, as measured per nozzle. In some embodiments, the high-frequency droplet dispenser dispenses droplets having a volume of 1 nanoliter or less.
[0008] In some embodiments, the average volume of each dispensed droplet of the plurality of droplets of formulation is from about 1 picoliter to about 50 picoliters.
[0009] In some embodiments, the plurality of formulation droplets are deposited onto the substrate according to an average number of droplets per square inch. In some embodiments, the average number of droplets deposited per square inch of substrate is from about 1 droplet per square inch to about 500 droplets per square inch.
[0010] In some embodiments, the plurality of droplets of formulation deposited on the substrate have an average diameter of about 5 μm to about 100 μm.
[0011] In some embodiments, the plurality of droplets of the formulation deposited on the substrate forms a continuous layer.
[0012] In some embodiments, the viscosity of the formulation is 0.5 cP to 3 cP. In some embodiments, the viscosity of the formulation is less than 2 cP and greater than 1 cP. In some embodiments, the viscosity of the formulation is between 1.2 cP and 1.8 cP.
[0013] In certain embodiments, the preparation further comprises a viscosity modifier. In certain embodiments, the viscosity modifier is a viscosity enhancer. In certain embodiments, the viscosity enhancer is selected from the group consisting of ethylene glycol, polyethylene glycol, glycerol and propylene glycerol. In certain embodiments, the viscosity modifier is a viscosity reducer. In certain embodiments, the viscosity reducer is a salt or an amino acid, or a combination thereof. In certain embodiments, the amount of the viscosity modifier in the mixture is based on the desired viscosity of the mixture. In certain embodiments, the viscosity enhancer is present in the preparation with a concentration of about 1% to about 40% v / v of the preparation. In certain embodiments, it further comprises adding the viscosity enhancer to the preparation to reach the viscosity of the preparation between about 1 cP and about 2 cP.
[0014] In some embodiments, the formulation is a suspension comprising: an aqueous carrier; and a plurality of nanoparticles suspended in the aqueous carrier, wherein the nanoparticles comprise a hydrophobic agent. In some embodiments, the suspension is a nanosuspension. In some embodiments, the suspension is a colloidal suspension.
[0015] In some embodiments, the aqueous carrier includes water and an organic solvent.
[0016] In some embodiments, the formulation has a ratio of viscosity enhancing agent to aqueous carrier of about 1:1000 to about 1:2 by volume.
[0017] In some embodiments, the hydrophobic agent is insoluble in an aqueous carrier. In some embodiments, the hydrophobic agent has a solubility in water of less than 1 mg / mL.
[0018] In some embodiments, the concentration of the hydrophobic agent in the suspension is from about 5 mg / mL to about 1,000 mg / mL.
[0019] In some embodiments, the suspension further comprises a stabilizing component. In some embodiments, the ratio of the stabilizing component of the suspension to the aqueous carrier is about 1:500 to about 1:10 by weight. In some embodiments, the stabilizing component comprises PVP and / or SDS.
[0020] In some embodiments, the average diameter of the plurality of nanoparticles is less than about 500 nm. In some embodiments, the plurality of nanoparticles has a D50 of about 100 nm to about 400 nm. In some embodiments, the plurality of nanoparticles has a D90 of about 250 μm to about 50 nm.
[0021] In some embodiments, at least a portion of the plurality of nanoparticles are deposited within the substrate. In some embodiments, at least a portion of the plurality of nanoparticles are deposited on top of the substrate.
[0022] In some embodiments, the formulation is an amorphous solid dispersion (ASD)-forming solution comprising: a hydrophobic agent; an organic carrier; and a polymer, wherein the ratio of polymer to hydrophobic agent inhibits crystallization of the hydrophobic agent on a substrate in a dry state. In some embodiments, the ASD-forming solution is a colloid.
[0023] In some embodiments, the organic vehicle of the ASD forming solution comprises any one or more components selected from the group consisting of acetone, dimethylformamide, ethanol, methanol, pentane, hexane, heptane, ethyl acetate, isopropanol, ethylene glycol, and dimethyl sulfoxide.
[0024] In some embodiments, the ASD-forming solution comprises at least 30% by volume of an organic vehicle.
[0025] In some embodiments, the ratio of viscosity modifier to organic vehicle is from 1:100 to 40:100 by volume.
[0026] In some embodiments, the polymer of the ASD forming solution is suitable for forming an amorphous solid dispersion (ASD) after being deposited by a droplet dispenser. In some embodiments, the polymer is selected based on one or more characteristics of the hydrophobic agent. In some embodiments, the polymer is selected from the group consisting of: cellulose derivatives, poly (vinyl pyrrolidone) (PVP), poly (vinyl pyrrolidone-co-vinyl acetate) (copolyvidone or PVPVA), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose or HPMC), and acetate HPMC succinate (acetate hydroxypropyl methylcellulose succinate or HPMC-AS), and acrylic resin (eudragit), or any combination thereof. In some embodiments, the polymer is a grade selected from the group consisting of: LF, MF, HF, LMP, MMP, HMP, LG, MG and HG. In some embodiments, the polymer is HPMC-AS-LF. In some embodiments, the ratio of the concentration of the polymer to the concentration of the hydrophobic agent is 1:20 to 20:1. In some embodiments, the ratio of the concentration of the polymer to the concentration of the hydrophobic agent is 1:2 to 2:1.
[0027] In some embodiments, the ASD forming solution further comprises a surfactant. In some embodiments, the surfactant is selected from Tween 80, Vit-E, TPGS or SDS, or any combination thereof. In some embodiments, the ASD forming solution comprises 10% to 20% surfactant by volume. In some embodiments, the ASD forming solution comprises a ratio of 1:100 to 5:1 surfactant to hydrophobic agent.
[0028] In some embodiments, less than 5% of the hydrophobic agent is crystallized in a dry state after being deposited by a droplet dispenser. In some embodiments, the hydrophobic agent does not substantially crystallize in a dry state.
[0029] In some embodiments, the ASD forming solution is supersaturated with the hydrophobic agent. In some embodiments, the concentration of the hydrophobic agent in the mixture is from about 5 mg / mL to about 1,000 mg / mL.
[0030] In some embodiments, at least a portion of the hydrophobic agent is within the substrate after deposition by the droplet dispenser. In some embodiments, at least a portion of the hydrophobic agent is on top of the substrate after deposition by the droplet dispenser.
[0031] In some embodiments, the hydrophobic agent is a therapeutic agent. In some embodiments, the therapeutic agent is a small molecule drug. In some embodiments, the therapeutic agent is a biomolecule. In some embodiments, the therapeutic agent is a Biopharmaceutics Classification System (BCS) Class II or Class IV agent. In some embodiments, the therapeutic agent has a narrow therapeutic index. In some embodiments, the therapeutic agent is a high potency drug. In some embodiments, the hydrophobic agent is an excipient or adjuvant.
[0032] In some embodiments, the hydrophobic agent is a diagnostic compound.
[0033] In some embodiments, the hydrophobic agent is a reagent.
[0034] In some embodiments, the hydrophobic agent has a solubility in water of less than 0.1 mg / mL.
[0035] In some embodiments, the amount of hydrophobic agent is less than 0.1 mg.
[0036] In some embodiments, the substrate is a pharmaceutically acceptable polymer.
[0037] In some embodiments, the substrate is selected from the group consisting of one or more of the following: chitosan, ethylenediaminetetraacetic acid, polyvinyl pyrrolidone, polyvinyl alcohol, alginate, agar, carrageenan, guar gum, xanthan gum, polycarbophil, and polyacrylic acid derivatives. In some embodiments, the substrate is a film substrate.
[0038] In some embodiments, the dosage form is an oral dosage form. In some embodiments, the dosage form is a buccal dosage form. In some embodiments, the dosage form is a transdermal dosage form. In some embodiments, the dosage form is sterile.
[0039] In other aspects, provided herein is a suspension comprising: an aqueous carrier; a plurality of nanoparticles comprising a hydrophobic agent suspended in the aqueous carrier, wherein the viscosity of the suspension is less than 3 cP.
[0040] In some embodiments, the viscosity of the suspension is less than 2 cP and greater than 1 cP. In some embodiments, the viscosity of the suspension is between 1.2 cP and 1.8 cP.
[0041] In some embodiments, the suspension further comprises a viscosity modifier. In some embodiments, the viscosity modifier is a viscosity enhancer. In some embodiments, the viscosity enhancer is selected from the group consisting of ethylene glycol, polyethylene glycol, glycerol, and propylene glycol.
[0042] In some embodiments, the viscosity enhancer is present in the suspension at a concentration of about 1% to about 40% v / v of the suspension. In some embodiments, the ratio of the viscosity enhancer to the aqueous carrier of the suspension is about 1:1000 to about 1:2 by volume. In some embodiments, it further comprises adding the viscosity enhancer to the suspension to achieve a viscosity of the suspension between about 1 cP and about 2 cP.
[0043] In some embodiments, the aqueous carrier includes water and an organic solvent.
[0044] In some embodiments, the suspension is a colloidal suspension.
[0045] In some embodiments, the suspension further comprises a stabilizing component. In some embodiments, the ratio of the stabilizing component of the suspension to the aqueous carrier is about 1:500 to about 1:10 by weight. In some embodiments, the stabilizing component comprises PVP and / or SDS.
[0046] In some embodiments, the average diameter of the plurality of nanoparticles is less than about 500 nm. In some embodiments, the plurality of nanoparticles has a D50 of about 100 nm to about 400 nm. In some embodiments, the plurality of nanoparticles has a D90 of about 250 μm to about 50 nm.
[0047] In some embodiments, the hydrophobic agent is insoluble in an aqueous carrier. In some embodiments, the hydrophobic agent has a solubility in water of less than 1 mg / mL.
[0048] In some embodiments, the hydrophobic agent is a therapeutic agent. In some embodiments, the therapeutic agent is a small molecule drug. In some embodiments, the therapeutic agent is a biomolecule. In some embodiments, the hydrophobic agent is a Biopharmaceutics Classification System (BCS) Class II or Class IV agent. In some embodiments, the therapeutic agent has a narrow therapeutic index. In some embodiments, the therapeutic agent is a high potency drug.
[0049] In some embodiments, the hydrophobic agent is an excipient or adjuvant.
[0050] In some embodiments, the concentration of the hydrophobic agent in the suspension is about 5 mg / mL to about 1,000 mg / mL. In some embodiments, the amount of the hydrophobic agent is less than 0.1 mg.
[0051] In other aspects, provided herein is an ASD-forming solution comprising: an organic carrier; a hydrophobic agent; and a polymer crystallization inhibitor, wherein the polymer inhibitor crystallizes in a dry state.
[0052] In some embodiments, the ASD forming solution has a viscosity of 0.5 cP to 3 cP. In some embodiments, the ASD forming solution has a viscosity between 1 cP to 2 cP. In some embodiments, the ASD forming solution has a viscosity of 1.2 cP to about 1.8 cP.
[0053] In some embodiments, the ASD forms a solution comprising a viscosity modifier. In some embodiments, the viscosity modifier is a viscosity enhancer. In some embodiments, the viscosity enhancer is ethylene glycol, polyethylene glycol, glycerol or propylene glycerol, or any combination thereof. In some embodiments, the viscosity modifier is a viscosity reducer. In some embodiments, the viscosity reducer is a salt or an amino acid, or a combination thereof. In some embodiments, the concentration of the viscosity modifier in the ASD formation solution is 1% to 40%. In some embodiments, by volume, the ratio of the viscosity modifier to the organic carrier is 1:100 to 40:100. In some embodiments, the amount of the viscosity modifier in the mixture is based on the desired viscosity of the mixture.
[0054] In some embodiments, the organic vehicle of the ASD forming solution comprises a component selected from the group consisting of acetone, dimethylformamide, ethanol, methanol, pentane, hexane, heptane, ethyl acetate, isopropanol, ethylene glycol, and dimethyl sulfoxide. In some embodiments, the ASD forming solution comprises at least 30% organic vehicle by volume.
[0055] In some embodiments, the polymer is selected based on one or more characteristics of the hydrophobic agent.
[0056] In some embodiments, the polymer is selected from the group consisting of: cellulose derivatives, poly(vinyl pyrrolidone) (PVP), poly(vinyl pyrrolidone-co-vinyl acetate) (copolyvidone or PVPVA), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose or HPMC), and HPMC acetate succinate (hydroxypropyl methylcellulose acetate succinate or HPMC-AS), and acrylic resin (eudragit), or any combination thereof. In some embodiments, the polymer is a grade selected from the group consisting of: LF, MF, HF, LMP, MMP, HMP, LG, MG, and HG. In some embodiments, the polymer is HPMC-AS-LF. In some embodiments, the ratio of the concentration of the polymer in the ASD forming solution to the concentration of the drug is 1:20 to 20:1. In some embodiments, the ratio of the concentration of the polymer in the ASD forming solution to the concentration of the drug is 1:2 to 2:1.
[0057] In other aspects, provided herein is a composition comprising a dried or lyophilized suspension, wherein upon reconstitution, any suspension described herein is formed.
[0058] In other aspects, provided herein is a dosage form prepared by any of the methods described herein. In some embodiments, the dosage form comprises: a fixed amount of a hydrophobic agent, wherein the hydrophobic agent is a therapeutic agent; and a fixed amount of a second hydrophobic agent. In some embodiments, the second hydrophobic agent is a therapeutic agent. In some embodiments, the second hydrophobic agent is a pharmaceutical excipient.
[0059] In other aspects, provided herein are a plurality of dosage forms described herein, prepared as a batch of pharmaceutical dosage forms, wherein the amount of the hydrophobic agent in each pharmaceutical dosage form in the batch varies by no more than 5% relative to the average.
[0060] In other aspects, provided herein is a system for producing a dosage form, the system comprising: a suspension comprising a hydrophobic agent, wherein the suspension comprises an aqueous carrier and a plurality of nanoparticles, wherein each of the plurality of nanoparticles comprises a hydrophobic agent, and wherein the viscosity of the suspension is less than 2 cP; and a high-frequency droplet dispenser comprising about 100 to about 1000 individual nozzles, each nozzle being configured to deposit at least one droplet of the suspension onto a substrate of the dosage form.
[0061] In some embodiments, each nozzle has an aperture of about 20 μm to about 120 μm.
[0062] In some embodiments, the suspension droplets are deposited onto the substrate using a thermal process. In some embodiments, the suspension droplets are deposited onto the substrate using a piezoelectric process.
[0063] In other aspects, a system for producing a dosage form is provided herein, the system comprising: an amorphous solid dispersion (ASD) comprising a hydrophobic agent, the method comprising using a droplet dispenser to deposit droplets of an ASD-forming solution comprising a hydrophobic agent, an organic carrier, and a polymer onto a substrate, wherein the ratio of the polymer to the hydrophobic agent inhibits crystallization of the hydrophobic agent on the substrate in a dry state, and wherein the viscosity of the ASD-forming solution is less than 2 cP; and a high-frequency droplet dispenser comprising about 100 to about 1000 individual nozzles, each of which is configured to deposit at least one solution droplet onto the substrate of the dosage form. In some embodiments, each nozzle has an aperture of about 20 μm to about 120 μm. In some embodiments, the solution droplets are deposited onto the substrate using a thermal process. In some embodiments, the solution droplets are deposited onto the substrate using a piezoelectric process.
[0064] In other aspects, provided herein is a dispensing cartridge comprising an ASD-forming solution as described herein.
[0065] In other aspects, provided herein is a dosage form comprising a nanosuspension of a hydrophobic agent deposited via droplets onto a substrate.
[0066] In other aspects, provided herein is a dosage form comprising an amorphous solid dispersion of a hydrophobic agent deposited on a substrate via droplets.
[0067] In other aspects, a method for determining the ratio of a hydrophobic agent to a polymer for forming an amorphous solid dispersion is provided herein, the method comprising dispensing a certain amount of a first precursor solution and a certain amount of a second precursor solution onto a substrate, the first precursor solution comprising a first organic carrier, a hydrophobic agent and a first viscosity enhancer, the second precursor solution comprising a second organic carrier, a polymer and a second viscosity enhancer, to determine the ratio of a hydrophobic agent to a polymer for forming an amorphous solid dispersion of a hydrophobic agent and a polymer, wherein the distribution causes the first precursor solution to contact the second precursor solution. In some embodiments, the distribution mixes the first precursor solution and the second precursor solution on the substrate. In some embodiments, the distribution mixes the first precursor solution and the second precursor solution before applying the first precursor solution and the second precursor solution to the substrate. In some embodiments, the first precursor solution and the second precursor solution are distributed in an amount so that a certain ratio gradient of agents and polymers is formed in an area on the substrate. In some embodiments, the first precursor solution and the second precursor solution are distributed in an amount so that an area on the substrate has a predetermined ratio of agents and polymers. In some embodiments, the amount of the first precursor solution is dispensed from a first sub-nanoliter droplet dispenser, and the amount of the second precursor solution is dispensed from a second sub-nanoliter droplet dispenser. In some embodiments, the method further comprises crystallization of the evaluation agent. In some embodiments, the first organic carrier and the second organic carrier are the same. In some embodiments, the first viscosity enhancer and the second viscosity enhancer are the same. In some embodiments, the substrate is a film.
[0068] In other aspects, the present invention provides a droplet dispenser for producing a dosage form of a nanosuspension containing a hydrophobic agent, the dispenser comprising: (a) a dispensing head comprising one or more nozzles; (b) a first cartridge containing a suspension, the suspension comprising: an aqueous carrier; and a plurality of nanoparticles containing a hydrophobic agent suspended in the aqueous carrier, wherein the viscosity of the suspension is less than 3 cP, wherein the first cartridge is operably connected to the first dispensing head; and (c) a control system configured to dispense the mixture via the first dispensing head according to a dispensing mode.
[0069] In some embodiments, the first dispensing head comprises about 100 to about 1000 nozzles. In some embodiments, each nozzle has an aperture of about 20 μm to about 120 μm. In some embodiments, the first dispensing head uses a thermal process to dispense the droplets. In some embodiments, the first dispensing head uses a piezoelectric process to dispense the droplets. In some embodiments, the method further comprises a second dispensing head operably coupled to a second cartridge, wherein the second cartridge contains a second dose. In some embodiments, the method further comprises a third dispensing head operably coupled to a third cartridge, wherein the third cartridge contains a protective coating. In some embodiments, the method further comprises a fourth dispensing head operably coupled to a fourth cartridge, wherein the fourth cartridge contains an edible dose.
[0070] In other aspects, the present invention provides a droplet dispenser for producing a dosage form of an amorphous solid dispersion containing a hydrophobic agent, the dispenser comprising: (a) a first dispensing head comprising one or more nozzles; (b) a first mixture cartridge containing an ASD forming solution, the forming solution comprising an organic carrier, an agent, a polymer and a viscosity modifier, wherein the agent and the polymer are present in the mixture in a certain ratio so that the inhibitor crystallizes on a substrate in a dry state, wherein the first mixture cartridge is operably connected to the first dispensing head; and (c) a control system configured to dispense the mixture through the dispensing head according to a dispensing pattern.
[0071] In some embodiments, the first dispensing head includes about 100 to about 1000 nozzles. In some embodiments, each nozzle has an aperture of about 20 μm to about 120 μm. In some embodiments, the first dispensing head uses a thermal process to dispense droplets. In some embodiments, the first dispensing head uses a piezoelectric process to dispense droplets. In some embodiments, the method further includes a second dispensing head operably connected to a second mixture cartridge, wherein the second mixture cartridge contains a second mixture comprising a second dose. In some embodiments, the method further includes a third dispensing head operably connected to a third mixture cartridge, wherein the third mixture cartridge contains a protective coating mixture. In some embodiments, the method further includes a fourth dispensing head operably connected to a fourth mixture cartridge, wherein the fourth mixture cartridge contains an edible mixture.
[0072] In other aspects, provided herein is a gradient of two components on a substrate, the gradient comprising: a first component comprising a hydrophobic agent; a second component comprising a polymer crystallization inhibitor; and a ratio of the first component to the second component, wherein the ratio varies across the gradient.
[0073] In some embodiments, the first component further comprises an organic carrier. In some embodiments, the first component further comprises a viscosity enhancer. In some embodiments, the second component further comprises an organic carrier. In some embodiments, the second component further comprises a viscosity enhancer. In some embodiments, the second component can inhibit the crystallization of the hydrophobic agent. In some embodiments, the first component and the second component each comprise an organic carrier, wherein the organic carrier is the same. In some embodiments, the first component and the second component each comprise a viscosity enhancer, wherein the viscosity enhancer is the same. In some embodiments, the ratio becomes sufficiently low at a certain point on the gradient to prevent the hydrophobic agent from crystallizing. In some embodiments, the first component and the second component are dispensed onto a substrate from a sub-nanoliter droplet dispenser. In some embodiments, the first component is dispensed onto a substrate from a first sub-nanoliter droplet dispenser, and the second component is dispensed onto a substrate from a second sub-nanoliter droplet dispenser. In some embodiments, the ratio changes at a consistent rate of change across the gradient. BRIEF DESCRIPTION OF THE DRAWINGS
[0074] Figure 1 Microscope images of the nanosuspensions are shown.
[0075] Figure 2 Microscope images of the dispensed nanosuspension on the substrate are shown.
[0076] Figure 3 Microscope images of the dispensed nanosuspension on the substrate are shown.
[0077] FIG. 4A to FIG. 4C Each shows a microscope image of a dispensed nanosuspension on a substrate exposed to wetting by a propulsive water line.
[0078] Figure 5 Microscope images of reconstituted nanosuspensions obtained from droplets of nanosuspension deposited on a substrate are shown. The resulting reconstituted nanosuspension was recovered and analyzed by optical microscopy, showing a homogeneous, well-dispersed suspension without significant aggregation.
[0079] Fig. 6A and Figure 6B Schematic diagrams including hydrophobic agent loading and / or deposition of polymers are shown. Fig. 6A A schematic diagram of gradient deposition with different amounts of hydrophobic agent and / or polymer is shown. Figure 6B A schematic diagram of a region having a deposit with an amount of hydrophobic agent relative to polymer is shown.
[0080] Fig. 7A and Figure 7B Schematic diagram showing the deposition of the rapid crystallization drug model griseofulvin and the polymer HPMCAS-LF. Fig. 7A Additionally shown are the crystalline drug form when deposited in the absence of polymer, and the amorphous polymer at 100% polymer loading. Figure 7B Additionally shown is the deposition of 20% drug loading, which resulted in an amorphous solid dispersion lacking crystalline form of the drug. DETAILED DESCRIPTION
[0081] In certain aspects, provided herein are methods of preparing a dosage form, the method comprising dispensing a plurality of droplets of a formulation comprising a hydrophobic agent (such as in the form of a pattern or patterned layer) onto a substrate via a droplet dispenser (such as a high-frequency droplet dispenser or a high-frequency sub-nanoliter droplet dispenser). In other aspects, provided herein are embodiments (such as compositions, devices, and systems) that can be used with or produced by the methods described herein. In some embodiments, the methods described herein can be used to prepare formulations (such as nanosuspensions and ASDs) in a precise manner (e.g., in personalized medicine), which can help improve the absorption and bioavailability of drugs.
[0082] In certain aspects, provided herein is a method of preparing a dosage form, the method comprising dispensing a plurality of droplets of a nanosuspension comprising a plurality of nanoparticles containing a hydrophobic agent (such as in the form of a pattern or patterned layer) onto a substrate via a droplet dispenser (such as a high-frequency droplet dispenser or a high-frequency sub-nanoliter droplet dispenser). In other aspects, provided herein are embodiments (such as compositions, devices, and systems) that can be used with or produced by the methods described herein.
[0083] The disclosure of the present application is based on the unique viewpoints and discoveries of droplet deposition of nanosuspensions (the nanosuspensions contain nanoparticles of hydrophobic agents) using a droplet dispenser (such as a high-frequency droplet dispenser or a high-frequency sub-nanoliter droplet dispenser), and the related production of dosage forms. As described herein, these findings show that nanoparticles containing hydrophobic agents in an accurate and reproducible amount of nanoparticles in a nanosuspension can be deposited on a substrate (such as a film) across a wide concentration range without affecting the nanoparticle size or chemical and physical stability during the process. Such deposition can be performed, for example, using a droplet dispenser that uses a thermal process and / or a piezoelectric process to deposit droplets. Importantly, after the deposited droplets are dried, the hydrophobic agent nanoparticles remain stable and can be successfully reconstructed by adding water. The compatibility of using nanosuspension formulations as suitable "inks" enables such deposition techniques to be used as a general method for poorly soluble drug molecules, thereby significantly expanding the utility of the embodiments described herein. In some embodiments, the resulting material is composed of a substrate (such as a film) containing ultra-low microgram amounts of nanoparticles (such as drug nanoparticles), making it suitable for preparing low-dose products, which is challenging for traditional solid dosage forms and has an impact on the products of high-efficiency molecules or pediatric preparations. In addition, in certain embodiments, the final deposited product can quickly dissolve and release hydrophobic agents (such as drugs), thereby enabling rapid absorption and precise delivery. Such deposition also allows individual dosage forms to be customized as needed by controlling the initial concentration in the preparation and adjusting the deposition of the material to form a dosage form. In addition, the results described herein show that the method can be performed with common commercially available off-the-shelf equipment (almost no custom modifications are required).
[0084] Thus, in some aspects, a method for preparing a dosage form comprising a hydrophobic agent is provided, the method comprising: using a high-frequency droplet dispenser to deposit a plurality of droplets of a nanosuspension onto a substrate to form a dosage form, wherein the nanosuspension comprises: an aqueous carrier; and a plurality of nanoparticles suspended in the aqueous carrier, wherein the nanoparticles comprise a hydrophobic agent, and wherein the viscosity of the nanosuspension is less than 2 cP.
[0085] In other aspects, provided herein is a nanosuspension comprising: an aqueous carrier; a plurality of nanoparticles comprising a hydrophobic agent suspended in the aqueous carrier, wherein the viscosity of the nanosuspension is less than 2 cP.
[0086] In other aspects, a composition comprising a dried or lyophilized nanosuspension is provided, wherein upon reconstitution, a nanosuspension as described herein is formed.
[0087] In other aspects, the plurality of dosage forms described herein are prepared as a batch of pharmaceutical dosage forms, wherein the amount of the hydrophobic agent in each pharmaceutical dosage form in the batch varies by no more than 5% from the average.
[0088] In other aspects, provided herein is a system for producing a dosage form, the system comprising: a nanosuspension comprising a hydrophobic agent, wherein the nanosuspension comprises an aqueous carrier and a plurality of nanoparticles, wherein each of the plurality of nanoparticles comprises a hydrophobic agent, and wherein the viscosity of the nanosuspension is less than 2 cP; and a high-frequency droplet dispenser comprising about 100 to about 1000 individual nozzles, each nozzle being configured to deposit at least one droplet of the nanosuspension onto a substrate of the dosage form.
[0089] In certain aspects, provided herein are methods of preparing a dosage form comprising an amorphous solid dispersion (ASD), the method comprising depositing droplets of an ASD-forming solution onto a substrate using a droplet dispenser. In other aspects, further provided are methods of identifying an ASD-forming solution comprising a pharmaceutical agent susceptible to crystallization, and embodiments encompassed by or produced using the methods described herein, e.g., ASD-forming solutions and / or precursor solutions thereof, pharmaceutical dosage forms, devices, and systems.
[0090] The disclosure of the present application is based on the inventors' unique perspectives and discoveries about low-volume dispensing and deposition of droplets that form ASDs using a droplet dispenser. Such low-volume dispensing and deposition greatly reduces the amount of easily crystallized agents (such as hydrophobic agents) required to identify and / or produce ASDs. In contrast, current methods for studying ASDs involve spray drying techniques (including micro-spray drying), which require at least about 100 mg of initial load material. The techniques taught herein can identify and produce ASDs from microgram amounts or less of starting materials. In addition, as taught herein, two or more precursor solutions can be dispensed from two or more droplet dispensers, thereby enabling gradient deposition studies to identify the ratio of easily crystallized agents to one or more polymers that provide the ASD of the agent. The findings detailed herein relate to the discovery that solutions containing organic carriers can be formed so that they are compatible for use with droplet dispensers (such as sub-nanoliter droplet dispensers).
[0091] Thus, in some aspects, a method of preparing a dosage form comprising an amorphous solid dispersion (ASD) containing a hydrophobic agent is provided, the method comprising using a droplet dispenser to deposit droplets of an ASD-forming solution comprising a hydrophobic agent, an organic carrier, and a polymer onto a substrate, wherein the ratio of polymer to hydrophobic agent inhibits crystallization of the hydrophobic agent on the substrate in a dry state.
[0092] In other aspects, provided herein is an ASD forming solution comprising: an organic carrier, a hydrophobic agent, a polymer, and a viscosity modifier, wherein the polymer inhibitor crystallizes in a dry state.
[0093] In other aspects, a dispensing cartridge is provided that includes an ASD forming solution or precursor solution as described herein.
[0094] In other aspects, a dosage form is provided that includes an amorphous solid dispersion of a hydrophobic agent deposited on a substrate via droplets.
[0095] In other aspects, provided is a dosage form prepared by the method described herein.
[0096] In other aspects, a method of determining a ratio of a hydrophobic agent to a polymer forming an amorphous solid dispersion is provided, the method comprising dispensing an amount of a first mixture comprising a first organic vehicle, a hydrophobic agent, and a first viscosity enhancer and an amount of a second mixture comprising a second organic vehicle, a polymer, and a second viscosity enhancer onto a substrate to determine a ratio of a hydrophobic agent to a polymer forming an amorphous solid dispersion, wherein the dispensing is performed in such a manner that the first mixture and the second mixture are mixed on the substrate or mixed prior to application to the substrate.
[0097] In other aspects, a droplet dispenser for producing a dosage form of an amorphous solid dispersion containing a hydrophobic agent is provided, the dispenser comprising: (a) a dispensing head comprising one or more nozzles; (b) an ASD forming solution comprising an organic carrier, an agent, a polymer and a viscosity modifier, wherein the agent and the polymer are present in a mixture in a ratio such that the inhibitor crystallizes on a substrate in a dry state, wherein a mixture cartridge is operably coupled to the dispensing head; and (c) a control system configured to dispense the mixture via the dispensing head according to a dispensing pattern.
[0098] In other aspects, a gradient on a substrate is provided, the gradient comprising: a first position, a second position, and a third position, each position comprising a mixture of an amount of a first deposit and an amount of a second deposit, wherein the first deposit comprises a hydrophobic agent, wherein the ratio of the amount of the first deposit to the amount of the second deposit in the first position is less than the ratio of the amount of the first deposit to the amount of the second deposit in the second position, and the ratio of the amount of the first deposit to the amount of the second deposit in the second position is less than the ratio of the amount of the first deposit to the amount of the second deposit in the third position, wherein the interaction between the first deposit and the second deposit in the mixture at the first position, the second position, and the third position produces a measurable effect of the hydrophobic agent of the first deposit. In some embodiments, the difference in the ratio of the amount of the first deposit to the amount of the second deposit in each of the first position, the second position, and the third position is the same.
[0099] I. Definitions
[0100] Unless otherwise defined, all technical terms, symbols and other technical and scientific terms or expressions used herein are intended to have the meanings commonly understood by those of ordinary skill in the art to which the claimed subject matter belongs. In some cases, terms with commonly understood meanings are defined herein for clarity and / or ease of reference, and these definitions contained herein are not necessarily to be construed as representing a significant difference from the commonly understood meaning in the art compared to the definitions of terms commonly understood in the prior art.
[0101] As used herein, the terms "polypeptide" and "protein" can be used interchangeably to refer to polymers comprising amino acid residues, and are not limited to a minimum length. Such polymers may contain natural or non-natural amino acid residues or combinations thereof, and include, but are not limited to, peptides, polypeptides, oligopeptides, dimers, trimers and polymers of amino acid residues. The definition encompasses full-length polypeptides or proteins, as well as fragments thereof. The term also includes modified species thereof, for example, post-translational modifications of one or more residues, such as methylation, phosphorylation, glycosylation, sialylation or acetylation.
[0102] Throughout this disclosure, various aspects of the claimed subject matter are presented in a range format. It should be understood that the description in a range format is only for convenience and brevity, and should not be interpreted as an inflexible limitation on the scope of the claimed subject matter. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and each numerical value within the range. For example, in the case of providing a numerical range, it should be understood that each intermediate value between the upper and lower limits of the range (based on one-tenth of the lower limit unit, unless the context clearly stipulates otherwise) and any other described or intermediate values within the range are included in the present disclosure, subject to any explicit exclusions within the range. If the specified range includes one or two limits, the range excluding any one or two of the included limits is also included in the present disclosure. In some embodiments, two opposite and open ranges are provided to the feature, and in such descriptions, it is envisioned that a combination of these two ranges is provided herein. For example, in some embodiments, it is described as a feature greater than about 10 units, and described as (such as in another sentence) a feature less than about 20 units, and therefore a range of about 10 units to about 20 units is described herein.
[0103] As used herein, the term "about" refers to the common error range of the corresponding value that is readily known in the art. References to "about" values or parameters herein include (and describe) variations involving the value or parameter itself. For example, a description referring to "about X" includes a description of "X".
[0104] As used herein (including the appended claims), the singular forms "a / kind", "or", and "the / said" include plural referents unless the context clearly dictates otherwise. For example, "a" or "an" means "at least one" or "one or more." It should be understood that the aspects and variations described herein include embodiments "consisting of" and / or "consisting essentially of" such aspects and variations.
[0105] As used herein, "subject" or "individual" are interchangeable terms and are mammals. In some embodiments, "mammals" include humans, non-human primates, domestic and farm animals, and zoo, sport, or pet animals, such as dogs, horses, rabbits, cows, pigs, hamsters, gerbils, mice, ferrets, rats, cats, monkeys, and the like. In some embodiments, the subject or individual is a human.
[0106] Those skilled in the art will recognize that several embodiments are possible within the scope and spirit of the present disclosure.The following description illustrates the present disclosure and should certainly not be construed in any way as limiting the scope of the invention described herein.
[0107] II. Methods of Preparing Dosage Forms
[0108] In some aspects, the present invention provides a method for preparing a dosage form comprising a plurality of nanoparticles, wherein the plurality of nanoparticles comprises a hydrophobic agent. As discussed herein, various aspects of the method are described in a modular manner in subsequent chapters, and it will be readily understood that the method encompasses the embodiments described therein. Such descriptions in a modular manner are not intended to limit the scope of the present disclosure, and based on the teachings provided herein, it will be readily understood by those of ordinary skill in the art that certain modules may be at least partially integrated. The section headings used herein are only for organizational purposes and should not be construed as limiting the subject matter described.
[0109] In some embodiments, the method includes dispensing droplets of a nanosuspension containing a plurality of nanoparticles containing a hydrophobic agent onto a substrate via a droplet dispenser (such as a high-frequency droplet dispenser or a high-frequency sub-nanoliter droplet dispenser), such as according to a pattern or patterned layer. In some embodiments, the nanosuspension is derived from a dispensing cartridge. In some embodiments, the method includes delivering the nanosuspension to a droplet dispenser or a component thereof, such as a dispensing head thereof. In some embodiments, the viscosity of the nanosuspension is about 1 cP to about 5 cP, such as less than 2 cP, including about 1 cP to less than 2 cP or about 1.2 cP to about 1.8 cP.
[0110] In some embodiments, the method comprises: delivering a nanosuspension (the nanosuspension comprising a plurality of nanoparticles suspended in an aqueous carrier, the plurality of nanoparticles comprising a hydrophobic agent) to a droplet dispenser (such as a high-frequency droplet dispenser or a high-frequency sub-nanoliter droplet dispenser), wherein the viscosity of the nanosuspension is less than 2 cP, such as from about 1 cP to less than 2 cP or from about 1.2 cP to about 1.8 cP; and depositing a plurality of droplets of the nanosuspension onto a substrate using a droplet dispenser, such as according to a pattern or patterned layer, to form a dosage form.
[0111] In some embodiments, the droplet dispenser distributes droplets in the direction of the substrate to deposit the droplets thereon. In general, the distributed droplets from the droplet dispenser may undergo a change in form during the deposition process, for example, (a) a droplet can merge with another droplet after being distributed from the droplet dispenser (whether in the air or on the substrate), and (b) the deposited droplets dry on the substrate. A description of the droplets is provided herein, and can be applied to various states occurring during the deposition process. Unless otherwise expressly stated, such description is not intended to be limited to a certain state. In some embodiments, deposition includes dispensing a plurality of nanosuspension droplets per square inch (also referred to herein as dots per inch). In some embodiments, the resulting pattern or patterned layer produced by the method described herein includes, at least to some extent, the merging of one or more distributed droplets of the nanosuspension. Such droplet patterns do not need to be regular, and in some embodiments, reflect a plurality of droplets applied to a set area of the substrate. In some embodiments, the deposited droplets (whether or not merging occurs before or after the substrate) are similar to patterns on a macroscopic scale, such as shapes. In some embodiments, the dosage form comprises one or more layers of droplets deposited on a substrate, such as formed by one or more passes of a droplet dispenser over the dosage form area. In some embodiments, the patterned layer is a continuous layer of the nanosuspension prior to drying, e.g., the deposited droplets are at least somewhat interconnected. In some embodiments, the droplets of the nanosuspension are deposited at about 1 dot per inch (dpi) to about 1,000 dpi, such as about 1 dpi to about 720 dpi, about 72 dpi to about 720 dpi, about 72 dpi to about 500 dpi, or about 72 dpi to about 300 dpi. In some embodiments, droplets of the nanosuspension are deposited at about 1 dpi or greater, such as about 20 dpi or greater, 50 dpi or greater, 72 dpi or greater, 100 dpi or greater, 120 dpi or greater, 150 dpi or greater, 200 dpi or greater, 250 dpi or greater, 300 dpi or greater, 350 dpi or greater, 400 dpi or greater, 450 dpi or greater, 500 dpi or greater, 550 dpi or greater, 600 dpi or greater, 650 dpi or greater, 700 dpi or greater, 720 dpi or greater, 750 dpi or greater, 800 dpi or greater, 850 dpi or greater, 900 dpi or greater, 950 dpi or greater, or 1,000 dpi or greater. In some embodiments, droplets of the nanosuspension are deposited at about 1 dot per inch (dpi) to about 1,000 dpi, such as any of about 1 dpi to about 720 dpi, about 72 dpi to about 720 dpi, about 72 dpi to about 500 dpi, or about 72 dpi to about 300 dpi.In some embodiments, droplets of the nanosuspension are deposited at about 1 dpi or greater, such as about 20 dpi or greater, 50 dpi or greater, 72 dpi or greater, 100 dpi or greater, 120 dpi or greater, 150 dpi or greater, 200 dpi or greater, 250 dpi or greater, 300 dpi or greater, 350 dpi or greater, 400 dpi or greater, 450 dpi or greater, 500 dpi or greater, 550 dpi or greater, 600 dpi or greater, 650 dpi or greater, 700 dpi or greater, 720 dpi or greater, 750 dpi or greater, 800 dpi or greater, 850 dpi or greater, 900 dpi or greater, 950 dpi or greater, or 1,000 dpi or greater.
[0112] In some embodiments, the dispensed or deposited droplets of the nanosuspension have a diameter of about 1 nm to about 200 μm, such as any of about 20 nm to about 800 nm, about 100 nm to about 500 nm, or about 10 μm to about 100 μm. In some embodiments, the dispensed or deposited droplets of the nanosuspension have a diameter of at least about 1 nm, such as at least about 10 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm, 200 nm, 210 nm, 220 nm, 230 nm, 240 nm, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, 300 nm, 310 nm, 320 nm, 330 nm, 340 nm, 350 nm, 360 nm, 370 nm, 380 nm, 390 nm, 400 nm, 410 nm, 420 nm, 430 nm, 440 nm, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 610 nm, 620 nm, 630 nm, 640 nm, 650 nm, 660 nm, 670 nm, 680 nm, 690 nm, 700 nm, The diameter of any one of 0nm, 410nm, 420nm, 430nm, 440nm, 450nm, 460nm, 470nm, 480nm, 490nm, 500nm, 525nm, 550nm, 575nm, 600nm, 625nm, 650nm, 675nm, 700nm, 725nm, 750nm, 775nm, 800nm, 825nm, 850nm, 875nm, 900nm, 925nm, 950nm, 975nm, 1μm, 5μm, 10μm, 15μm, 20μm, 25μm, 30μm, 35μm, 40μm, 45μm, 50μm, 60μm, 70μm, 80μm, 90μm or 100μm. In some embodiments, the mean of a population of dispensed or deposited droplets of a dosage form described herein meets the criteria discussed above.
[0113] In some embodiments, the dispensed or deposited droplets of the nanosuspension comprise an average volume of about 1 picoliter (pL) to about 1 nL, such as about 1 pL to about 500 pL or about 1 pL to about 50 pL. In some embodiments, the dispensed or deposited droplets of the nanosuspension comprise an average volume of about 1 nL or less, such as about any of 950 pL or less, 900 pL or less, 850 pL or less, 800 pL or less, 750 pL or less, 700 pL or less, 650 pL or less, 600 pL or less, 550 pL or less, 500 pL or less, 450 pL or less, 400 pL or less, 350 pL or less, 300 pL or less, 250 pL or less, 200 pL or less, 150 pL or less, 100 pL or less, 75 pL or less, 50 pL or less, or 25 pL or less.
[0114] In some embodiments, the method further comprises coupling a cartridge containing the nanosuspension with a droplet dispenser (such as a high-frequency droplet dispenser or a high-frequency sub-nanoliter droplet dispenser). In some embodiments, the method further comprises selecting a cartridge comprising a nanosuspension to produce a desired dosage form, such as based on one or more of the following: desired features of the final dosage form or one or more patterned layers thereon (e.g., the amount of hydrophobic agent to be deposited on the dosage form), features of the patterned layer (such as any of dpi, shape, size, and position on the dosage form), release profile of the hydrophobic agent, and features of the final dosage form (e.g., structural integrity and / or protection of the patterned layer). In certain embodiments, the method comprises dispensing at least one nanosuspension and optionally another material (e.g., a food safety material to form a label), wherein the method encompasses the selection of each dispensed component. In some embodiments, the method comprises selecting a nanosuspension from a library of nanosuspensions (such as compiled in a kit). In some embodiments, the method further comprises preparing a nanosuspension.
[0115] In some embodiments, the method includes designing a pattern of droplets of a nanosolution comprising a plurality of nanoparticles containing a hydrophobic agent (such as characterized by a dpi). In some embodiments, the design method includes determining (such as calculating) one or more settings based on any one or more of the following: the total amount of hydrophobic agent of the dosage form; the concentration of the hydrophobic agent in the nanosuspension; the desired exposed surface area of the nanosuspension of the dosage form or its dry form; the desired release profile of the hydrophobic agent; and the characteristics of the sub-nanoliter droplet dispenser (or its use), such as the aperture, the jetting frequency, and the droplet size produced.
[0116] In some embodiments, the method includes creating and / or receiving instructions to control a droplet dispenser, such as to form a dosage form described herein. In some embodiments, the instructions are personalized to an individual.
[0117] In some embodiments, the method further comprises performing a drying time after dispensing the nanosuspension on the substrate, for example, so that the nanosuspension can dry at least to some extent, and / or the nanosuspension can associate with the substrate (such as being absorbed into the substrate). In some embodiments, the method further comprises one or more processing steps after dispensing the nanosuspension on the substrate, such as cutting the substrate into individual dosage forms and / or packaging one or more dosage forms.
[0118] In some embodiments, the method further comprises cleaning one or more dispensing heads of the droplet dispenser, such as by dispensing a solvent without the drug. For example, such a cleaning step helps ensure that the nanosuspension has not blocked the nozzle of the dispensing head and / or helps reduce the residue of the hydrophobic agent.
[0119] III. Nanosuspensions
[0120] In certain aspects, provided herein are nanosuspensions comprising a plurality of nanoparticles comprising a hydrophobic agent suitable for use in and / or with the embodiments described herein, including methods, devices, dispensing cartridges, compositions, and systems disclosed herein. In some embodiments, the nanosuspension comprises a carrier (such as an aqueous carrier); and a plurality of nanoparticles comprising a hydrophobic agent suspended in the carrier, wherein the nanosuspension has a viscosity suitable for use in the embodiments described herein, including methods for preparing dosage forms using a sub-nanoliter droplet dispenser. In some embodiments, the nanosuspension comprises a viscosity modifier, such as a viscosity enhancer. Without being bound by theory, the nanosuspension can stabilize low-solubility drugs into nanoparticles that can be rapidly absorbed by a patient or subject.
[0121] In some embodiments, a nanosuspension is provided herein, comprising: a carrier (such as an aqueous carrier); a plurality of nanoparticles comprising a hydrophobic agent suspended in an aqueous carrier; and a stabilizing component. In some embodiments, the aqueous carrier comprises a slurry (such as about 100% water). In some embodiments, the stabilizing component is a polymer (e.g., polyvinyl pyrrolidone, PVP), a surfactant (e.g., sodium dodecyl sulfate, SDS), or a mixture thereof. In some embodiments, the polymer stabilizing component includes any one or more of the following: polyvinyl pyrrolidone (PVP) (including any type and / or grade thereof), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), methyl cellulose (MC), poloxamer (including any type and / or grade thereof) and polyethylene glycol (PEG, including any type and / or grade thereof). In some embodiments, the surfactant stabilizing component includes any one or more of the following: polysorbate or Tween (including any type and / or grade thereof), Vit-E TPGS, lecithin, sodium salt of alkyl sulfonate and sodium salt of cholate. In some embodiments, the concentration of the hydrophobic agent in the nanosuspension (such as contained in the plurality of nanoparticles) is from about 20 mg / mL to about 200 mg / mL, such as about 100 mg / mL. In some embodiments, the viscosity is less than 5 cP, such as less than about 4 cP, 3 cP, or 2 cP, including about 1.2 cP to about 1.8 cP. In some embodiments, the nanosuspension comprises a viscosity modifier, such as a viscosity enhancer.
[0122] In some embodiments, a nanosuspension is provided herein, comprising an aqueous carrier, a plurality of nanoparticles comprising a hydrophobic agent suspended in an aqueous carrier, and a stabilizing component, wherein the viscosity of the nanosuspension is less than 5 cP, such as less than about 4 cP, 3 cP or 2 cP, including about 1 cP to less than 2 cP or about 1.2 cP to about 1.8 cP, and wherein the concentration of the hydrophobic agent (such as contained in the plurality of nanoparticles) in the nanosuspension is about 20 mg / mL to about 200 mg / mL, such as about 100 mg / mL. In some embodiments, the aqueous carrier comprises water (such as about 100% water). In some embodiments, the stabilizing component is a polymer (e.g., PVP), a surfactant (e.g., SDS), or a mixture thereof. In some embodiments, the nanosuspension comprises a viscosity modifier, such as a viscosity enhancer.
[0123] In some embodiments, a nanosuspension is provided herein, comprising: an aqueous carrier (water); a plurality of nanoparticles comprising a hydrophobic agent suspended in an aqueous carrier; and a stabilizing component comprising a polymer (e.g., PVP), a surfactant (e.g., SDS), or a mixture thereof, wherein the viscosity of the nanosuspension is less than 5 cP, such as less than about any of 4 cP, 3 cP, or 2 cP, including about 1 cP to less than 2 cP or about 1.2 cP to about 1.8 cP, and wherein the concentration of the hydrophobic agent in the nanosuspension (such as contained in the plurality of nanoparticles) is about 20 mg / mL to about 200 mg / mL, such as about 100 mg / mL. In some embodiments, the nanosuspension comprises a viscosity modifier, such as a viscosity enhancer.
[0124] In some embodiments, a nanosuspension is provided, comprising: (a) an aqueous carrier, wherein the aqueous carrier comprises about 100% water (wt %); (b) a plurality of nanoparticles comprising a hydrophobic agent (such as naproxen) suspended in the aqueous carrier; and (c) PVP and SDS, wherein the ratio of the hydrophobic agent, PVP to SDS is about 1:0.25:0.01 (100:25:1), wherein the concentration of the hydrophobic agent in the nanosuspension is about 100 mg / mL, and wherein the viscosity of the nanosuspension is between about 1 cP and about 3 cP, including about 2.1 cP. In some embodiments, the nanosuspension comprises a viscosity modifier, such as a viscosity enhancer.
[0125] In some embodiments, a nanosuspension is provided comprising: (a) an aqueous carrier, wherein the aqueous carrier comprises water; (b) a plurality of nanoparticles comprising a hydrophobic agent (such as naproxen) suspended in the aqueous carrier; (c) PVP and SDS, wherein the ratio of the hydrophobic agent, PVP to SDS is about 1:0.25:0.01 (100:25:1); and (d) a viscosity modifier (such as a viscosity enhancer), for example ethylene glycol, wherein the concentration of the hydrophobic agent in the nanosuspension is about 10 mg / mL, and wherein the viscosity of the nanosuspension is between about 1 cP and about 3 cP, including about 1.5 cP.
[0126] In the following subsections, additional descriptions of various aspects of the nanosuspensions described herein are provided. Such modular descriptions are not intended to limit the scope of the present disclosure, and based on the teachings provided herein, one of ordinary skill in the art will readily appreciate that certain modules may be at least partially integrated. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0127] A. Aqueous carrier
[0128] In some embodiments, nano suspension is a colloidal suspension of nanoparticles containing hydrophobic agents in an aqueous carrier. In some embodiments, the aqueous carrier does not dissolve the nanoparticles containing hydrophobic agents contained therein. In some embodiments, the aqueous carrier is substantially an aqueous solution, for example, comprising at least about 50% v / v, such as at least about 55% v / v, 60% v / v, 65% v / v, 70% v / v, 75% v / v, 80% v / v, 85% v / v, 90% v / v, 95% v / v or 100% v / v of any one of the aqueous medium (such as water). In some embodiments, the aqueous medium is water, which includes distilled water, double distilled water, deionized water, purified water, ultrapure water, water without DNA enzymes and / or RNA enzymes, water without proteases, water suitable for injection or pharmaceutical grade water.
[0129] In some embodiments, the aqueous carrier of the nanosuspension comprises water and an organic solvent. In some embodiments, the ratio of water to the organic solvent in the aqueous carrier is between about 6:4 and about 9.9:1, such as any one of 6:4, 7:3, 8:2 or 9:1. In some embodiments, the ratio of water to the organic solvent is greater than 10:1, greater than 100:1, greater than 1000:1 or greater than 10000:1. In some embodiments, the organic solvent is selected from the group consisting of the following items: acetonitrile, ethanol, isopropanol, DMSO, polyethylene glycol (PEG) and propylene glycol, or a mixture thereof. In some embodiments, the organic solvent is suitable for use to an individual (such as a human being). In some embodiments, the organic solvent in the amount retained in the dosage form is suitable for use to an individual, and the dosage form is used to an individual and produced by the nanosuspension described herein.
[0130] B. Viscosity
[0131] The nanosuspensions provided herein have a viscosity that makes the nanosuspensions suitable for use in the embodiments described herein, which include methods of preparing dosage forms and droplet dispensers. In some embodiments, the viscosity of the nanosuspensions provided herein is such that they can be printed with a sub-nanoliter droplet dispenser. In some embodiments, the viscosity of the nanosuspensions provided herein is such that they do not leak from the dispensing cartridges described herein.
[0132] In some embodiments, the viscosity of the nanosuspension is from about 0.5 cP to about 5 cP, such as any of from about 0.5 cP to about 2.5 cP, from about 1 cP to about 2.5 cP, from about 1.5 cP to about 2.5 cP, or from about 1.2 cP to about 1.8 cP. In some embodiments, the viscosity of the nanosuspension is less than about 5 cP, such as less than about 4.9 cP, 4.8 cP, 4.7 cP, 4.6 cP, 4.5 cP, 4.4 cP, 4.3 cP, 4.2 cP, 4.1 cP, 4.0 cP, 3.9 cP, 3.8 cP, 3.7 cP, 3.6 cP, 3.5 cP, 3.4 cP, 3.3 cP, 3.2 cP, 3.1 cP, 3.0 cP, 2.9 Any one of cP, 2.8cP, 2.7cP, 2.6cP, 2.5cP, 2.4cP, 2.3cP, 2.2cP, 2.1cP, 2.0cP, 1.9cP, 1.8cP, 1.7cP, 1.6cP, 1.5cP, 1.4cP, 1.3cP, 1.2cP, 1.1cP, 1.0cP, 0.9cP, 0.8cP, 0.7cP, 0.6cP or 0.5cP. In some embodiments, the viscosity of the nanosuspension is less than about 2 cP, such as less than about any of 1.95 cP, 1.9 cP, 1.85 cP, 1.8 cP, 1.75 cP, 1.7 cP, 1.65 cP, 1.6 cP, 1.55 cP, 1.5 cP, 1.45 cP, 1.4 cP, 1.35 cP, 1.3 cP, 1.25 cP, 1.2 cP, 1.15 cP, 1.1 cP, 1.05 cP, 1 cP, 0.95 cP, 0.9 cP, 0.85 cP, 0.8 cP, 0.75 cP, 0.7 cP, 0.65 cP, 0.6 cP, 0.55 cP, or 0.5 cP. In some embodiments, the viscosity of the nanosuspension is at least about 0.5 cP, such as at least about 0.6 cP, 0.7 cP, 0.8 cP, 0.9 cP, 1.0 cP, 1.1 cP, 1.2 cP, 1.3 cP, 1.4 cP, 1.5 cP, 1.6 cP, 1.7 cP, 1.8 cP, 1.9 cP, 2.0 cP, 2.1 cP, 2.2 cP, 2.3 cP, 2.4 cP, 2.5 cP, 2.6 cP, 2.7 cP, 2.8 cP, 2.9 cP, 3.0 cP, 3.1 cP, 3.2 cP, 3.3 cP, 3.4 cP, 3.5 cP, 3.6 cP, 3.7 cP, 3.8 cP, 3.9 cP, 4.1 cP, 4.2 cP, 4.3 cP, 4.4 cP, 4.5 cP, 4.6 cP, 4.7 cP, 4.8 cP, 4.9 cP, 5. Any one of 6cP, 2.7cP, 2.8cP, 2.9cP, 3.0cP, 3.1cP, 3.2cP, 3.3cP, 3.4cP, 3.5cP, 3.6cP, 3.7cP, 3.8cP, 3.9cP, 4.0cP, 4.1cP, 4.2cP, 4.3cP, 4.4cP, 4.5cP, 4.6cP, 4.7cP, 4.8cP, 4.9cP or 5.0cP.In some embodiments, the viscosity of the nanosuspension is at least about 0.5 cP, such as at least about any of 0.55 cP, 0.6 cP, 0.65 cP, 0.7 cP, 0.75 cP, 0.8 cP, 0.85 cP, 0.9 cP, 0.95 cP, 1 cP, 1.05 cP, 1.1 cP, 1.15 cP, 1.2 cP, 1.25 cP, 1.3 cP, 1.35 cP, 1.4 cP, 1.45 cP, 1.5 cP, 1.55 cP, 1.6 cP, 1.65 cP, 1.7 cP, 1.75 cP, 1.8 cP, 1.85 cP, 1.9 cP, 1.95 cP, or 2.0 cP. In some embodiments, the viscosity of the nanosuspension is about 0.5 cP, 0.6 cP, 0.7 cP, 0.8 cP, 0.9 cP, 1.0 cP, 1.1 cP, 1.2 cP, 1.3 cP, 1.4 cP, 1.5 cP, 1.6 cP, 1.7 cP, 1.8 cP, 1.9 cP, 2.0 cP, 2.1 cP, 2.2 cP, 2.3 cP, 2.4 cP, 2.5 cP, 2.6 cP , 2.7cP, 2.8cP, 2.9cP, 3.0cP, 3.1cP, 3.2cP, 3.3cP, 3.4cP, 3.5cP, 3.6cP, 3.7cP, 3.8cP, 3.9cP, 4.0cP, 4.1cP, 4.2cP, 4.3cP, 4.4cP, 4.5cP, 4.6cP, 4.7cP, 4.8cP, 4.9cP or 5.0cP. In some embodiments, the viscosity of the nanosuspension is about any of 0.5 cP, 0.55 cP, 0.6 cP, 0.65 cP, 0.7 cP, 0.75 cP, 0.8 cP, 0.85 cP, 0.9 cP, 0.95 cP, 1 cP, 1.05 cP, 1.1 cP, 1.15 cP, 1.2 cP, 1.25 cP, 1.3 cP, 1.35 cP, 1.4 cP, 1.45 cP, 1.5 cP, 1.55 cP, 1.6 cP, 1.65 cP, 1.7 cP, 1.75 cP, 1.8 cP, 1.85 cP, 1.9 cP, 1.95 cP, or 2.0 cP. In the embodiments described herein, the viscosity of the nanosuspension is assessed at about room temperature, such as about 20°C to about 22°C, including at any of about 20°C, 21°C, or 22°C.
[0133] In certain embodiments, various components can contribute to the viscosity of the nanosuspension, including the concentration of hydrophobic agent and nanoparticle thereof. In certain embodiments, the nanosuspension further comprises a viscosity modifier. In certain embodiments, the viscosity modifier is a viscosity enhancer, for example, increases the viscosity of the nanosuspension. In certain embodiments, the viscosity modifier is a viscosity reducer, for example, reduces the viscosity of the nanosuspension.
[0134] In some embodiments, the viscosity enhancer is selected from the group consisting of ethylene glycol, polyethylene glycol, glycerol, propylene glycol, and a cellulosic polymer, or a mixture thereof. In some embodiments, the cellulosic polymer is selected from methylcellulose, hydroxymethylcellulose, and hydroxypropylmethylcellulose, or a mixture thereof.
[0135] In some embodiments, the viscosity reducing agent is selected from the group consisting of salts and amino acids, or mixtures thereof.
[0136] In some embodiments, the viscosity modifier (such as a viscosity enhancer or a viscosity reducer) has a concentration of about 0.1% v / v to about 40% v / v in the nanosuspension, such as about 1% v / v to about 10% v / v, about 5% v / v to about 15% v / v, about 10% v / v to about 20% v / v, about 15% v / v to about 25% v / v, about 20% v / v to about 30% v / v, about 25% v / v to about 35% v / v, or about 30% v / v to about 40% v / v. In some embodiments, the viscosity modifier (such as a viscosity enhancer or a viscosity reducer) has a concentration of about 40% v / v or less in the nanosuspension, such as about 35% v / v, 30% v / v, 25% v / v, 20% v / v, 15% v / v, 10% v / v, 9% v / v, 8% v / v, 7% v / v, 6% v / v, 5% v / v, 4% v / v, 3% v / v, 2% v / v, 1% v / v, 0.9% v / v, 0.8% v / v, 0.7% v / v, 0.6% v / v, 0.5% v / v, 0.4% v / v, 0.3% v / v, 0.2% v / v, or 0.1% v / v. In some embodiments, the concentration of the viscosity modifier (such as a viscosity enhancer or a viscosity reducer) in the nanosuspension is based on the desired viscosity of the nanosuspension.
[0137] In some embodiments, the ratio of the viscosity modifier (such as a viscosity enhancer or viscosity reducer) to the aqueous carrier of the nanosuspension is about 1:1000 to about 1:2, such as about 1:500 to about 1:2, about 1:100 to about 1:2, about 1:50 to about 1:2, about 1:20 to about 1:2, about 1:1000 to about 1:5, about 1:500 to about 1:5, about 1:100 to about 1:5, about 1:50 to about 1:5, about 1:20 to about 1:5, about 1:1000 to about 1:10, about 1:500 to about 1:10, about 1:100 to about 1:10, about 1:50 to about 1:10, or about 1:20 to about 1:10 or about 1:10 to about 1:5. In some embodiments, the ratio is about 1:5. In some embodiments, the ratio is about 1:10.
[0138] D. Hydrophobic agent and its nanoparticles
[0139] The nanosuspensions described herein include a hydrophobic agent in the form of nanoparticles. In the methods described herein, the nanosuspensions are deposited onto a substrate using a droplet dispenser. In some embodiments, the droplet dispenser includes a dispensing head including a nozzle having a determined aperture size characteristic. In some embodiments, the nanoparticles of the nanosuspension containing the hydrophobic agent have a characteristic (such as a size) that is based on an aperture size characteristic (such as a diameter or a maximum cross dimension).
[0140] In some embodiments, the nanoparticles of the nanosuspension (e.g., each nanoparticle in a plurality of nanoparticles) have a diameter of about 500 μm or less, such as about 490 μm or less, 480 μm or less, 470 μm or less, 460 μm or less, 450 μm or less, 440 μm or less, 430 μm or less, 420 μm or less, 410 μm or less, 400 μm or less, 390 μm or less, 380 μm or less, 370 μm or less, 380 μm or less, 390 μm or less, 390 μm or less, 38 ... 360μm or less, 350μm or less, 340μm or less, 330μm or less, 320μm or less, 310μm or less, 300μm or less, 290μm or less, 280μm or less, 270μm or less, 260μm or less, 250μm or less, 240μm or less, 230μm or less, 220μm or less, 210μm or less, 200μm or less, 190μm or less, 180μm or less , 170μm or less, 160μm or less, 150μm or less, 140μm or less, 130μm or less, 120μm or less, 110μm or less, 100μm or less, 90μm or less, 80μm or less, 70μm or less, 60μm or less, 50μm or less, 40μm or less, 30μm or less, 20μm or less, 10μm or less, 1μm or less, 950nm or less, 900nm or less, A diameter (or maximum cross dimension) of any one of 850 nm or less, 800 nm or less, 750 nm or less, 700 nm or less, 650 nm or less, 600 nm or less, 550 nm or less, 500 nm or less, 450 nm or less, 400 nm or less, 350 nm or less, 300 nm or less, 250 nm or less, 200 nm or less, 150 nm or less, 100 nm or less, or 50 nm or less.
[0141] In some embodiments, the nanoparticles of the nanosuspension have a D50 (also known as Dv(50) median diameter (or largest intersection dimension) or median of a particle size distribution) of about 250 μm to about 50 nm, such as any of about 100 μm to about 1 μm, about 50 μm to about 500 nm, about 400 nm to about 100 nm, or about 250 nm to about 100 nm. In some embodiments, the nanoparticles of the nanosuspension have a diameter of about 250 μm or less, such as about 240 μm or less, 230 μm or less, 220 μm or less, 210 μm or less, 200 μm or less, 190 μm or less, 180 μm or less, 170 μm or less, 160 μm or less, 150 μm or less, 140 μm or less, 130 μm or less, 120 μm or less, 110 μm or less, 100 μm or less, 90 μm or less, 80 μm or less, 70 μm or less, 60 μm or less, 50 μm or less, 40 μm or less. or less, a D50 of any of 30 μm or less, 20 μm or less, 10 μm or less, 1 μm or less, 950 nm or less, 900 nm or less, 850 nm or less, 800 nm or less, 750 nm or less, 700 nm or less, 650 nm or less, 600 nm or less, 550 nm or less, 500 nm or less, 450 nm or less, 400 nm or less, 350 nm or less, 300 nm or less, 250 nm or less, 200 nm or less, 150 nm or less, 100 nm or less, or 50 nm or less.
[0142] In some embodiments, the nanoparticles of the nanosuspension have a D90 (also referred to as Dv(90)) of about 250 μm to about 50 nm, such as any of 100 μm to about 1 μm, about 50 μm to about 500 nm, about 400 nm to about 100 nm, or about 250 nm to about 100 nm. In some embodiments, the nanoparticles of the nanosuspension have a diameter of about 250 μm or less, such as about 240 μm or less, 230 μm or less, 220 μm or less, 210 μm or less, 200 μm or less, 190 μm or less, 180 μm or less, 170 μm or less, 160 μm or less, 150 μm or less, 140 μm or less, 130 μm or less, 120 μm or less, 110 μm or less, 100 μm or less, 90 μm or less, 80 μm or less, 70 μm or less, 60 μm or less, 50 μm or less, 40 μm or less. or less, a D90 of any of 30 μm or less, 20 μm or less, 10 μm or less, 1 μm or less, 950 nm or less, 900 nm or less, 850 nm or less, 800 nm or less, 750 nm or less, 700 nm or less, 650 nm or less, 600 nm or less, 550 nm or less, 500 nm or less, 450 nm or less, 400 nm or less, 350 nm or less, 300 nm or less, 250 nm or less, 200 nm or less, 150 nm or less, 100 nm or less, or 50 nm or less.
[0143] In some embodiments, the diameter (or maximum intersection dimension) of the apertures of the droplet dispenser is at least about 20% larger than the diameter (or maximum intersection dimension) of the nanoparticles of the nanosuspension (e.g., the diameter (or maximum intersection dimension) of each nanoparticle in a plurality of nanoparticles), such as at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%, 300%, 350%, 400%, 450%, or 500% larger.
[0144] There are a variety of techniques known in the art for measuring particle characteristics (such as nanoparticle size). The description provided herein encompasses all techniques for evaluating the particle characteristics of the nanosuspensions described herein. In some embodiments, particle characteristics (such as size, for example, diameter or maximum cross dimension) are measured using dynamic light scattering (DLS). In some embodiments, particle characteristics (such as size, for example, diameter or maximum cross dimension) are measured using disk centrifugation. In some embodiments, particle characteristics (such as size, for example, diameter or maximum cross dimension) are measured using nanoparticle tracking analysis. In some embodiments, particle characteristics (such as size, for example, diameter or maximum cross dimension) are measured using adjustable resistive pulse sensing. In some embodiments, particle characteristics (such as size, for example, diameter or maximum cross dimension) are measured using atomic force microscopy. In some embodiments, particle characteristics (such as size, for example, diameter or maximum cross dimension) are measured using electron microscopy.
[0145] In some embodiments, hydrophobic agents are poorly soluble in water. In some embodiments, the drug has a solubility in a solvent (e.g., water) of about 1 mg / mL or less, such as about 750 μg / mL or less, 500 μg / mL or less, 250 μg / mL or less, 200 μg / mL or less, 150 μg / mL or less, 100 μg / mL or less, 50 μg / mL or less, 25 μg / mL or less, 1 μg / mL or less, 500 ng / mL or less or 100 ng / mL. In some embodiments, the solvent is an aqueous solvent, such as water, a bicarbonate buffer, a bio-related medium, or a solvent comprising a surfactant. In some embodiments, the hydrophobic agent is insoluble at the target concentration of the nanosuspension.
[0146] In some embodiments, the hydrophobic agent is slightly soluble, slightly soluble, very slightly soluble or almost insoluble (insoluble), as defined in the United States Pharmacopeia-National Formulary (USP-NF). In some embodiments, when the hydrophobic agent has a solubility between about 30 parts of solvent required for 1 part of solute to about 100 parts of solvent required for 1 part of solute, the hydrophobic agent is classified as slightly soluble. In some embodiments, when the hydrophobic agent has a solubility between about 100 parts of solvent required for 1 part of solute to about 1,000 parts of solvent required for 1 part of solute, the hydrophobic agent is classified as slightly soluble. In some embodiments, when the hydrophobic agent has a solubility between about 1,000 parts of solvent required for 1 part of solute to about 10,000 parts of solvent required for 1 part of solute, the hydrophobic agent is classified as slightly soluble. In some embodiments, when the hydrophobic agent has a solubility of about 10,000 parts of solvent required for 1 part of solute or more, the hydrophobic agent is classified as slightly soluble. In some embodiments, the solvent is an aqueous solvent, such as water, bicarbonate buffer, a biorelevant medium, or a solvent comprising a surfactant.
[0147] In some embodiments, the hydrophobic agent is a Biopharmaceutics Classification System (BCS) Class II drug. In some embodiments, the hydrophobic agent is a BCS Class IV drug.
[0148] In some embodiments, the hydrophobic agent is a drug, such as a therapeutic agent useful for treating and / or preventing a disorder.
[0149] In some embodiments, the hydrophobic agent comprises or is a small molecule drug. In some embodiments, the small molecule drug is a synthetic small molecule drug. In some embodiments, the small molecule drug has a molecular weight of about 1,500 Da or less, such as about 1,250 Da or less, 1,000 Da or less, 750 Da or less, or 500 Da or less. In some embodiments, the small molecule drug satisfies one or more of Lipinski's five rules (no more than 5 hydrogen bond donors (the total number of nitrogen-hydrogen bonds and oxygen-hydrogen bonds), no more than 10 hydrogen bond acceptors (all nitrogen atoms or oxygen atoms), a molecular weight of less than 500 Daltons, and an octanol-water partition coefficient
[10] (log P) of no more than 5).
[0150] In some embodiments, the hydrophobic agent comprises or is a biomolecule. In some embodiments, the biomolecule is a polypeptide, a lipid or a nucleic acid. In some embodiments, the polypeptide is an antibody or a fragment thereof, including an antibody-drug conjugate (ADC). In some embodiments, the polypeptide is a hormone. In some embodiments, the nucleic acid comprises RNA or DNA, including pDNA, siRNA, miRNA, mRNA and lnRNA.
[0151] In some embodiments, the hydrophobic agent has a narrow therapeutic index, e.g., a drug that requires an accurate dose for safety purposes. In some embodiments, the hydrophobic agent has a wide therapeutic index. In some embodiments, the hydrophobic agent is a high potency drug, e.g., a drug that requires a low dose (such as less than about 1 mg).
[0152] In some embodiments, the hydrophobic agent is a regulatory approved compound, such as a drug approved by the U.S. Food and Drug Administration for medical treatment. In some embodiments, the hydrophobic agent is a prodrug. In some embodiments, the hydrophobic agent is a novel agent. In some embodiments, the hydrophobic agent is a fermentation product, a semi-synthetic product, a radiopharmaceutical product, a biological product, a biotechnology derived product, an herbal product, or a crude product of animal or plant origin.
[0153] In some embodiments, the concentration of the hydrophobic agent in the nanosuspensions described herein is about 1 μg / mL to about 1,000 mg / mL, such as any of about 0.1 mg / mL to about 1,000 mg / mL, about 1 mg / mL to about 500 mg / mL, about 5 mg / mL to about 1,000 mg / mL, or about 5 mg / mL to about 1,000 mg / mL. In some embodiments, the concentration of the hydrophobic agent in the nanosuspension described herein is about 1,000 mg / mL or less, such as about any of 750 mg / mL or less, 500 mg / mL or less, 250 mg / mL or less, 200 mg / mL or less, 150 mg / mL or less, 100 mg / mL or less, 50 mg / mL or less, 40 mg / mL or less, 30 mg / mL or less, 20 mg / mL or less, 10 mg / mL or less, 1 mg / mL or less, 900 μg / mL or less, 800 μg / mL or less, 700 μg / mL or less, 600 μg / mL or less, 500 μg / mL or less, 400 μg / mL or less, 300 μg / mL or less, 200 μg / mL or less, 100 μg / mL or less, 50 μg / mL or less, or 1 μg / mL or less. In some embodiments, the concentration of the hydrophobic agent in the nanosuspensions described herein is at least about 1 μg / mL, such as at least about any of 50 μg / mL, 100 μg / mL, 200 μg / mL, 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, 700 μg / mL, 800 μg / mL, 900 μg / mL, 1 mg / mL, 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 100 mg / mL, 150 mg / mL, 200 mg / mL, 250 mg / mL, 500 mg / mL, 750 mg / mL, or 1,000 mg / mL.
[0154] In some embodiments, the nanoparticles containing the hydrophobic agent of the nanosuspension described herein are stable for at least about 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, or 72 hours. In some embodiments, the nanosuspension has a dispersion index of about 0.5 or less, such as about 0.4 or less, 0.3 or less, 0.2 or less, or 0.1 or less. In some embodiments, the nanosuspension has an Ostwald ripening of about 20% or less, such as 15% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less within about 12 hours. In some embodiments, the nanoparticles containing the hydrophobic agent of the nanosuspension have an aggregation of about 20% or less, such as any of 15% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less within about 12 hours.
[0155] In some embodiments, the nanoparticles containing hydrophobic agents of the nanosuspensions described herein are produced via a grinding technique. In some embodiments, the grinding technique is selected from the group consisting of a ball mill, a wet media mill, a dry media mill, a jet mill (such as a fluidized bed jet mill), and a grinder. In some embodiments, the nanoparticles containing hydrophobic agents of the nanosuspensions described herein are produced via a hydrodynamic cavitation technique. In some embodiments, the nanoparticles containing hydrophobic agents of the nanosuspensions described herein are produced via an acoustic technique.
[0156] C. Stabilizing components
[0157] In some embodiments, the nanosuspension comprises a stabilizing component. In some embodiments, the stabilizing component is suitable for stabilizing the hydrophobic agent-containing nanoparticles in the nanosuspension described herein.
[0158] In some embodiments, the stabilizing component comprises any one or more of PVP, SDS, HPC, HPMC, Pluronic (poloxamer), Tween (polysorbate) or Vit-E TPGS. In some embodiments, the stabilizing component comprises PVP and / or SDS.
[0159] In some embodiments, the amount of stabilizing component in the nanosuspensions described herein is at least about 0.1% w / w, such as at least about any of 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, or 10% w / w. In some embodiments, the amount of stabilizing component in the nanosuspension described herein is about 5% w / w or less, such as any of 4.5% w / w or less, 4.0% w / w or less, 3.5% w / w or less, 3.0% w / w or less, 2.5% w / w or less, 2.0% w / w or less, 1.5% w / w or less, 1.0% w / w or less, 0.9% w / w or less, 0.8% w / w or less, 0.7% w / w or less, 0.6% w / w or less, 0.5% w / w or less, 0.4% w / w or less, 0.3% w / w or less, 0.2% w / w or less, or 0.1% w / w or less.
[0160] In some embodiments, the amount of the stabilizing component in the nanosuspensions described herein is based on the weight ratio of the stabilizer component to the drug. In some embodiments, the weight ratio of the stabilizer component to the drug is about 1:100 to about 2:1.
[0161] In some embodiments, the weight ratio of the stabilizer component to the drug is at least about 1:100, such as at least about 2:100, 3:100, 4:100, 5:100, 6:100, 7:100, 8:100, 9:100, 10:100, 11:100, 12:100, 13:100, 14:100, 15:100, 16:100, 17:100, 18:100, 19:100, 20:100, 21:100, 22:100, 23:100. , 24:100, 25:100, 30:100, 35:100, 40:100, 45:100, 50:100, 55:100, 60:100, 65:100, 70:100, 75:100, 80:100, 85:100, 90:100, 95:100, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1 or 2:1.
[0162] In some embodiments, the amount of the stabilizing component in the nanosuspension described herein is based on the ratio of the stabilizer component to the carrier. In some embodiments, the ratio of the stabilizer component to the carrier is less than about 1:10, 1:50, 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, or 1:1000. In some embodiments, the ratio of the stabilizer component to the carrier is greater than about 1:10,000, 1:1000, or 1:500. In some embodiments, the ratio of the stabilizer component to the carrier is about 1:10, 1:50, 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, or 1:1000. In some embodiments, the ratio of the stabilizer component to the carrier is about 1:50 to about 1:500. In some embodiments, the ratio of stabilizer component to carrier is about 1:50 or about 1:500.
[0163] IV. Nanosuspension dispensing cartridges and compositions therein
[0164] In certain aspects, a dispensing cartridge is provided herein, comprising a nanosuspension described herein or a derivative or precursor thereof (or suitable for use therewith). The dispensing cartridge described herein is generally suitable for containing one or more nanosuspensions described herein, such as in a reservoir of the dispensing cartridge, and is configured to engage with a dispensing head of a droplet dispenser so that the nanosuspension can be delivered to the dispensing head. In some embodiments, the dispensing cartridge is a disposable cartridge. In some embodiments, the dispensing cartridge is suitable for disposable or time-limited use.
[0165] In some embodiments, the dispensing cartridge comprises a material suitable for use with the nanosuspensions described herein. In some embodiments, the dispensing cartridge comprises a material suitable for use in pharmaceutical applications, for example, the material does not dissolve or leach its components in the presence of the nanosuspension.
[0166] In some embodiments, the dispensing cartridge includes a reservoir configured to hold a nanosuspension described herein. In some embodiments, the dispensing cartridge includes more than one reservoir configured to hold a nanosuspension described herein. In embodiments of the dispensing cartridge having more than one reservoir, in some cases, the dispensing cartridge includes any one or more of the following: (i) a first nanosuspension comprising a hydrophobic agent and a second nanosuspension comprising another agent (such as a hydrophobic agent); (ii) a first nanosuspension comprising a hydrophobic agent and a second nanosuspension comprising a hydrophobic agent, for example, wherein the hydrophobic agent is at different concentrations in the first nanosuspension and the second nanosuspension and / or the first nanosuspension and the second nanosuspension comprise different non-drug components or concentrations thereof; and (iii) a first nanosuspension comprising a hydrophobic agent and a second solution comprising a material useful in embodiments described herein, wherein the material is not a nanosuspension described herein. In some embodiments, a dispensing cartridge is provided that includes a material useful in embodiments described herein, wherein the material is not a nanosuspension described herein. For example, in some embodiments, the dispensing cartridge includes a fluid suitable for deposition on a substrate, such as to convey the characteristics or identity (including a unique identity) of the dosage form via a logo and / or label. In some embodiments, the label is a machine-readable label, such as a QR code or a barcode. Also disclosed herein is a kit comprising one or more dispensing cartridges described herein.
[0167] In some embodiments, the dispensing cartridge includes a reservoir, such as to contain a volume of a nanosuspension as described herein. In some embodiments, the dispensing cartridge includes a reservoir port, such as to facilitate the flow of material into or out of the reservoir. In some embodiments, the dispensing cartridge includes a sponge material. In some embodiments, the sponge material is in the reservoir. In some embodiments, the dispensing cartridge includes a dispensing head interface configured to enable the nanosuspension to be transferred from the reservoir to the dispensing head of the droplet dispenser.
[0168] In some embodiments, a composition is provided herein, which comprises a form of a nanosuspension (including derivatives or precursors thereof). In some embodiments, the form of the nanosuspension is a frozen form, a dried form, or a lyophilized form of the nanosuspension. In some embodiments, the form of the nanosuspension can be processed to produce a nanosuspension as described herein, such as via reconstruction. In some embodiments, the composition is contained in a dispensing cartridge.
[0169] V. Nanosuspension Dosage Form
[0170] In certain aspects, provided herein is a dosage form comprising a patterned layer comprising a plurality of nanoparticles comprising a hydrophobic agent. In some embodiments, the dosage form comprises: a film substrate; and a patterned layer comprising a plurality of nanoparticles, wherein the nanoparticles comprise a hydrophobic agent.
[0171] In some embodiments, the dosage form is an oral dosage form (including oral pharmaceutical dosage forms, such as capsules comprising a film substrate (e.g., a rolled and / or folded film substrate)). In some embodiments, the dosage form is an intraoral dosage form. In some embodiments, the dosage form is a buccal dosage form. In some embodiments, the dosage form is a sublingual dosage form. In some embodiments, the dosage form is a vaginal dosage form. In some embodiments, the dosage form is a rectal dosage form. In some embodiments, the dosage form is an ophthalmic dosage form. In some embodiments, the dosage form comprises the following components, which are derived from the deposition of the nanosuspension using the methods provided herein. In some embodiments, the film substrate is suitable for human consumption. In some embodiments, the dosage form is suitable for contact-based delivery of hydrophobic agents, such as transdermal dosage forms. In some embodiments, the dosage form is an ophthalmic dosage form. In some embodiments, the film substrate comprises a polymer (e.g., the film substrate is a polymer film). In some embodiments, the film substrate comprises one or more of chitosan, ethylenediaminetetraacetic acid, polyvinyl pyrrolidone, polyvinyl alcohol, alginate, agar, carrageenan, guar gum, xanthan gum, polycarbophil, and a polyacrylic acid derivative.
[0172] The dosage forms described herein may have a patterned layer of any shape and / or size. In some embodiments, the features of the patterned layer are based on the amount of the hydrophobic agent of the dosage form. For example, such features of the patterned layer may be based on the hydrophobic agent concentration of the nanosuspension and the total desired amount of the hydrophobic agent to be deposited on the film substrate. In some embodiments, the features of the patterned layer (such as any one of the shape, size, and position on the dosage form) are based on the desired release curve of the hydrophobic agent (for example, the patterned layer can be designed to increase the surface area of the body fluid) and / or the features of the final dosage form (for example, the structural integrity and / or protection of the patterned layer). In some embodiments, the term "layer" should not be interpreted as meaning only a single deposition from a droplet dispenser described herein. In some embodiments, the patterned layer is formed by many instances of droplet deposition from a droplet dispenser described herein (for example, using a nanosuspension described herein to repeatedly print an area). For example, when producing a dosage form comprising a patterned layer, the droplet dispenser may be controlled to pass through once or multiple times to deposit droplets of the nanosuspension to form a final patterned layer.
[0173] In some embodiments, the patterned layer is produced via a droplet dispenser that deposits the nanosuspension at any of about 1 dot per inch (dpi) to about 1,000 dpi, such as about 1 dpi to about 720 dpi, about 72 dpi to about 720 dpi, about 72 dpi to about 500 dpi, or about 72 dpi to about 300 dpi. In some embodiments, the patterned layer is produced via a droplet dispenser that deposits a nanosuspension at about 1 dpi or greater, such as about 20 dpi or greater, 50 dpi or greater, 72 dpi or greater, 100 dpi or greater, 120 dpi or greater, 150 dpi or greater, 200 dpi or greater, 250 dpi or greater, 300 dpi or greater, 350 dpi or greater, 400 dpi or greater, 450 dpi or greater, 500 dpi or greater, 550 dpi or greater, 600 dpi or greater, 650 dpi or greater, 700 dpi or greater, 720 dpi or greater, 750 dpi or greater, 800 dpi or greater, 850 dpi or greater, 900 dpi or greater, 950 dpi or greater, or 1,000 dpi or greater. In some embodiments, the patterned layer comprises a nanosuspension deposited at about 1 dot per inch (dpi) to about 1,000 dpi, such as any of about 1 dpi to about 720 dpi, about 72 dpi to about 720 dpi, about 72 dpi to about 500 dpi, or about 72 dpi to about 300 dpi. In some embodiments, the patterned layer comprises a nanosuspension deposited at about 1 dpi or greater, such as about 20 dpi or greater, 50 dpi or greater, 72 dpi or greater, 100 dpi or greater, 120 dpi or greater, 150 dpi or greater, 200 dpi or greater, 250 dpi or greater, 300 dpi or greater, 350 dpi or greater, 400 dpi or greater, 450 dpi or greater, 500 dpi or greater, 550 dpi or greater, 600 dpi or greater, 650 dpi or greater, 700 dpi or greater, 720 dpi or greater, 750 dpi or greater, 800 dpi or greater, 850 dpi or greater, 900 dpi or greater, 950 dpi or greater, or 1,000 dpi or greater.
[0174] In some embodiments, the deposited droplets of the nanosuspension have a diameter (or maximum cross dimension) of about 1 nm to about 200 μm, such as any of about 20 nm to about 800 nm, about 100 nm to about 500 nm, or about 10 μm to about 100 μm. In some embodiments, the deposited droplets of the nanosuspension have a diameter of at least about 1 nm, such as at least about 10 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm, 200 nm, 210 nm, 220 nm, 230 nm, 240 nm, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, 300 nm, 310 nm, 320 nm, 330 nm, 340 nm, 350 nm, 360 nm, 370 nm, 380 nm, 390 nm, 400 nm, 410 nm, 0nm, 420nm, 430nm, 440nm, 450nm, 460nm, 470nm, 480nm, 490nm, 500nm, 525nm, 550nm, 575nm, 600nm, 625nm, 650nm, 675nm, 700nm, 725nm, 750nm, 775nm, 800nm, 825nm, 850nm, 875nm, 900nm, 925nm, 950nm, 975nm, 1μm, 5μm, 10μm, 15μm, 20μm, 25μm, 30μm, 35μm, 40μm, 45μm, 50μm, 60μm, 70μm, 80μm, 90μm or 100μm. In some embodiments, the average of a population of droplets (such as a patterned layer) described herein meets the criteria discussed above.
[0175] In some embodiments, the patterned layer is at least partially within the film substrate (e.g., at least a portion of the nanosuspension described herein penetrates and / or is absorbed into the film substrate). In some embodiments, the patterned layer is at least partially on top of the film substrate (e.g., at least a portion of the nanosuspension described herein is at or above the surface of the film substrate). In some embodiments, the patterned layer is at least partially within the film substrate and at least partially on top of the film substrate.
[0176] In some embodiments, the dosage form comprises more than one patterned layer, for example, a first patterned layer and a second patterned layer. In some embodiments, the first patterned layer comprises nanoparticles comprising a hydrophobic agent, and the second patterned layer comprises another agent. In some embodiments, the first patterned layer comprises nanoparticles comprising a hydrophobic agent, and the second patterned layer comprises nanoparticles comprising a hydrophobic agent. In some embodiments, the first patterned layer comprises nanoparticles comprising a hydrophobic agent, and the second patterned layer comprises nanoparticles comprising a second hydrophobic agent. In some embodiments, each patterned layer is produced via a layer-by-layer deposition technique.
[0177] In some embodiments, the dosage form comprises a hydrophobic agent in an amount of about 1 ng to about 1 mg, such as about 100 ng to about 500 ng, about 250 ng to about 750 ng, about 500 ng to about 1 μg, about 750 ng to about 1.25 μg, about 1 μg to about 2 μg, about 1 μg to about 10 μg, about 10 μg to about 50 μg, or about 25 μg to about 100 μg.
[0178] In some embodiments, the dosage form comprises at least about 1 ng, such as at least about 5 ng, 10 ng, 20 ng, 30 ng, 40 ng, 50 ng, 60 ng, 70 ng, 80 ng, 90 ng, 100 ng, 125 ng, 150 ng, 175 ng, 200 ng, 225 ng, 250 ng, 275 ng, 300 ng, 325 ng, 350 ng, 375 ng, 400 ng, 425 ng, 450 ng, 475 ng, 500 ng, 525 ng, 550 ng, 575 ng, 600 ng, 625 ng, 650 ng, 675 ng. , 700ng, 725ng, 750ng, 775ng, 800ng, 825ng, 850ng, 875ng, 900ng, 925ng, 950ng, 975ng, 1μg, 2μg, 3μg, 4μg, 5μg, 6μg, 7μg, 8μg, 9μg, 10μg, 15μg, 20μg, 25μg, 30μg, 35μg, 40μg, 45μg, 50μg, 55μg, 60μg, 65μg, 70μg, 75μg, 80μg, 85μg, 90μg, 95μg or 100μg of a hydrophobic agent.
[0179] In some embodiments, the dosage form further comprises a mark and / or label. For example, in certain embodiments, the dosage form may contain printed information related to any one or more of the following: active agent, amount of active agent, date of manufacture, individual (for which the dosage form is manufactured), production site, traceable identification code, expiration date, instructions for use, storage instructions, or company name and / or logo. In some embodiments, the mark and / or label is suitable for consumption, for example, comprises a food safe dye.
[0180] In some embodiments, the dosage form comprises a protective coating, e.g., applied over the patterned layer. In some embodiments, the protective coating is applied to the dosage form via a droplet dispenser, such as a sub-nanoliter droplet dispenser or a high frequency sub-nanoliter droplet dispenser. In some embodiments, the dosage form comprises a film coating.
[0181] In some embodiments, the dosage form is suitable for human use and / or consumption. In some embodiments, the dosage form is sterile.
[0182] In some embodiments, the dosage form is produced according to any of the methods described herein. For example, in some embodiments, a dosage form produced by dispensing a patterned layer of a nanosuspension (the nanosuspension comprising a plurality of nanoparticles containing a hydrophobic agent) onto a substrate via a droplet dispenser (such as a sub-nanoliter droplet dispenser or a high-frequency sub-nanoliter droplet dispenser) is provided.
[0183] In certain aspects, provided herein is a batch of dosage forms described herein. In some embodiments, the batch of dosage forms comprises at least 5 dosage forms, such as any of 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 dosage forms. In some embodiments, the batch of pharmaceutical dosage forms comprises a single dosage form having an amount of a hydrophobic agent that varies by no more than 5% relative to the mean.
[0184] VI. Devices for dispensing the nanosuspensions described herein
[0185] In certain aspects, provided herein are devices for distributing and depositing droplets of nanosuspensions described herein. In some embodiments, the device comprises a sub-nanoliter droplet dispenser. In some embodiments, the device comprises a high-frequency sub-nanoliter droplet dispenser. Sub-nanoliter droplet dispensers (including sub-nanoliter high-frequency droplet dispensers) are known in the art, including as described in U.S. Patent Nos. 7,585,038, 7,963,635, and 6,851,786, which are incorporated herein by reference in their entirety.
[0186] In some embodiments, a droplet dispenser for producing a dosage form (such as a sub-nanoliter droplet dispenser or a high-frequency sub-nanoliter droplet dispenser) is provided, the dispenser comprising: (a) a dispensing head operably connected to a reservoir for a nanosuspension; and (b) a control system configured to control the deposition of the nanosuspension via the dispensing head. In some embodiments, a droplet dispenser for producing a dosage form (such as a sub-nanoliter droplet dispenser or a high-frequency sub-nanoliter droplet dispenser) is provided, the dispenser comprising: (a) a dispensing head; (b) a nanosuspension dispensing cartridge receiving space, wherein the nanosuspension dispensing cartridge receiving space is configured to operably connect the nanosuspension dispensing cartridge to the dispensing head; and (c) a control system configured to control the deposition of the nanosuspension via the dispensing head according to a dispensing mode. In some embodiments, a droplet dispenser (such as a sub-nanoliter droplet dispenser or a high-frequency sub-nanoliter droplet dispenser) for producing a dosage form is provided, the dispenser comprising: (a) a dispensing head; (b) a nanosuspension dispensing cartridge comprising a nanosuspension comprising a hydrophobic agent, wherein the nanosuspension dispensing cartridge is operably coupled to the dispensing head, wherein the nanosuspension comprises an aqueous carrier and a plurality of nanoparticles, wherein each of the plurality of nanoparticles comprises a hydrophobic agent; and (c) a control system configured to deposit the nanosuspension via the dispensing head according to a dispensing mode. In some embodiments, the viscosity of the nanosuspension is less than 2 cP, such as between about 1 cP and less than 2 cP or between 1.8 cP and about 1.2 cP.
[0187] In some embodiments, the dispensing head comprises about 10 to about 1000 individual nozzles. In some embodiments, the dispensing head comprises at least about 10, such as at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1,000 individual nozzles.
[0188] In some embodiments, each nozzle of the dispensing head has an aperture (from which the nanosuspension is dispensed) having a maximum cross-section (such as a diameter) of about 20 μm to about 120 μm, such as about 20 μm to about 70 μm or about 30 μm to about 60 μm. In some embodiments, the nozzle of the dispensing head has an aperture having a maximum cross-section (such as a diameter) of at least about 20 μm, such as at least about any of 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 75 μm, 100 μm, or 120 μm.
[0189] In some embodiments, each nozzle of the dispensing head is configured to dispense droplets of the nanosuspension having a volume of about 1 pL to about 500 pL (pL). In some embodiments, the nozzles of the dispensing head are configured to dispense droplets of the nanosuspension having a volume of about 500 pL or less, such as about 450 pL or less, 400 pL or less, 350 pL or less, 300 pL or less, 250 pL or less, 200 pL or less, 150 pL or less, 100 pL or less, 75 pL or less, 50 pL or less, or 25 pL or less.
[0190] In some embodiments, the dispensing head is a continuous dispensing head. In some embodiments, the dispensing head is a drop-on-demand print head. In some embodiments, the dispensing head is a thermal inkjet print head. In some embodiments, the dispensing head is a piezoelectric inkjet print head. In some embodiments, the dispensing head is a solenoid valve print head. In some embodiments, the dispensing head is an electrostatic print head. In some embodiments, the dispensing head is an acoustic print head.
[0191] In some embodiments, the dispensing head is a sub-nanoliter dispensing head. In some embodiments, the dispensing head is a high frequency sub-nanoliter dispensing head (e.g., a dispensing head operating at a jetting frequency greater than 2,000 Hz, such as greater than about 2.5 kHz, 3 kHz, 3.5 kHz, 4 kHz, 4.5 kHz, or 5 kHz).
[0192] In some embodiments, the dispensing device includes more than one dispensing head. In some embodiments, the dispensing device further includes a second dispensing head operably coupled to a second dispensing cartridge. In some embodiments, the dispensing device further includes a third dispensing head operably coupled to a third dispensing cartridge. In some embodiments, the dispensing device further includes a fourth dispensing head operably coupled to a fourth dispensing cartridge. In a configuration including more than one dispensing head, the dispensing device is configured to be operably coupled to a dispensing cartridge comprising any kind of material, such as a nanosuspension, a protective coating, and a label material and / or a marking material (such as an edible ink).
[0193] VII. Systems and Applications Incorporating Nanosuspension Embodiments Described Herein
[0194] In certain aspects, provided herein are systems and applications utilizing methods of preparing dosage forms described herein, and features associated therewith. In some embodiments, a system is provided comprising a dispensing device configured to receive instructions for printing dosage forms described herein. In some embodiments, the system is established at a point of care, such as in a hospital, a care facility, a pharmacy, or a home. In some embodiments, the dosage form is a personalized dosage form, for example, designed for an individual based on dosage form characteristics, such as the amount of a hydrophobic agent.
[0195] In some embodiments, the methods and dispensing devices described herein are suitable for personalized medicine. In some embodiments, the methods and dispensing devices described herein are suitable for point-of-care applications. In some embodiments, the methods and dispensing devices described herein are suitable for rapid dosage form production (including small-scale production, such as less than 100 dosage forms). In some embodiments, the methods and dispensing devices described herein are suitable for producing dosage forms with precise and accurate amounts of hydrophobic agents (such as those required for hydrophobic agents with narrow therapeutic index, high efficacy and / or pediatric use). In some embodiments, the methods and dispensing devices described herein are suitable for producing dosage forms with hydrophobic agents with poor stability (such as unstable for a long time after production, for example, greater than 24 hours). In some embodiments, the methods and dispensing devices described herein are suitable for non-pharmacological applications, such as nutritional products.
[0196] VIII. ASD forming solution and its precursor solution
[0197] In certain aspects, provided herein are amorphous solid dispersion (ASD) forming solutions and precursor solutions thereof. Such ASD forming solutions and precursor solutions thereof can be used to form ASD and / or study and identify conditions that lead to (or do not lead to) the formation of ASD containing an agent that is easy to crystallize (such as a hydrophobic agent). As taught herein, the ASD forming solution (including its components and precursors) can be distributed and deposited in a variety of ways. In some embodiments, an ASD forming solution in the form of a single solution is distributed from a droplet dispenser. In some embodiments, an ASD forming solution is distributed from two or more droplet dispensers, wherein an ASD forming solution is formed after being distributed from two or more droplet dispensers (e.g., precursor solutions from two or more droplet dispensers are mixed before and / or on a substrate to form an ASD forming solution and / or ASD). In some embodiments, the ASD forming solution is in the form of a single solution. In some embodiments, the precursor solutions described herein are combined to form an ASD forming solution. For example, the ASD forming solution can be formed from two precursor solutions, such as a first precursor solution containing at least one component of the ASD forming solution (e.g., a pharmaceutical agent that is easily crystallized, such as a hydrophobic agent) and a second precursor solution containing at least one component of the ASD forming solution (e.g., a polymer). In some embodiments, the ASD forming solution is formulated so that when and / or after the precursor solution is dispensed and / or deposited, the ADS forming solution will produce an ASD containing a pharmaceutical agent that is easily crystallized (such as a hydrophobic agent). In certain aspects described herein, one or more precursor solutions do not form an ASD under deposition conditions (e.g., at a deposition ratio between the pharmaceutical agent and the polymer). Without being bound by theory, the ASD converts crystalline drug materials into amorphous materials, which increases their solubility and thus enhances absorption.
[0198] In some aspects, the ASD forming solution provided herein comprises an organic carrier, a polymer, and an agent that is easy to crystallize (such as a hydrophobic agent), and a precursor solution comprising at least one component of the ASD forming solution. As discussed herein, various aspects of the ASD forming solution and its precursor solution are described in a modular manner in the chapters provided herein, and it will be readily understood that the ASD forming solution and its precursor solution cover the embodiments described herein and any combination thereof. Such modular descriptions are not intended to limit the scope of the present disclosure, and based on the teachings provided herein, it will be readily understood by those of ordinary skill in the art that certain modules may be at least partially integrated. The section titles used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0199] A. Organic carrier
[0200] In some aspects, provided herein is an ASD forming solution or a precursor solution thereof comprising an organic carrier. In some embodiments, the organic carrier improves the solubility of an agent that is susceptible to crystallization (such as a hydrophobic agent), and / or improves carrier evaporation during the deposition process of a droplet dispenser. In some embodiments, the precursor solution does not comprise an organic carrier, for example, a precursor solution comprising a component that is compatible with an aqueous carrier.
[0201] In some embodiments, the organic carrier of the ASD forming solution comprises any one or more of acetone, dimethylformamide, ethanol, methanol, pentane, hexane, heptane, ethyl acetate, isopropanol, ethylene glycol, and dimethyl sulfoxide, or a combination thereof.
[0202] In some embodiments, the ASD forming solution or a precursor solution thereof comprises at least about 30% by volume of an organic carrier, such as at least about 35% by volume of an organic carrier, 40% by volume of an organic carrier, 45% by volume of an organic carrier, 50% by volume of an organic carrier, 55% by volume of an organic carrier, 60% by volume of an organic carrier, 65% by volume of an organic carrier, 70% by volume of an organic carrier, 75% by volume of an organic carrier, 80% by volume of an organic carrier, 85% by volume of an organic carrier, 90% by volume of an organic carrier, 95% by volume of an organic carrier, or any of 100% by volume of an organic carrier.
[0203] In some embodiments, the organic vehicle comprises water. In some embodiments, the organic vehicle comprises less than 30% water by volume, less than 20% water by volume, less than 10% water by volume, less than 5% water by volume, less than 2% water by volume, less than 1% water by volume, or less than 0.5% water by volume. In some embodiments, the organic vehicle does not contain any water. In some embodiments, the organic vehicle contains only trace amounts of water.
[0204] In some embodiments, the ASD forming solution or its precursor solution may include an aqueous carrier and a solubilizing agent. In such cases, the aqueous carrier replaces the organic carrier in the ASD forming solution or its precursor solution. The aqueous carrier may replace the organic carrier in any of the embodiments presented herein. In some embodiments, the solubilizing agent is selected from the group consisting of a surfactant, an emulsifier, polyethylene glycol, propylene glycol, polysorbate, cyclodextrin or a metal chelator (e.g., ethylenediaminetetraacetic acid).
[0205] B. Polymer
[0206] In some aspects, provided herein is an ASD forming solution or a precursor solution thereof, comprising a polymer suitable for forming an ASD with an agent that is susceptible to crystallization, such as a hydrophobic agent. In general, the polymer at certain concentrations or ratios inhibits the formation of a crystalline form of the agent relative to the agent that is susceptible to crystallization. In some embodiments, the precursor solution does not comprise a polymer, for example, the polymer is contained in another precursor solution.
[0207] In some embodiments, the polymer of the ASD forming solution is suitable for forming an amorphous solid dispersion (ASD) after deposition by a droplet dispenser. In some embodiments, the polymer adjusts the viscosity of the ASD forming solution or a precursor solution thereof.
[0208] In some embodiments, the polymer is selected based on one or more characteristics of an agent that is prone to crystallization, such as a hydrophobic agent. In some embodiments, the polymer is selected based on its interaction with an agent that is prone to crystallization, such as a hydrophobic agent. For example, in some embodiments, the interaction between the polymer and the agent includes one or more of van der Waals forces, ionic interactions, or hydrogen bonds.
[0209] In some embodiments, the polymer is selected from the group consisting of cellulose derivatives, poly(vinyl pyrrolidone) (PVP), poly(vinyl pyrrolidone-co-vinyl acetate) (copolyvidone or PVPVA), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose or HPMC), and HPMC acetate succinate (hydroxypropyl methylcellulose acetate succinate or HPMC-AS), and acrylic resin (eudragit), or any combination thereof. In some embodiments, the polymer is a grade selected from the group consisting of LF, MF, HF, LMP, MMP, HMP, LG, MG, and HG.
[0210] In some embodiments, the polymer is HPMC-AS-LF.
[0211] In some embodiments, the weight ratio of the polymer to the easily crystallizable pharmaceutical agent (such as a hydrophobic agent) in the ASD-forming solution is 1:20 to 20: 1, such as 1:20 to any one of 1:15, 1:10, 1:5, 1:2, 1:1, 2:1, 5:1, 10:1, 15:1, or 20: 1. In some embodiments, the weight ratio is 1:15 to any one of 1:10, 1:5, 1:2, 1:1, 2:1, 5:1, 10:1, 15:1, or 20: 1. In some embodiments, the weight ratio is 1:10 to any one of 1:5, 1:2, 1:1, 2:1, 5:1, 10:1, 15:1, or 20:1. In some embodiments, the weight ratio is any one of 1:5 to any one of the following: 1:2, 1:1, 2:1, 5:1, 10:1, 15:1, or 20:1. In some embodiments, the weight ratio is 1:2 to any one of the following: 1:1, 2:1, 5:1, 10:1, 15:1, or 20:1. In some embodiments, the weight ratio is 1:1 to any one of the following: 2:1, 5:1, 10:1, 15:1, or 20:1. In some embodiments, the weight ratio is 2:1 to 5:1, 10:1, 15:1, or 20:1. In some embodiments, the weight ratio is 5:1 to any one of the following: 10:1, 15:1, or 20:1. In some embodiments, the weight ratio is 10:1 to 15:1 or 20:1. In some embodiments, the weight ratio is 15:1 to 20:1.
[0212] In some embodiments, the weight ratio of the concentration of the polymer to the concentration of the easily crystallizable agent (such as a hydrophobic agent) in the ASD-forming solution is 1:2 to 2:1.
[0213] In some embodiments, the polymer loading of the ASD forming solution or its precursor solution is about 1% to about 99% (w / w), such as about 5% to about 15%, about 15% to about 25%, about 25% to about 25%, about 35% to about 45%, about 45% to about 55%, about 55% to about 65%, about 65% to about 75%, about 75% to about 85%, or about 85% to about 95%. In some embodiments, the polymer loading of the ASD forming solution or its precursor solution is about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
[0214] C. Drugs that are prone to crystallization
[0215] The ASD forming solution described herein comprises one or more medicaments that are easy to crystallize, such as a hydrophobic agent comprising a hydrophobic drug. In some embodiments, the medicament is easy to crystallize during the processing and / or production of the dosage form (e.g., spray drying and / or deposition via a droplet dispenser as described herein). In some embodiments, the medicament is easy to crystallize at a desired concentration in a final product (such as a pharmaceutical dosage form) as described herein. The techniques for measuring crystallization are well known in the art, for example, imaging, such as microscopy and polarizing microscopy, Raman spectroscopy, and differential scanning calorimetry. In some embodiments, crystallization is assessed when ASD is produced (such as after the ASD is deposited to form a solution according to the methods described herein). In some embodiments, crystallization is assessed after a period of time after the ASD is produced (such as about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 3 months, 6 months, 9 months, or 1 year after the ASD is produced). In some embodiments, the ASD is kept at a temperature above room temperature (such as at or above 37°C) for a period of time.
[0216] In some embodiments, the medicament that is easy to crystallize is a hydrophobic agent. In some embodiments, the hydrophobic agent is poorly soluble in water. In some embodiments, the hydrophobic agent has a solubility in a solvent (e.g., pure water) of about 1 mg / mL or less, such as about 750 μg / mL or less, 500 μg / mL or less, 250 μg / mL or less, 200 μg / mL or less, 150 μg / mL or less, 100 μg / mL or less, 50 μg / mL or less, 25 μg / mL or less, 1 μg / mL or less, 500 ng / mL or less or 100 ng / mL. In some embodiments, the solvent used to assess solubility is an aqueous solvent, such as water, bicarbonate buffer, a bio-related medium, or a solvent comprising a surfactant. In some embodiments, the hydrophobic agent is insoluble at the target concentration of the ASD forming solution.
[0217] In some embodiments, the hydrophobic agent is slightly soluble, slightly soluble, very slightly soluble or almost insoluble (insoluble), as defined in the United States Pharmacopeia-National Formulary (USP-NF). In some embodiments, when the hydrophobic agent has a solubility between about 30 parts of solvent required for 1 part of solute to about 100 parts of solvent required for 1 part of solute, the hydrophobic agent is classified as slightly soluble. In some embodiments, when the hydrophobic agent has a solubility between about 100 parts of solvent required for 1 part of solute to about 1,000 parts of solvent required for 1 part of solute, the hydrophobic agent is classified as slightly soluble. In some embodiments, when the hydrophobic agent has a solubility between about 1,000 parts of solvent required for 1 part of solute to about 10,000 parts of solvent required for 1 part of solute, the hydrophobic agent is classified as slightly soluble. In some embodiments, when the hydrophobic agent has a solubility of about 10,000 parts of solvent required for 1 part of solute or more, the hydrophobic agent is classified as slightly soluble. In some embodiments, the solvent is an aqueous solvent, such as water, bicarbonate buffer, a biorelevant medium, or a solvent comprising a surfactant.
[0218] In some embodiments, the hydrophobic agent is a Biopharmaceutics Classification System (BCS) Class II drug. In some embodiments, the hydrophobic agent is a BCS Class IV drug.
[0219] In some embodiments, the hydrophobic agent is a drug, such as a therapeutic agent useful for treating and / or preventing a disorder.
[0220] In some embodiments, the hydrophobic agent comprises or is a small molecule drug. In some embodiments, the small molecule drug is a synthetic small molecule drug. In some embodiments, the small molecule drug has a molecular weight of about 1,500 Da or less, such as about 1,250 Da or less, 1,000 Da or less, 750 Da or less, or 500 Da or less. In some embodiments, the small molecule drug satisfies one or more of Lipinski's five rules (no more than 5 hydrogen bond donors (the total number of nitrogen-hydrogen bonds and oxygen-hydrogen bonds), no more than 10 hydrogen bond acceptors (all nitrogen atoms or oxygen atoms), a molecular weight of less than 500 Daltons, and an octanol-water partition coefficient
[10] (log P) of no more than 5).
[0221] In some embodiments, the hydrophobic agent comprises or is a biomolecule. In some embodiments, the biomolecule is a polypeptide, a lipid or a nucleic acid. In some embodiments, the polypeptide is an antibody or a fragment thereof, including an antibody-drug conjugate (ADC). In some embodiments, the polypeptide is a hormone. In some embodiments, the nucleic acid comprises RNA or DNA, including pDNA, siRNA, miRNA, mRNA and lnRNA.
[0222] In some embodiments, the hydrophobic agent has a narrow therapeutic index, e.g., a drug that requires an accurate dose for safety purposes. In some embodiments, the hydrophobic agent has a wide therapeutic index. In some embodiments, the hydrophobic agent is a high potency drug, e.g., a drug that requires a low dose (such as less than about 1 mg).
[0223] In some embodiments, the hydrophobic agent is a regulatory approved compound, such as a drug approved by the U.S. Food and Drug Administration for medical treatment. In some embodiments, the hydrophobic agent is a prodrug. In some embodiments, the hydrophobic agent is a novel agent. In some embodiments, the hydrophobic agent is a fermentation product, a semi-synthetic product, a radiopharmaceutical product, a biological product, a biotechnology derived product, an herbal product, or a crude product of animal or plant origin.
[0224] In some embodiments, the concentration of the hydrophobic agent in the ASD-forming solution or a precursor thereof described herein is from about 1 μg / mL to about 1,000 mg / mL, such as any of from about 0.1 mg / mL to about 1,000 mg / mL, from about 1 mg / mL to about 500 mg / mL, from about 5 mg / mL to about 1,000 mg / mL, or from about 5 mg / mL to about 1,000 mg / mL. In some embodiments, the concentration of the hydrophobic agent in the ASD-forming solution or a precursor thereof described herein is about 1,000 mg / mL or less, such as about any of 750 mg / mL or less, 500 mg / mL or less, 250 mg / mL or less, 200 mg / mL or less, 150 mg / mL or less, 100 mg / mL or less, 50 mg / mL or less, 40 mg / mL or less, 30 mg / mL or less, 20 mg / mL or less, 10 mg / mL or less, 1 mg / mL or less, 900 μg / mL or less, 800 μg / mL or less, 700 μg / mL or less, 600 μg / mL or less, 500 μg / mL or less, 400 μg / mL or less, 300 μg / mL or less, 200 μg / mL or less, 100 μg / mL or less, 50 μg / mL or less, or 1 μg / mL or less. In some embodiments, the concentration of the hydrophobic agent in the ASD-forming solution or a precursor solution thereof described herein is at least about 1 μg / mL, such as at least about any of 50 μg / mL, 100 μg / mL, 200 μg / mL, 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, 700 μg / mL, 800 μg / mL, 900 μg / mL, 1 mg / mL, 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 100 mg / mL, 150 mg / mL, 200 mg / mL, 250 mg / mL, 500 mg / mL, 750 mg / mL, or 1,000 mg / mL.
[0225] In some embodiments, the loading of the ASD forming solution or a precursor solution thereof with a pharmaceutical agent that is susceptible to crystallization, such as a hydrophobic agent, is about 1% to about 99% (w / w), such as about 5% to about 15%, about 15% to about 25%, about 25% to about 25%, about 35% to about 45%, about 45% to about 55%, about 55% to about 65%, about 65% to about 75%, about 75% to about 85%, or about 85% to about 95%. In some embodiments, the loading of the ASD forming solution or a precursor solution thereof with a pharmaceutical agent is about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
[0226] The ASD forming solutions described herein can prevent one or more pharmaceutical agents susceptible to crystallization from crystallizing indefinitely or for a limited period of time. In some embodiments, the ASD forming solution forms an ASD wherein the pharmaceutical agent susceptible to crystallization never crystallizes.
[0227] D. Viscosity and Viscosity Modifiers
[0228] The ASD forming solutions and their precursor solutions provided herein have a viscosity that makes the solutions suitable for use in the embodiments described herein, which include methods of preparing dosage forms and droplet dispensers. In some embodiments, the viscosity of the solutions provided herein (e.g., ASD forming solutions or their precursor solutions, such as solutions that are dispensed to form ASD forming solutions) is such that it can be dispensed with a droplet dispenser (e.g., a sub-nanoliter droplet dispenser or a high-frequency sub-nanoliter droplet dispenser). In some embodiments, the viscosity of the ASD forming solutions or their precursor solutions provided herein is such that it does not leak from the dispensing cartridges or droplet dispensers described herein.
[0229] In some embodiments, the viscosity of the ASD forming solution or its precursor solution is about 0.5 cP to about 5 cP, such as about 0.5 cP to about 3 cp, about 0.5 cP to about 2.5 cP, about 1 cP to about 2.5 cP, about 1.5 cP to about 2.5 cP, about 1 cp to about 2 cp, or about 1.2 cP to about 1.8 cP. In some embodiments, the viscosity of the ASD forming solution or its precursor solution is less than about 5 cP, such as less than about 4.9 cP, 4.8 cP, 4.7 cP, 4.6 cP, 4.5 cP, 4.4 cP, 4.3 cP, 4.2 cP, 4.1 cP, 4.0 cP, 3.9 cP, 3.8 cP, 3.7 cP, 3.6 cP, 3.5 cP, 3.4 cP, 3.3 cP, 3.2 cP, 3.1 cP, 3.0 cP , 2.9cP, 2.8cP, 2.7cP, 2.6cP, 2.5cP, 2.4cP, 2.3cP, 2.2cP, 2.1cP, 2.0cP, 1.9cP, 1.8cP, 1.7cP, 1.6cP, 1.5cP, 1.4cP, 1.3cP, 1.2cP, 1.1cP, 1.0cP, 0.9cP, 0.8cP, 0.7cP, 0.6cP or 0.5cP. In some embodiments, the viscosity of the ASD forming solution or its precursor solution is less than about 2 cP, such as less than about any of 1.95 cP, 1.9 cP, 1.85 cP, 1.8 cP, 1.75 cP, 1.7 cP, 1.65 cP, 1.6 cP, 1.55 cP, 1.5 cP, 1.45 cP, 1.4 cP, 1.35 cP, 1.3 cP, 1.25 cP, 1.2 cP, 1.15 cP, 1.1 cP, 1.05 cP, 1 cP, 0.95 cP, 0.9 cP, 0.85 cP, 0.8 cP, 0.75 cP, 0.7 cP, 0.65 cP, 0.6 cP, 0.55 cP or 0.5 cP. In some embodiments, the viscosity of the ASD forming solution or its precursor solution is at least about 0.5 cP, such as at least about 0.6 cP, 0.7 cP, 0.8 cP, 0.9 cP, 1.0 cP, 1.1 cP, 1.2 cP, 1.3 cP, 1.4 cP, 1.5 cP, 1.6 cP, 1.7 cP, 1.8 cP, 1.9 cP, 2.0 cP, 2.1 cP, 2.2 cP, 2.3 cP, 2.4 cP, 2.5 cP Any one of P, 2.6cP, 2.7cP, 2.8cP, 2.9cP, 3.0cP, 3.1cP, 3.2cP, 3.3cP, 3.4cP, 3.5cP, 3.6cP, 3.7cP, 3.8cP, 3.9cP, 4.0cP, 4.1cP, 4.2cP, 4.3cP, 4.4cP, 4.5cP, 4.6cP, 4.7cP, 4.8cP, 4.9cP or 5.0cP.In some embodiments, the viscosity of the ASD forming solution or its precursor solution is at least about 0.5 cP, such as at least about any of 0.55 cP, 0.6 cP, 0.65 cP, 0.7 cP, 0.75 cP, 0.8 cP, 0.85 cP, 0.9 cP, 0.95 cP, 1 cP, 1.05 cP, 1.1 cP, 1.15 cP, 1.2 cP, 1.25 cP, 1.3 cP, 1.35 cP, 1.4 cP, 1.45 cP, 1.5 cP, 1.55 cP, 1.6 cP, 1.65 cP, 1.7 cP, 1.75 cP, 1.8 cP, 1.85 cP, 1.9 cP, 1.95 cP or 2.0 cP. In some embodiments, the viscosity of the ASD forming solution or its precursor solution is about 0.5 cP, 0.6 cP, 0.7 cP, 0.8 cP, 0.9 cP, 1.0 cP, 1.1 cP, 1.2 cP, 1.3 cP, 1.4 cP, 1.5 cP, 1.6 cP, 1.7 cP, 1.8 cP, 1.9 cP, 2.0 cP, 2.1 cP, 2.2 cP, 2.3 cP, 2.4 cP, 2.5 cP, 2.6 cP, 2.7 cP, 2.8 cP, 2.9 cP, 3.0 cP, 3.1 cP, 3.2 cP, 3.3 cP, 3.4 cP, 3.5 cP, 3.6 cP, 3.7 cP, 3.8 cP, 3.9 cP, 4. Any one of .6cP, 2.7cP, 2.8cP, 2.9cP, 3.0cP, 3.1cP, 3.2cP, 3.3cP, 3.4cP, 3.5cP, 3.6cP, 3.7cP, 3.8cP, 3.9cP, 4.0cP, 4.1cP, 4.2cP, 4.3cP, 4.4cP, 4.5cP, 4.6cP, 4.7cP, 4.8cP, 4.9cP or 5.0cP. In some embodiments, the viscosity of the ASD forming solution or its precursor solution is about 0.5 cP, 0.55 cP, 0.6 cP, 0.65 cP, 0.7 cP, 0.75 cP, 0.8 cP, 0.85 cP, 0.9 cP, 0.95 cP, 1 cP, 1.05 cP, 1.1 cP, 1.15 cP, 1.2 cP, 1.25 cP, 1.3 cP, 1.35 cP, 1.4 cP, 1.45 cP, 1.5 cP, 1.55 cP, 1.6 cP, 1.65 cP. cp, 2.1 cp, 2.2 cp, 2.25 cp, 2.3 cp, 2.35 cp, 2.4 cp, 2.45 cp, 2.5 cp, 2.55 cp, 2.6 cp, 2.65 cp, 2.7 cp, 2.75 cp, 2.8, 2.85 cp, 2.9 cp, 2.95 cp, or 3 cp. In the embodiments described herein, the viscosity of the ASD forming solution or its precursor solution is assessed at about room temperature, such as about 20° C. to about 22° C., including at about 20° C., 21° C., or 22° C.In some embodiments, wherein the ASD forming solution is produced from two or more precursor solutions thereof, at least two of the two or more precursor solutions have the same viscosity. In some embodiments, wherein the ASD forming solution is produced from two or more precursor solutions thereof, at least two of the two or more precursor solutions have different viscosities.
[0230] In some embodiments, various components can contribute to the viscosity of the ASD formation solution or its precursor solution, including the type and / or concentration of hydrophobic agent and / or polymer. In some embodiments, the ASD formation solution or its precursor solution further comprises a viscosity modifier. In some embodiments, the viscosity modifier is a viscosity enhancer, for example, increasing the viscosity of the ASD formation solution or its precursor solution. In some embodiments, the viscosity modifier is a viscosity reducer, for example, reducing the viscosity of the ASD formation solution or its precursor solution.
[0231] In some embodiments, the viscosity enhancer is selected from the group consisting of ethylene glycol, polyethylene glycol, glycerol, propylene glycol, and a cellulosic polymer, or a mixture thereof. In some embodiments, the cellulosic polymer is selected from methylcellulose, hydroxymethylcellulose, and hydroxypropylmethylcellulose, or a mixture thereof. In some embodiments, the viscosity enhancer is a polymer that can be used to form an ASD, such as discussed in other sections of this application.
[0232] In some embodiments, the viscosity reducing agent is selected from the group consisting of salts and amino acids, or mixtures thereof.
[0233] In some embodiments, the viscosity modifier (such as a viscosity enhancer or a viscosity reducer) has a concentration of about 0.1% v / v to about 40% v / v in the ASD forming solution or a precursor solution thereof, such as about 1% v / v to about 10% v / v, about 5% v / v to about 15% v / v, about 10% v / v to about 20% v / v, about 15% v / v to about 25% v / v, about 20% v / v to about 30% v / v, about 25% v / v to about 35% v / v, or about 30% v / v to about 40% v / v. In some embodiments, the viscosity modifier (such as a viscosity enhancer or a viscosity reducer) has a concentration of about 40% v / v or less, such as about any of 35% v / v, 30% v / v, 25% v / v, 20% v / v, 15% v / v, 10% v / v, 9% v / v, 8% v / v, 7% v / v, 6% v / v, 5% v / v, 4% v / v, 3% v / v, 2% v / v, 1% v / v, 0.9% v / v, 0.8% v / v, 0.7% v / v, 0.6% v / v, 0.5% v / v, 0.4% v / v, 0.3% v / v, 0.2% v / v or 0.1% v / v in the ASD forming solution or a precursor solution thereof. In some embodiments, the concentration of a viscosity modifier (such as a viscosity enhancer or a viscosity reducer) in the ASD-forming solution or a precursor solution thereof is based on the desired viscosity of the ASD-forming solution or a precursor solution thereof.
[0234] In some embodiments, the ratio of the viscosity modifier (such as a viscosity enhancer or viscosity reducer) to the organic vehicle of the ASD forming solution or its precursor solution is about 1:1000 to about 1:2, such as about 1:500 to about 1:2, about 1:100 to about 1:2, about 1:50 to about 1:2, about 1:20 to about 1:2, about 1:1000 to about 1:5, about 1:500 to about 1:5, about 1:100 to about 1:5, about 1:500 to about 1:5, about 1:100 to about 1:5, about 1:50 to about 1:5, about 1:20 to about 1:5, about 1:1000 to about 1:10, about 1:500 to about 1:10, about 1:100 to about 1:10, about 1:50 to about 1:10, or about 1:20 to about 1:10 or about 1:10 to about 1:5. In some embodiments, the ratio is about 1:5. In some embodiments, the ratio is about 1:10.
[0235] E. Precursor solution
[0236] In certain aspects, provided herein is a precursor solution for an ASD forming solution. As described herein, a method of depositing an ASD forming solution onto a substrate comprises dispensing an ASD forming solution or a component thereof from one or more droplet dispensers. In some embodiments, the ASD forming solution is formed by dispensing two or more precursor solutions comprising its components. For example, in some embodiments, the ASD forming solution can be formed by dispensing a first precursor solution comprising an easily crystallizable agent and dispensing a second precursor solution comprising a polymer, wherein the first precursor solution and the second precursor solution are mixed after dispensing to form an ASD forming solution. Therefore, the precursor solution can contain components of the ASD forming solution in any configuration and / or concentration, such that mixing of two or more precursor solutions produces an ADS forming solution.
[0237] In some embodiments, the precursor solution does not contain components of the ASD forming solution. For example, in some embodiments, the ASD forming solution comprises an organic carrier, a polymer and an agent that is easy to crystallize, wherein the ASD forming solution inhibits (such as prevents) the agent from crystallizing in a dry state. In some embodiments, the ADS forming solution optionally comprises a viscosity modifier, such as a viscosity modifier different from a polymer. In some embodiments, the precursor solution does not contain an organic carrier. In some embodiments, wherein the precursor solution does not contain an organic carrier, the precursor solution does not contain an agent that is easy to crystallize. In some embodiments, the precursor solution does not contain an agent that is easy to crystallize. In some embodiments, the precursor solution does not contain a viscosity modifier.
[0238] In some embodiments, where the precursor solution does not contain an organic carrier, the precursor solution comprises any carrier suitable for use in a droplet dispenser. In some embodiments, the precursor solution comprises an aqueous carrier.
[0239] In some aspects provided herein, one or more precursor solutions are deposited onto a substrate and no ASD is formed. For example, in some embodiments, a first precursor solution comprising an agent that is easily crystallized and a second precursor solution comprising a polymer are deposited onto a substrate so that a gradient comprising two or more different ratios of agent to polymer is formed. In such embodiments, not all or any ratios of agent to polymer will produce an ASD. In view of the disclosure provided herein, the term precursor solution is not intended to limit the scope of such solutions to those that form ASD-forming solutions.
[0240] IX. Methods of Identifying ASD and / or ASD Forming Solutions and Products Thereof
[0241] In certain aspects, methods for identifying ASDs and / or ASD-forming solutions are provided herein. ASDs are typically optimized to balance the amount of polymer required to inhibit crystallization of a pharmaceutical agent and the amount of polymer required to provide certain characteristics associated with the pharmaceutical agent (e.g., drug release from a pharmaceutical dosage form containing the ASD). Conventional identification of ASDs and their component ratios is a laborious process that requires large amounts of raw materials and high costs. In certain aspects, methods provided herein include depositing ASD-forming solutions and / or precursor solutions, such as from one or more droplet dispensers, so that both ASD formation conditions and ASDs having desired characteristics (such as a ratio of a pharmaceutical agent to a polymer having a desired release therefrom) can be identified.
[0242] To illustrate techniques for identifying ASD and / or ASD formation solutions, a Fig. 6A and Figure 6B .like Fig. 6A As shown, in some embodiments, a precursor solution containing an agent that is easily crystallized (such as a hydrophobic agent) and a precursor solution containing a polymer suitable for ASD formation are dispensed from separate droplet dispensers. The amount of the first precursor solution dispensed from the first droplet dispenser and the amount of the second precursor solution dispensed from the second droplet dispenser can vary across regions so that a gradient deposition is produced. The degree of variation can be controlled as needed. Fig. 6A In the figure, the left side of the gradient deposition includes 100% loading of the pharmaceutical agent that is easy to crystallize, and the right side of the gradient deposition includes 100% polymer loading. The amount of each precursor solution deposited in the gradient deposition is shown with black (agent) and white (polymer) triangles. The resulting gradient deposition can then be evaluated to identify conditions suitable for forming an ASD containing a pharmaceutical agent. In some embodiments, provided herein are products of the method, such as gradient depositions containing different ratios of pharmaceutical agents that are easy to crystallize and polymers. Figure 6B Another technique encompassed by the methods provided herein is shown. Using a precursor solution containing an agent that is susceptible to crystallization (such as a hydrophobic agent) and a precursor solution containing a suitable polymer, deposition of regions (such as the circles shown) can be performed to produce a specific agent load. The resulting regions can then be assessed to identify conditions suitable for forming an ASD containing the agent.
[0243] In some aspects, a method for determining the ratio of an agent that is easy to crystallize (such as a hydrophobic agent) to a polymer that forms an ASD is provided herein, the method comprising dispensing a certain amount of a first precursor solution containing an agent and a certain amount of a second precursor solution containing a polymer onto a substrate to determine the ratio of the agent to the polymer that forms the ASD, wherein the dispensing is performed in such a manner that the first precursor solution and the second precursor solution are mixed on the substrate, or mixed before being applied to the substrate. In some embodiments, the method includes generating a plurality of regions on a substrate, each region having a different ratio of an agent to a polymer from a precursor solution. In some embodiments, different regions form a gradient of the ratio of the agent to the polymer, such as from 0% agent and 100% polymer to 100% agent and 0% polymer. In some embodiments, the first precursor solution comprises an organic carrier and an agent. In some embodiments, the first precursor solution further comprises a polymer. In some embodiments, the first precursor solution further comprises a viscosity enhancer. In some embodiments, the second precursor solution comprises a polymer and another carrier, such as an organic carrier. In some embodiments, the second precursor solution comprises another viscosity enhancer.
[0244] In some embodiments, the first precursor solution is dispensed from a first droplet dispenser (such as a sub-nanoliter droplet dispenser, e.g., a high-frequency sub-nanoliter dispenser). In some embodiments, the second precursor solution is dispensed from a second droplet dispenser (such as a sub-nanoliter droplet dispenser, e.g., a high-frequency sub-nanoliter dispenser).
[0245] In some embodiments, the method includes: mixing the components of the first precursor solution and the second precursor solution, such as to obtain an ASD forming solution or a candidate thereof, and dispensing the ASD forming solution or a candidate thereof onto a substrate using a droplet dispenser to determine whether an ASD is formed. In some embodiments, multiple ADS forming solutions are independently deposited on a substrate to determine the ratio of an agent that is easily crystallized (such as a hydrophobic agent) to a polymer that forms an ASD.
[0246] In some embodiments, the method further comprises assessing crystallization of an agent susceptible to crystallization, such as a hydrophobic agent.
[0247] In some embodiments, the substrate is a film, such as a pharmaceutical film substrate described herein.
[0248] In other aspects, a gradient on a substrate is provided, the gradient comprising: a first position, a second position, and a third position, each position comprising a mixture of an amount of a first deposit and an amount of a second deposit, wherein the first deposit comprises an agent that is susceptible to crystallization (such as a hydrophobic agent), wherein the ratio of the amount of the first deposit to the amount of the second deposit in the first position is less than the ratio of the amount of the first deposit to the amount of the second deposit in the second position, and the ratio of the amount of the first deposit to the amount of the second deposit in the second position is less than the ratio of the amount of the first deposit to the amount of the second deposit in the third position, wherein the interaction between the first deposit and the second deposit in the mixture at the first position, the second position, and the third position produces a measurable effect of the agent of the first deposit. In some embodiments, the difference in the ratio of the amount of the first deposit to the amount of the second deposit in each of the first position, the second position, and the third position is the same.
[0249] In some embodiments, the first deposition comprises a hydrophobic deposition and the second deposition comprises a polymer. In some embodiments, the first deposition further comprises a first organic carrier and a first viscosity enhancer, and the second deposition further comprises a second organic carrier and a second viscosity enhancer. In some embodiments, the first organic carrier and the second organic carrier are the same. In some embodiments, the first viscosity enhancer and the second viscosity enhancer are the same. In some embodiments, the amount of the first deposition and the amount of the second deposition are concentrations. In some embodiments, the measurable effect of the hydrophobic agent is crystallinity. In some embodiments, the first deposition is dispensed from a first droplet dispenser (such as a sub-nanoliter droplet dispenser), and wherein the second deposition is dispensed from a second droplet dispenser (e.g., a sub-nanoliter droplet dispenser).
[0250] X. Methods of Preparing Dosage Forms Containing ASD
[0251] In some aspects, a method for preparing a dosage form comprising an amorphous solid dispersion (ASD) containing an agent that is easy to crystallize (e.g., a hydrophobic agent) is provided herein, the method comprising using a droplet dispenser to deposit droplets of an ASD-forming solution comprising an agent, an organic carrier, and a polymer onto a substrate, wherein the ratio of the polymer to the agent inhibits crystallization on the substrate in a dry state. In some embodiments, the droplets of the ASD-forming solution are deposited onto the substrate including dispensing the ASD-forming solution from a droplet dispenser. In some embodiments, the droplets of the ASD-forming solution are deposited onto the substrate via dispensing the ASD-forming solution and / or its precursor solution from more than one droplet dispenser, wherein the ASD-forming solution is formed on the substrate and / or during travel from the droplet dispenser to the substrate. In some embodiments, the ASD-forming solution precursor comprises a subset of the components of the ASD-forming solution. In some embodiments, the ASD-forming solution precursor comprises a component of the ASD-forming solution having a concentration different from that of the resulting ASD-forming solution. In some embodiments, different ASD-forming solutions and / or their precursor solutions can each be dispensed from different droplet dispensers.
[0252] In the methods provided herein, a droplet dispenser ejects droplets that travel to a substrate. Based on, for example, the configuration of one or more droplet dispensers and an ASD forming solution, many configurations of the method are provided herein. In some embodiments, an ASD forming solution is formed during travel from a droplet dispenser to a substrate. In some embodiments, an ASD forming solution is formed once deposited on a substrate by a droplet dispenser. In some embodiments, an ASD forming solution is formed during travel from a droplet dispenser to a substrate and once deposited on a substrate by a droplet dispenser. In some embodiments, an ASD is formed during travel from a droplet dispenser to a substrate. In some embodiments, an ASD is formed once deposited on a substrate by a droplet dispenser. In some embodiments, an ASD is formed during travel from a droplet dispenser to a substrate and once deposited on a substrate by a droplet dispenser.
[0253] In some embodiments, the method includes depositing an ASD-forming solution onto a substrate, wherein the ASD-forming solution is identified using the methods described herein. The methods provided herein can utilize any of the components described herein, such as an ASD-forming solution and / or its precursor solution, a droplet dispenser, and a substrate. The modular approach of this description is not intended to limit the scope of the teachings provided herein, and one of ordinary skill in the art will readily appreciate that the method encompasses the embodiments described therein and any combination thereof.
[0254] In some embodiments, the method includes using a droplet dispenser to deposit droplets of an ASD-forming solution containing an agent that is easy to crystallize (such as a hydrophobic agent), an organic carrier, and a polymer onto a substrate, wherein the ratio of the polymer to the agent that is easy to crystallize inhibits crystallization on the substrate in a dry state. In some embodiments, depositing droplets of the ASD-forming solution includes dispensing the ASD-forming solution from a droplet dispenser. In some embodiments, depositing droplets of the ASD-forming solution includes dispensing a precursor solution from a droplet dispenser. In some embodiments, the ASD-forming solution or its precursor solution has a viscosity of about 0.5 cp to about 5 cP, including about 1 cP to less than 2 cP or about 1.2 cP to about 1.8 cP. In some embodiments, the droplet dispenser is a sub-nanoliter droplet dispenser. In some embodiments, the droplet dispenser is a high-frequency sub-nanoliter droplet dispenser. In some embodiments, the ASD-forming solution or its precursor solution is derived from a dispensing cartridge. In some embodiments, the method includes conveying the ASD-forming solution or its precursor solution to a droplet dispenser or a component thereof, such as a dispensing head thereof.
[0255] In some embodiments, the droplet dispenser dispenses droplets in the direction of the substrate to deposit the droplets thereon. In general, the dispensed droplets from the droplet dispenser may undergo changes in form during the deposition process, for example, (a) a droplet can merge with another droplet (whether in the air or on the substrate) after being dispensed from the droplet dispenser, (b) the deposited droplets dry on the substrate, and (c) solvent loss occurs during the travel from the droplet dispenser to the substrate. A description of droplets is provided herein and may be applicable to various states occurring during the deposition process. Unless otherwise expressly stated, such descriptions are not intended to be limited to a certain state. In some embodiments, deposition includes dispensing a plurality of ASD-forming solution droplets per square inch (also referred to herein as dots per inch). In some embodiments, the resulting pattern or patterned layer produced by the method described herein includes, at least to some extent, the merging of one or more dispensed droplets of the ASD-forming solution. Such droplet patterns do not need to be regular, and in some embodiments, reflect a plurality of droplets applied to a set area of the substrate. In some embodiments, the deposited droplets (whether or not merging occurs before or after the substrate) resemble a pattern on a macro scale, such as a printed shape. In some embodiments, the dosage form comprises one or more layers of droplets deposited on a substrate, such as formed by one or more passes of a droplet dispenser over the dosage form area. In some embodiments, the patterned layer is a continuous layer of the ADS forming solution before drying, for example, the deposited droplets are interconnected at least to some extent. In some embodiments, the droplets of the ADS forming solution are deposited at about 1 dot per inch (dpi) to about 1,000 dpi, such as about 1 dpi to about 720 dpi, about 72 dpi to about 720 dpi, about 72 dpi to about 500 dpi, or about 72 dpi to about 300 dpi. In some embodiments, droplets of the ASD forming solution are deposited at about 1 dpi or greater, such as about 20 dpi or greater, 50 dpi or greater, 72 dpi or greater, 100 dpi or greater, 120 dpi or greater, 150 dpi or greater, 200 dpi or greater, 250 dpi or greater, 300 dpi or greater, 350 dpi or greater, 400 dpi or greater, 450 dpi or greater, 500 dpi or greater, 550 dpi or greater, 600 dpi or greater, 650 dpi or greater, 700 dpi or greater, 720 dpi or greater, 750 dpi or greater, 800 dpi or greater, 850 dpi or greater, 900 dpi or greater, 950 dpi or greater, or 1,000 dpi or greater.In some embodiments, droplets of the ASD forming solution are deposited at about 1 dot per inch (dpi) to about 1,000 dpi, such as any of about 1 dpi to about 720 dpi, about 72 dpi to about 720 dpi, about 72 dpi to about 500 dpi, or about 72 dpi to about 300 dpi. In some embodiments, droplets of the ASD forming solution are deposited at about 1 dpi or greater, such as about 20 dpi or greater, 50 dpi or greater, 72 dpi or greater, 100 dpi or greater, 120 dpi or greater, 150 dpi or greater, 200 dpi or greater, 250 dpi or greater, 300 dpi or greater, 350 dpi or greater, 400 dpi or greater, 450 dpi or greater, 500 dpi or greater, 550 dpi or greater, 600 dpi or greater, 650 dpi or greater, 700 dpi or greater, 720 dpi or greater, 750 dpi or greater, 800 dpi or greater, 850 dpi or greater, 900 dpi or greater, 950 dpi or greater, or 1,000 dpi or greater.
[0256] In some embodiments, dispensed or deposited droplets of the ASD forming solution or a precursor solution thereof have a diameter of about 1 nm to about 200 μm, such as any of about 20 nm to about 800 nm, about 100 nm to about 500 nm, or about 10 μm to about 100 μm. In some embodiments, the dispensed or deposited droplets of the ASD forming solution or a precursor solution thereof have a diameter of at least about 1 nm, such as at least about 10 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm, 200 nm, 210 nm, 220 nm, 230 nm, 240 nm, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, 300 nm, 310 nm, 320 nm, 330 nm, 340 nm, 350 nm, 360 nm, 370 nm, 380 nm, 390 nm, The diameter of the particle is any one of 1 μm, 5 μm, 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm or 100 μm. In some embodiments, the mean of a population of dispensed or deposited droplets of a dosage form described herein meets the criteria discussed above.
[0257] In some embodiments, the dispensed or deposited droplets of the ASD forming solution or a precursor solution thereof comprise an average volume of about 1 picoliter (pL) to about 1 nL, such as about 1 pL to about 500 pL or about 1 pL to about 50 pL. In some embodiments, the dispensed or deposited droplets of the ASD forming solution or a precursor solution thereof comprise an average volume of about 1 nL or less, such as about 950 pL or less, 900 pL or less, 850 pL or less, 800 pL or less, 750 pL or less, 700 pL or less, 650 pL or less, 600 pL or less, 550 pL or less, 500 pL or less, 450 pL or less, 400 pL or less, 350 pL or less, 300 pL or less, 250 pL or less, 200 pL or less, 150 pL or less, 100 pL or less, 75 pL or less, 50 pL or less, or 25 pL or less.
[0258] As described in more detail in other sections of this document, in some embodiments, the droplet dispenser uses a thermal process to dispense the ASD forming solution or its precursor solution. In some embodiments, the droplet dispenser uses a piezoelectric process to dispense the ASD forming solution or its precursor solution. In some embodiments, the droplet dispenser is a sub-nanoliter droplet dispenser. In some embodiments, such as described in more detail in other sections of this document, the sub-nanoliter droplet dispenser is a high-frequency sub-nanoliter droplet dispenser. In some embodiments, the droplet dispenser includes about 100 to about 1000 individual nozzles. In some embodiments, each nozzle includes a hole having a diameter of about 20 μm to about 120 μm. In some embodiments, the high-frequency sub-nanoliter droplet dispenser dispenses droplets at more than 3kHz, as measured per nozzle.
[0259] In some embodiments, the method further includes connecting a cartridge containing an ASD forming solution or a precursor solution thereof to a droplet dispenser (such as a high-frequency droplet dispenser or a high-frequency sub-nanoliter droplet dispenser). In some embodiments, the method further includes selecting a cartridge including an ASD forming solution or a precursor solution thereof to produce a desired dosage form, such as based on one or more of the following: the desired characteristics of the final dosage form or one or more patterned layers thereon (e.g., the amount of hydrophobic agent to be deposited on the dosage form, the amount of polymer to be deposited on the dosage form), the characteristics of the patterned layer (such as any of dpi, shape, size, and position on the dosage form), the release profile of the hydrophobic agent, and the characteristics of the final dosage form (e.g., the structural integrity and / or protection of the patterned layer). In certain embodiments, the method includes dispensing or depositing at least one ASD forming solution and optionally another material (e.g., a food safety material to form a label), wherein the method encompasses the selection of each dispensed component. In some embodiments, the method includes selecting an ASD forming solution or a precursor solution thereof from a library (such as compiled in a kit). In some embodiments, the method further includes preparing an ASD forming solution and / or a precursor solution thereof.
[0260] In some embodiments, the method includes designing a pattern of droplets (such as characterized by dpi) of an ASD-forming solution containing a pharmaceutical agent that is susceptible to crystallization (e.g., a hydrophobic agent). In some embodiments, the design method includes determining (such as calculating) one or more settings based on any one or more of the following: the total amount of the pharmaceutical agent (such as a hydrophobic agent) of the dosage form; the concentration of the pharmaceutical agent in the ASD-forming solution or its precursor solution; the desired exposed surface area of the resulting ASD of the dosage form or its dry form; the desired release profile of the pharmaceutical agent; the amount of polymer relative to the pharmaceutical agent; and characteristics of the droplet dispenser (or its use), such as the aperture, the jetting frequency, and the droplet size produced.
[0261] In some embodiments, the method includes creating and / or receiving instructions to control a droplet dispenser, such as to form a dosage form described herein. In some embodiments, the instructions are personalized to an individual.
[0262] In some embodiments, the method further comprises performing a drying time after depositing the ASD-forming solution on the substrate, e.g., so that the ASD-forming solution can be dried at least to some extent, and / or the ASD can be formed. In some embodiments, the method further comprises one or more processing steps after depositing the ASD-forming solution on the substrate, such as cutting the substrate into individual dosage forms and / or packaging one or more dosage forms.
[0263] In some embodiments, the method further includes cleaning one or more dispensing heads of the droplet dispenser, such as by dispensing a solvent without a drug. For example, such a cleaning step helps ensure that the ASD forming solution or its precursor solution has not blocked the nozzle of the dispensing head and / or helps reduce the residue of the components dispensed therefrom.
[0264] XI. ASD dispensing cartridges and compositions therein
[0265] In certain aspects, a dispensing cartridge is provided herein, comprising an ASD forming solution and / or a precursor solution thereof, or a derivative or precursor thereof, as described herein (or suitable for use therewith). The dispensing cartridges described herein are generally suitable for containing one or more ASD forming solutions and / or precursor solutions thereof as described herein, such as in a reservoir of a dispensing cartridge, and are configured to engage with a dispensing head of a droplet dispenser so that the contents of the dispensing cartridge can be delivered to the dispensing head. In some embodiments, the dispensing cartridge is a disposable cartridge. In some embodiments, the dispensing cartridge is suitable for disposable or time-limited use.
[0266] In some embodiments, the dispensing cartridge comprises a material suitable for use with the ASD forming solution and / or its precursor solution described herein. In some embodiments, the dispensing cartridge comprises a material suitable for use in pharmaceutical applications, for example, the material does not dissolve or leach its components in the presence of the ASD forming solution and / or its precursor solution.
[0267] In some embodiments, the dispensing cartridge includes a reservoir configured to hold an ASD forming solution and / or a precursor solution thereof as described herein. In some embodiments, the dispensing cartridge includes more than one reservoir configured to hold an ASD forming solution and / or a precursor solution thereof as described herein. In some embodiments, a dispensing cartridge is provided that includes a material that can be used for the embodiments described herein, wherein the material is not an ASD forming solution and / or a precursor solution thereof as described herein. For example, in some embodiments, the dispensing cartridge includes a fluid suitable for deposition onto a substrate, such as to convey the characteristics or identity (including a unique identity) of a dosage form via a mark and / or a label. In some embodiments, the label is a machine-readable label, such as a QR code or a barcode. Also disclosed herein is a kit comprising one or more dispensing cartridges as described herein.
[0268] In some embodiments, the dispensing cartridge includes a reservoir, such as to contain a volume of an ASD forming solution and / or a precursor solution thereof as described herein. In some embodiments, the dispensing cartridge includes a reservoir port, such as to facilitate the flow of material into or out of the reservoir. In some embodiments, the dispensing cartridge includes a sponge material. In some embodiments, the sponge material is in the reservoir. In some embodiments, the dispensing cartridge includes a dispensing head interface configured to enable the ASD forming solution and / or a precursor solution thereof to be transferred from the reservoir to the dispensing head of the droplet dispenser.
[0269] In some embodiments, a composition is provided herein, which comprises an ASD forming solution and / or a form of a precursor solution thereof (including derivatives or precursors thereof). In some embodiments, the ASD forming solution and / or a precursor solution thereof is in a frozen form, a dried form, or a lyophilized form. In some embodiments, the ASD forming solution and / or a precursor solution thereof can be processed to produce the desired ASD forming solution and / or a precursor solution thereof described herein, such as via reconstitution. In some embodiments, the composition is contained in a dispensing cartridge.
[0270] XII. ASD Dosage Forms
[0271] In certain aspects, provided herein is a dosage form comprising an ASD comprising a pharmaceutical agent (such as a hydrophobic agent) that is easily crystallized and deposited onto a substrate. In some embodiments, provided herein is a dosage form produced according to the methods provided herein. In some embodiments, the dosage form has different mechanical properties compared to dosage forms produced by conventional means (such as solvent casting).
[0272] In some embodiments, the pharmaceutical agent susceptible to crystallization is present in a dosage form wherein less than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of the pharmaceutical agent is in crystalline form. In some embodiments, the pharmaceutical agent susceptible to crystallization is present in a dosage form wherein less than 5% of the pharmaceutical agent is in crystalline form. In some embodiments, the crystalline form of the pharmaceutical agent susceptible to crystallization is substantially absent from the dosage form.
[0273] In some embodiments, the dosage form is an oral dosage form (including oral pharmaceutical dosage forms, such as capsules comprising a film substrate (e.g., a rolled and / or folded film substrate)). In some embodiments, the dosage form is an intraoral dosage form. In some embodiments, the dosage form is a buccal dosage form. In some embodiments, the dosage form is a sublingual dosage form. In some embodiments, the dosage form is a vaginal dosage form. In some embodiments, the dosage form is a rectal dosage form. In some embodiments, the dosage form is an ophthalmic dosage form. In some embodiments, the dosage form comprises the following components, which are derived from the deposition of the ASD-forming solution using the methods provided herein. In some embodiments, the film substrate is suitable for human consumption. In some embodiments, the dosage form is suitable for contact-based delivery of hydrophobic agents, such as transdermal dosage forms. In some embodiments, the dosage form is an ophthalmic dosage form. In some embodiments, the film substrate comprises a polymer (e.g., the film substrate is a polymer film). In some embodiments, the film substrate comprises one or more of chitosan, ethylenediaminetetraacetic acid, polyvinyl pyrrolidone, polyvinyl alcohol, alginate, agar, carrageenan, guar gum, xanthan gum, polycarbophil, and a polyacrylic acid derivative.
[0274] The dosage forms described herein may have patterned layers of any shape and / or size. In some embodiments, the features of the patterned layer are based on the amount of an agent (such as a hydrophobic agent) that is easy to crystallize in the dosage form. For example, such features of the patterned layer can be based on the hydrophobic agent concentration of the ASD forming solution and the total desired amount of the hydrophobic agent to be deposited on a substrate (such as a film substrate). In some embodiments, the features of the patterned layer (such as any one of the shape, size, and position on the dosage form) are based on the desired release curve of the agent (such as a hydrophobic agent) that is easy to crystallize (e.g., the patterned layer can be designed to increase the surface area of body fluids) and / or the features of the final dosage form (e.g., the structural integrity and / or protection of the patterned layer). In some embodiments, the term "layer" should not be interpreted as meaning only a single deposition from a droplet dispenser described herein. In some embodiments, the patterned layer is formed by many instances of droplet deposition from a droplet dispenser described herein (e.g., using the ASD forming solution described herein and / or its precursor solution to repeatedly print the region). For example, when producing a dosage form comprising a patterned layer, the droplet dispenser can be controlled to make one or more passes to deposit droplets of the ASD-forming solution and / or its precursor solution to form the final patterned layer.
[0275] In some embodiments, the dosage form comprises an ASD forming solution deposited onto a substrate at about 1 dot per inch (dpi) to about 1,000 dpi, such as any of about 1 dpi to about 720 dpi, about 72 dpi to about 720 dpi, about 72 dpi to about 500 dpi, or about 72 dpi to about 300 dpi. In some embodiments, the dosage form comprises an ASD forming solution that is deposited onto a substrate at about 1 dpi or greater, such as about 20 dpi or greater, 50 dpi or greater, 72 dpi or greater, 100 dpi or greater, 120 dpi or greater, 150 dpi or greater, 200 dpi or greater, 250 dpi or greater, 300 dpi or greater, 350 dpi or greater, 400 dpi or greater, 450 dpi or greater, 500 dpi or greater, 550 dpi or greater, 600 dpi or greater, 650 dpi or greater, 700 dpi or greater, 720 dpi or greater, 750 dpi or greater, 800 dpi or greater, 850 dpi or greater, 900 dpi or greater, 950 dpi or greater, or 1,000 dpi or greater. In some embodiments, the dosage form comprises an ASD forming solution deposited onto a substrate at about 1 dot per inch (dpi) to about 1,000 dpi, such as any of about 1 dpi to about 720 dpi, about 72 dpi to about 720 dpi, about 72 dpi to about 500 dpi, or about 72 dpi to about 300 dpi. In some embodiments, the dosage form comprises an ASD forming solution that is deposited onto a substrate at about 1 dpi or greater, such as about 20 dpi or greater, 50 dpi or greater, 72 dpi or greater, 100 dpi or greater, 120 dpi or greater, 150 dpi or greater, 200 dpi or greater, 250 dpi or greater, 300 dpi or greater, 350 dpi or greater, 400 dpi or greater, 450 dpi or greater, 500 dpi or greater, 550 dpi or greater, 600 dpi or greater, 650 dpi or greater, 700 dpi or greater, 720 dpi or greater, 750 dpi or greater, 800 dpi or greater, 850 dpi or greater, 900 dpi or greater, 950 dpi or greater, or 1,000 dpi or greater.
[0276] In some embodiments, deposited droplets of the ASD forming solution have a diameter (or maximum cross dimension) of about 1 nm to about 200 μm, such as any of about 20 nm to about 800 nm, about 100 nm to about 500 nm, or about 10 μm to about 100 μm. In some embodiments, the deposited droplets of the ASD forming solution have a diameter of at least about 1 nm, such as at least about 10 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm, 200 nm, 210 nm, 220 nm, 230 nm, 240 nm, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, 300 nm, 310 nm, 320 nm, 330 nm, 340 nm, 350 nm, 360 nm, 370 nm, 380 nm, 390 nm, 400 nm, 410 nm, 420 nm, 430 nm, 440 nm, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, 650 nm, 660 nm, 670 nm, 680 nm, 690 nm, 700 nm, 710 nm, 720 nm, 730 nm, 740 nm, 750 nm, 760 nm, 770 nm, 780 nm, 790 nm, 800 nm, 810 nm, 82 The diameter (or maximum cross dimension) of any one of 10nm, 420nm, 430nm, 440nm, 450nm, 460nm, 470nm, 480nm, 490nm, 500nm, 525nm, 550nm, 575nm, 600nm, 625nm, 650nm, 675nm, 700nm, 725nm, 750nm, 775nm, 800nm, 825nm, 850nm, 875nm, 900nm, 925nm, 950nm, 975nm, 1μm, 5μm, 10μm, 15μm, 20μm, 25μm, 30μm, 35μm, 40μm, 45μm, 50μm, 60μm, 70μm, 80μm, 90μm or 100μm. In some embodiments, the average of a population of droplets (such as a patterned layer) described herein meets the criteria discussed above.
[0277] In some embodiments, the patterned layer is at least partially within a substrate, such as a thin film substrate (e.g., at least a portion of an ASD described herein penetrates and / or is absorbed into the thin film substrate). In some embodiments, the patterned layer is at least partially on top of a substrate, such as a thin film substrate (e.g., at least a portion of an ASD described herein is at or above the surface of the thin film substrate). In some embodiments, the patterned layer is at least partially within a substrate, such as a thin film substrate, and at least partially on top of the substrate.
[0278] In some embodiments, the dosage form comprises more than one patterned layer, for example, a first patterned layer and a second patterned layer. In some embodiments, the first patterned layer comprises an ASD containing an agent that is prone to crystallization (such as a hydrophobic agent), and the second patterned layer comprises another agent. In some embodiments, the first patterned layer comprises an ASD containing an agent that is prone to crystallization (such as a hydrophobic agent), and the second patterned layer comprises an ASD containing an agent. In some embodiments, the first patterned layer comprises an ASD containing an agent that is prone to crystallization (such as a hydrophobic agent), and the second patterned layer comprises an ASD containing a second agent that is prone to crystallization (such as a second hydrophobic agent). In some embodiments, each patterned layer is produced via a layer-by-layer deposition technique.
[0279] In some embodiments, the dosage form comprises an agent susceptible to crystallization (such as a hydrophobic agent) in an amount of about 1 ng to about 1 mg, such as about 100 ng to about 500 ng, about 250 ng to about 750 ng, about 500 ng to about 1 μg, about 750 ng to about 1.25 μg, about 1 μg to about 2 μg, about 1 μg to about 10 μg, about 10 μg to about 50 μg, or about 25 μg to about 100 μg.
[0280] In some embodiments, the dosage form comprises at least about 1 ng, such as at least about 5 ng, 10 ng, 20 ng, 30 ng, 40 ng, 50 ng, 60 ng, 70 ng, 80 ng, 90 ng, 100 ng, 125 ng, 150 ng, 175 ng, 200 ng, 225 ng, 250 ng, 275 ng, 300 ng, 325 ng, 350 ng, 375 ng, 400 ng, 425 ng, 450 ng, 475 ng, 500 ng, 525 ng, 550 ng, 575 ng, 600 ng, 625 ng, 650 ng, 675 ng, 700 ng. In some embodiments, the present invention relates to an agent that is susceptible to crystallization (such as a hydrophobic agent) in an amount of any of 1 μg, 725 ng, 750 ng, 775 ng, 800 ng, 825 ng, 850 ng, 875 ng, 900 ng, 925 ng, 950 ng, 975 ng, 1 μg, 2 μg, 3 μg, 4 μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg or 100 μg.
[0281] In some embodiments, the dosage form further comprises a mark and / or label. For example, in certain embodiments, the dosage form may contain printed information related to any one or more of the following: active agent, amount of active agent, date of manufacture, individual (for which the dosage form is manufactured), production site, traceable identification code, expiration date, instructions for use, storage instructions, or company name and / or logo. In some embodiments, the mark and / or label is suitable for consumption, for example, comprises a food safe dye.
[0282] In some embodiments, the dosage form comprises a protective coating, e.g., applied over the deposited ASD or a portion thereof. In some embodiments, the protective coating is applied to the dosage form via a droplet dispenser, such as a sub-nanoliter droplet dispenser or a high frequency sub-nanoliter droplet dispenser. In some embodiments, the dosage form comprises a film coating.
[0283] In some embodiments, the dosage form is suitable for human use and / or consumption. In some embodiments, the dosage form is sterile.
[0284] In certain aspects, provided herein is a batch of dosage forms described herein. In some embodiments, the batch of dosage forms comprises at least 5 dosage forms, such as any of 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 dosage forms. In some embodiments, the batch of pharmaceutical dosage forms comprises a single dosage form having an amount of a pharmaceutical agent (such as a hydrophobic agent) that is susceptible to crystallization and does not vary by more than 5% relative to the mean.
[0285] XIII. Apparatus for dispensing and depositing ASD
[0286] In certain aspects, provided herein are devices for dispensing and depositing droplets, such as droplets of the ASD forming solution and / or its precursor solution as described herein. In some embodiments, the device comprises a sub-nanoliter droplet dispenser. In some embodiments, the device comprises a high-frequency sub-nanoliter droplet dispenser. Sub-nanoliter droplet dispensers (including sub-nanoliter high-frequency droplet dispensers) are known in the art, including as described in U.S. Patent Nos. 7,585,038, 7,963,635, and 6,851,786, which are incorporated herein by reference in their entirety.
[0287] In some embodiments, a droplet dispenser (such as a sub-nanoliter droplet dispenser or a high-frequency sub-nanoliter droplet dispenser) for producing a dosage form is provided, the dispenser comprising: (a) a dispensing head operably connected to a reservoir for an ASD forming solution or a precursor solution thereof; and (b) a control system configured to control the deposition of the ASD forming solution or a precursor solution thereof via the dispensing head. In some embodiments, a droplet dispenser (such as a sub-nanoliter droplet dispenser or a high-frequency sub-nanoliter droplet dispenser) for producing a dosage form is provided, the dispenser comprising: (a) a dispensing head; (b) an ASD forming solution or a precursor solution dispensing cartridge receiving space, wherein the dispensing cartridge receiving space is configured to operably connect the dispensing cartridge to the dispensing head; and (c) a control system configured to control the deposition of the ASD forming solution or a precursor solution thereof via the dispensing head according to a dispensing configuration (such as a dpi feature). In some embodiments, the viscosity of the ASD-forming solution or its precursor solution is about 0.5 cp to about 5 cP, such as about 1 cP to about 2 cP or about 1.8 cP and about 1.2 cP.
[0288] In some embodiments, the dispensing head comprises about 10 to about 1000 individual nozzles. In some embodiments, the dispensing head comprises at least about 10, such as at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1,000 individual nozzles.
[0289] In some embodiments, each nozzle of the dispensing head has an aperture (from which the nanosuspension is dispensed) having a maximum cross-section (such as a diameter) of about 20 μm to about 120 μm, such as about 20 μm to about 70 μm or about 30 μm to about 60 μm. In some embodiments, the nozzle of the dispensing head has an aperture having a maximum cross-section (such as a diameter) of at least about 20 μm, such as at least about any of 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 75 μm, 100 μm, or 120 μm.
[0290] In some embodiments, each nozzle of the dispensing head is configured to dispense droplets of the ASD forming solution or its precursor solution having a volume of about 1 pL to about 500 pL (pL). In some embodiments, the nozzles of the dispensing head are configured to dispense droplets of the ASD forming solution or its precursor solution having a volume of about 500 pL or less, such as about 450 pL or less, 400 pL or less, 350 pL or less, 300 pL or less, 250 pL or less, 200 pL or less, 150 pL or less, 100 pL or less, 75 pL or less, 50 pL or less, or 25 pL or less.
[0291] In some embodiments, the dispensing head is a continuous dispensing head. In some embodiments, the dispensing head is a drop-on-demand print head. In some embodiments, the droplet dispenser uses a thermal process to dispense the droplets. In some embodiments, the droplet dispenser uses a piezoelectric process to dispense the droplets. In some embodiments, the dispensing head is a thermal inkjet print head. In some embodiments, the dispensing head is a piezoelectric inkjet print head. In some embodiments, the dispensing head is a solenoid valve print head. In some embodiments, the dispensing head is an electrostatic print head. In some embodiments, the dispensing head is an acoustic print head.
[0292] In some embodiments, the dispensing head is a sub-nanoliter dispensing head. In some embodiments, the dispensing head is a high frequency sub-nanoliter dispensing head (e.g., a dispensing head operating at a jetting frequency greater than 2,000 Hz, such as greater than about 2.5 kHz, 3 kHz, 3.5 kHz, 4 kHz, 4.5 kHz, or 5 kHz).
[0293] In some embodiments, the dispensing device includes more than one dispensing head. In some embodiments, the dispensing device further includes a second dispensing head operably coupled to a second dispensing cartridge. In some embodiments, the dispensing device further includes a third dispensing head operably coupled to a third dispensing cartridge. In some embodiments, the dispensing device further includes a fourth dispensing head operably coupled to a fourth dispensing cartridge. In a configuration including more than one dispensing head, the dispensing device is configured to be operably coupled to a dispensing cartridge comprising any kind of material, such as a nanosuspension, a protective coating, and a label material and / or a marking material (such as an edible ink).
[0294] XIV. Systems and Applications Including ASD Embodiments Described Herein
[0295] In certain aspects, provided herein are systems and applications utilizing methods of preparing dosage forms described herein, and features associated therewith. In some embodiments, a system is provided comprising a dispensing device configured to receive instructions for printing dosage forms described herein. In some embodiments, the system is established at a point of care, such as in a hospital, a care facility, a pharmacy, or a home. In some embodiments, the dosage form is a personalized dosage form, for example, designed for an individual based on dosage form characteristics, such as the amount of a hydrophobic agent.
[0296] In some embodiments, the methods and dispensing devices described herein are suitable for personalized medicine. In some embodiments, the methods and dispensing devices described herein are suitable for point-of-care applications. In some embodiments, the methods and dispensing devices described herein are suitable for rapid dosage form production (including small-scale production, such as less than 100 dosage forms). In some embodiments, the methods and dispensing devices described herein are suitable for producing dosage forms with precise and accurate amounts of easily crystallized pharmaceutical agents (such as hydrophobic agents) (such as those required for pharmaceutical agents with narrow therapeutic index, high efficacy and / or pediatric use), which dosage forms are in the form of ASDs. In some embodiments, the methods and dispensing devices described herein are suitable for producing dosage forms with easily crystallized pharmaceutical agents (such as hydrophobic agents) with poor stability (such as instability for a long time after production, for example, greater than 24 hours), which dosage forms are in the form of ASDs. In some embodiments, the methods and dispensing devices described herein are suitable for non-pharmacological applications, such as nutritional products. XV. Embodiments having and / or produced by a combination of nanosuspensions and ASDs
[0297] In certain aspects, provided herein are embodiments having and / or produced by nanosuspension formulations as described herein and amorphous solid dispersion (ASD) formulations as described herein. For example, in some embodiments, provided herein is a method for preparing a dosage form, the method comprising: using a high-frequency droplet dispenser to deposit multiple droplets of a nanosuspension formulation as described herein onto a substrate, and using a high-frequency droplet dispenser to deposit multiple droplets of an ASD formulation as described herein onto a substrate, thereby preparing a dosage form. In some embodiments, the devices, systems, and / or dispensing cartridges disclosed herein may include nanosuspension formulations as described herein and ASD formulations as described herein. For example, in some embodiments, the device and / or system includes a first dispensing cartridge comprising a nanosuspension formulation as described herein, and a second dispensing cartridge comprising an ASD formulation as described herein.
[0298] It should be understood that in each embodiment comprising an amorphous solid dispersion (ASD), embodiments in which the ASD is an ASD that forms nanoparticles are also contemplated. In some embodiments, such ASDs that form nanoparticles can be further defined by the teachings provided herein for nanosuspensions and products produced therefrom (e.g., particle size). In some embodiments, the nanosuspension is an ASD formulation (as described herein). In one embodiment, the ASD formulation is an ASD that forms nanoparticles (as described herein).
[0299] The present invention is not intended to be limited in scope to the specific disclosed embodiments, which are provided, for example, to illustrate various aspects of the invention. Various modifications to the described compositions and methods will become apparent from the description and teachings herein. Such variations may be practiced without departing from the true scope and spirit of the present disclosure, and the enumerated embodiments are intended to fall within the scope of the present disclosure.
[0300] Example 1. A method for preparing a dosage form containing a hydrophobic agent, the method comprising:
[0301] A high frequency droplet dispenser is used to deposit a plurality of droplets of a nanosuspension onto a substrate to form a dosage form, wherein the nanosuspension comprises:
[0302] Aqueous carriers, and
[0303] a plurality of nanoparticles suspended in the aqueous carrier, wherein the nanoparticles comprise a hydrophobic agent, and
[0304] The viscosity of the nanosuspension is less than 3 cP.
[0305] Embodiment 2. The method of embodiment 1, wherein the high frequency droplet dispenser uses a thermal process to deposit the plurality of droplets.
[0306] Embodiment 3. The method of embodiment 1, wherein the high frequency droplet dispenser uses a piezoelectric process to deposit the plurality of droplets.
[0307] Embodiment 4. The method of any one of embodiments 1 to 3, wherein the high-frequency droplet distributor comprises about 100 to about 1000 individual nozzles.
[0308] Embodiment 5. The method of embodiment 4, wherein each nozzle comprises a hole having a diameter of about 20 μm to about 120 μm.
[0309] Embodiment 6. The method according to any one of embodiments 1 to 5, wherein the high-frequency droplet dispenser is a high-frequency sub-nanoliter droplet dispenser.
[0310] Embodiment 7. The method of any one of embodiments 1 to 6, wherein the high frequency droplet dispenser dispenses droplets having a volume of 1 nanoliter or less.
[0311] Embodiment 8. The method of embodiment 7, wherein the average volume of each dispensed droplet of the plurality of droplets of the nanosuspension is from about 1 picoliter to about 50 picoliters.
[0312] Embodiment 9. The method of embodiment 7 or 8, wherein the plurality of nanosuspension droplets are deposited onto the substrate based on an average number of droplets per square inch.
[0313] Embodiment 10. The method of embodiment 9, wherein the average number of droplets deposited per square inch of substrate is from about 1 droplet per square inch to about 500 droplets per square inch.
[0314] Embodiment 11. The method of embodiment 9 or 10, wherein the plurality of droplets of the nanosuspension deposited on the substrate have an average diameter of about 5 μm to about 100 μm.
[0315] Embodiment 12. The method of any one of embodiments 1 to 11, wherein the plurality of droplets of the nanosuspension deposited on the substrate forms a continuous layer.
[0316] Embodiment 13. The method of any one of embodiments 1 to 12, wherein the viscosity of the nanosuspension is less than 2 cP and greater than 1 cP.
[0317] Embodiment 14. The method of any one of embodiments 1 to 13, wherein the viscosity of the nanosuspension is between 1.2 cP and 1.8 cP.
[0318] Embodiment 15. The method according to any one of embodiments 1 to 14, wherein the nanosuspension further comprises a viscosity modifier.
[0319] Embodiment 16. The method of embodiment 15, wherein the viscosity modifier is a viscosity enhancer.
[0320] Embodiment 17. The method of embodiment 16, wherein the viscosity enhancer is selected from the group consisting of ethylene glycol, polyethylene glycol, glycerol, and propylene glycol.
[0321] Embodiment 18. The method of embodiment 16 or 17, wherein the viscosity enhancing agent is present in the nanosuspension at a concentration of about 1% to about 40% v / v of the nanosuspension.
[0322] Embodiment 19. The method of any one of embodiments 16 to 18, wherein the ratio of the viscosity enhancer to the aqueous carrier of the nanosuspension is from about 1:1000 to about 1:2 by volume.
[0323] Embodiment 20. The method of any one of embodiments 16 to 19, further comprising adding a viscosity enhancer to the nanosuspension to achieve a viscosity of the nanosuspension between about 1 cP and about 2 cP.
[0324] Embodiment 21. The method of any one of embodiments 1 to 20, wherein the aqueous carrier comprises water and an organic solvent.
[0325] Embodiment 22. The method according to any one of embodiments 1 to 21, wherein the nanosuspension is a colloidal suspension.
[0326] Embodiment 23. The method according to any one of embodiments 1 to 22, wherein the nanosuspension further comprises a stabilizing component.
[0327] Embodiment 24. The method of embodiment 23, wherein the ratio of the stabilizing component of the nanosuspension to the aqueous carrier is from about 1:500 to about 1:10 by weight.
[0328] Embodiment 25. The method of embodiment 23, wherein the stabilizing component comprises PVP and / or SDS.
[0329] Embodiment 26. The method of any one of embodiments 1 to 25, wherein the average diameter of the plurality of nanoparticles is less than about 500 nm.
[0330] Embodiment 27. The method of any one of Embodiments 1 to 26, wherein the plurality of nanoparticles have a D50 of about 100 nm to about 400 nm.
[0331] Embodiment 28. The method of any one of embodiments 1 to 27, wherein the plurality of nanoparticles have a D90 of about 250 μm to about 50 nm.
[0332] Embodiment 29. The method of any one of embodiments 1 to 28, wherein the hydrophobic agent is insoluble in the aqueous carrier.
[0333] Embodiment 30. The method of embodiment 29, wherein the hydrophobic agent has a solubility in water of less than 1 mg / mL.
[0334] Embodiment 31. The method of Embodiment 29, wherein the hydrophobic agent is a therapeutic agent.
[0335] Embodiment 32. The method of embodiment 31, wherein the therapeutic agent is a small molecule drug.
[0336] Embodiment 33. The method of embodiment 31, wherein the therapeutic agent is a biomolecule.
[0337] Embodiment 34. The method of embodiment 31, wherein the therapeutic agent is a Biopharmaceutics Classification System (BCS) Class II or Class IV drug
[0338] Embodiment 35. The method of any one of embodiments 32 to 34, wherein the therapeutic agent has a narrow therapeutic index.
[0339] Embodiment 36. The method of any one of embodiments 32 to 35, wherein the therapeutic agent is a highly potent drug.
[0340] Embodiment 37. The method according to embodiment 29 or 30, wherein the hydrophobic agent is an excipient or adjuvant.
[0341] Embodiment 38. The method according to any one of embodiments 1 to 37, wherein the concentration of the hydrophobic agent in the nanosuspension is about 5 mg / mL to about 1,000 mg / mL.
[0342] Embodiment 39. The method of any one of embodiments 1 to 38, wherein the amount of the hydrophobic agent is less than 0.1 mg.
[0343] Embodiment 40. The method of any one of embodiments 1 to 39, wherein the substrate is a pharmaceutically acceptable polymer.
[0344] Embodiment 41. The method of any one of embodiments 1 to 40, wherein the substrate is selected from the group consisting of one or more of the following: chitosan, ethylenediaminetetraacetic acid, polyvinyl pyrrolidone, polyvinyl alcohol, alginate, agar, carrageenan, guar gum, xanthan gum, polycarbophil and polyacrylic acid derivatives.
[0345] Embodiment 42. The method according to any one of embodiments 1 to 41, wherein the pharmaceutically acceptable substrate is a film substrate.
[0346] Embodiment 43. The method of any one of Embodiments 1 to 42, wherein at least a portion of the plurality of nanoparticles are within a substrate.
[0347] Embodiment 44. The method of any one of Embodiments 1 to 43, wherein at least a portion of the plurality of nanoparticles are on top of a substrate.
[0348] Embodiment 45. The method of any one of embodiments 1 to 44, wherein the dosage form is an oral dosage form.
[0349] Embodiment 46. The method of any one of embodiments 1 to 44, wherein the dosage form is a buccal dosage form.
[0350] Embodiment 47. The method of any one of embodiments 1 to 44, wherein the dosage form is a transdermal dosage form.
[0351] Embodiment 48. The method of any one of embodiments 1 to 47, wherein the dosage form is sterile.
[0352] Embodiment 49. A nanosuspension comprising:
[0353] Aqueous carrier;
[0354] A plurality of nanoparticles comprising a hydrophobic agent are suspended in an aqueous carrier, wherein the viscosity of the nanosuspension is less than 3 cP.
[0355] Embodiment 50. The nanosuspension of embodiment 49, wherein the viscosity of the nanosuspension is less than 2 cP and greater than 1 cP.
[0356] Embodiment 51. The nanosuspension of embodiment 49 or 50, wherein the viscosity of the nanosuspension is between 1.2 cP and 1.8 cP.
[0357] Embodiment 52. The nanosuspension of any one of embodiments 49 to 51, wherein the nanosuspension further comprises a viscosity modifier.
[0358] Embodiment 53. The nanosuspension of embodiment 52, wherein the viscosity modifier is a viscosity enhancer.
[0359] Embodiment 54. The nanosuspension of embodiment 53, wherein the viscosity enhancer is selected from the group consisting of ethylene glycol, polyethylene glycol, glycerol, and propylene glycol.
[0360] Embodiment 55. The nanosuspension of embodiment 52 or 53, wherein the viscosity enhancer is present in the nanosuspension at a concentration of about 1% to about 40% v / v of the nanosuspension.
[0361] Embodiment 56. The nanosuspension of any one of embodiments 53 to 55, wherein the ratio of viscosity enhancer to aqueous carrier of the nanosuspension is from about 1:1000 to about 1:2 by volume.
[0362] Embodiment 57. The nanosuspension of any one of embodiments 53 to 56, further comprising adding a viscosity enhancer to the nanosuspension to achieve a viscosity of the nanosuspension between about 1 cP and about 2 cP.
[0363] Embodiment 58. The nanosuspension of any one of embodiments 49 to 57, wherein the aqueous carrier comprises water and an organic solvent.
[0364] Embodiment 59. The nanosuspension of any one of embodiments 49 to 58, wherein the nanosuspension is a colloidal suspension.
[0365] Embodiment 60. The nanosuspension of any one of embodiments 49 to 59, wherein the nanosuspension further comprises a stabilizing component.
[0366] Embodiment 61. The nanosuspension of embodiment 60, wherein the ratio of the stabilizing component of the nanosuspension to the aqueous carrier is from about 1:500 to about 1:10 by weight.
[0367] Embodiment 62. The nanosuspension of embodiment 60, wherein the stabilizing component comprises PVP and / or SDS.
[0368] Embodiment 63. The nanosuspension of any one of Embodiments 49 to 62, wherein the average diameter of the plurality of nanoparticles is less than about 500 nm.
[0369] Embodiment 64. The nanosuspension of any one of Embodiments 49 to 63, wherein the plurality of nanoparticles have a D50 of about 100 nm to about 400 nm.
[0370] Embodiment 65. The nanosuspension of any one of Embodiments 49 to 64, wherein the plurality of nanoparticles have a D90 of about 250 μm to about 50 nm.
[0371] Embodiment 66. The nanosuspension of any one of embodiments 49 to 65, wherein the hydrophobic agent is insoluble in the aqueous carrier.
[0372] Embodiment 67. The nanosuspension of Embodiment 66, wherein the hydrophobic agent has a solubility in water of less than 1 mg / mL.
[0373] Embodiment 68. The nanosuspension of Embodiment 66, wherein the hydrophobic agent is a therapeutic agent.
[0374] Embodiment 69. The nanosuspension of Embodiment 68, wherein the therapeutic agent is a small molecule drug.
[0375] Embodiment 70. The nanosuspension of Embodiment 68, wherein the therapeutic agent is a biomolecule.
[0376] Embodiment 71. The nanosuspension of embodiment 66, wherein the hydrophobic agent is a Biopharmaceutics Classification System (BCS) Class II or Class IV agent.
[0377] Embodiment 72. The nanosuspension of any one of Embodiments 69 to 71, wherein the therapeutic agent has a narrow therapeutic index.
[0378] Embodiment 73. The nanosuspension of any one of embodiments 67 to 72, wherein the therapeutic agent is a highly potent drug.
[0379] Embodiment 74. The nanosuspension of embodiment 66 or 67, wherein the hydrophobic agent is an excipient or adjuvant.
[0380] Embodiment 75. The nanosuspension according to any one of embodiments 49 to 74, wherein the concentration of the hydrophobic agent in the nanosuspension is about 5 mg / mL to about 1,000 mg / mL.
[0381] Embodiment 76. The nanosuspension form of any one of Embodiments 49 to 75, wherein the amount of the hydrophobic agent is less than 0.1 mg.
[0382] Embodiment 77. A composition comprising a dried or lyophilized nanosuspension, wherein upon reconstitution, the nanosuspension according to any one of embodiments 49 to 76 is formed.
[0383] Embodiment 78. A dosage form prepared by the method described in embodiment 1.
[0384] Embodiment 79. The dosage form of embodiment 78, wherein the dosage form comprises: a fixed amount of a hydrophobic agent, wherein the hydrophobic agent is a therapeutic agent; and a fixed amount of a second hydrophobic agent.
[0385] Embodiment 80. The dosage form of embodiment 79, wherein the second hydrophobic agent is a therapeutic agent.
[0386] Embodiment 81. The dosage form of embodiment 79, wherein the second hydrophobic agent is a pharmaceutically acceptable excipient.
[0387] Embodiment 82. A plurality of dosage forms according to any one of embodiments 78 to 81, prepared as a batch of pharmaceutical dosage forms, wherein the amount of the hydrophobic agent in each pharmaceutical dosage form in the batch varies by no more than 5% relative to the average value.
[0388] Embodiment 83. A system for producing a dosage form, the system comprising:
[0389] A nanosuspension comprising a hydrophobic agent, wherein the nanosuspension comprises an aqueous carrier and a plurality of nanoparticles, wherein each nanoparticle of the plurality of nanoparticles comprises the hydrophobic agent, and wherein the viscosity of the nanosuspension is less than 2 cP; and
[0390] A high frequency droplet dispenser comprising from about 100 to about 1000 individual nozzles, each nozzle being configured to deposit at least one nanosuspension droplet onto a substrate of a dosage form.
[0391] Embodiment 84. The system of Embodiment 83, wherein each nozzle has an aperture size of about 20 μm to about 120 μm.
[0392] Embodiment 85. The system of Embodiment 83 or 84, wherein the nanosuspension droplets are deposited onto the substrate using a thermal process.
[0393] Embodiment 86. The system of Embodiment 83 or 84, wherein the nanosuspension droplets are deposited onto the substrate using a piezoelectric process.
[0394] Second enumeration list of examples:
[0395] Example 1A. A method of preparing a dosage form comprising an amorphous solid dispersion (ASD) containing a hydrophobic agent, the method comprising using a droplet dispenser to deposit droplets of an ASD-forming solution comprising a hydrophobic agent, an organic carrier, and a polymer onto a substrate,
[0396] The ratio of polymer to hydrophobic agent is such that crystallization of the hydrophobic agent on the substrate is inhibited in a dry state.
[0397] Embodiment 2A. The method of Embodiment 1A, wherein the droplet dispenser uses a thermal process to dispense the plurality of droplets.
[0398] Embodiment 3A. The method of Embodiment 1A, wherein the droplet dispenser uses a piezoelectric process to dispense the plurality of droplets.
[0399] Embodiment 4A. The method of any one of Embodiments 1A to 3A, wherein the droplet dispenser comprises from about 100 to about 1000 individual nozzles.
[0400] Embodiment 5A. The method of Embodiment 4A, wherein each nozzle comprises an orifice having a diameter of about 20 μm to about 120 μm.
[0401] Embodiment 6A. The method of any one of Embodiments 1A to 5A, wherein the droplet dispenser is a sub-nanoliter droplet dispenser.
[0402] Embodiment 7A. The method of Embodiment 6A, wherein the sub-nanoliter droplet dispenser is a high frequency sub-nanoliter droplet dispenser.
[0403] Embodiment 8A. The method of Embodiment 7A, wherein the high frequency sub-nanoliter droplet dispenser dispenses droplets at greater than 3 kHz, as measured per nozzle.
[0404] Embodiment 9A. The method of any one of Embodiments 1A to 8A, wherein the droplet dispenser dispenses droplets having a volume of 1 nanoliter or less.
[0405] Embodiment 10A. The method of Embodiment 9A, wherein the average volume of the dispensed droplets of the ASD forming solution is from about 1 picoliter to about 50 picoliters.
[0406] Embodiment 11A. The method of any one of Embodiments 1A to 10A, wherein the droplets of the ASD-forming solution are deposited onto the substrate according to an average number of droplets per square inch.
[0407] Embodiment 12A. The method of Embodiment 11A, wherein the average number of droplets of the ASD-forming solution deposited per square inch of substrate is from about 1 droplet per square inch to about 500 droplets per square inch.
[0408] Embodiment 13A. The method of any one of Embodiments 9A to 12A, wherein the droplets of the ASD-forming solution dispensed from the droplet dispenser have an average maximum intersection dimension of about 5 μm to about 100 μm.
[0409] Embodiment 14A. The method of any one of Embodiments 1A to 13A, wherein the droplets of the ASD-forming solution deposited on the substrate form a continuous layer.
[0410] Embodiment 15A. The method of any one of Embodiments 1A to 14A, wherein the ASD forming solution has a viscosity of 0.5 cP to 3 cP.
[0411] Embodiment 16A. The method of any one of Embodiments 1A to 15A, wherein the ASD forming solution has a viscosity between 1 cP and 2 cP.
[0412] Embodiment 17A. The method of any one of Embodiments 1A to 16A, wherein the ASD forming solution has a viscosity of 1.2 cP to about 1.8 cP.
[0413] Embodiment 18A. The method of any one of Embodiments 1A to 17A, wherein the ASD-forming solution further comprises a viscosity modifier.
[0414] Embodiment 19A. The method of Embodiment 18A, wherein the viscosity modifier is a viscosity enhancer.
[0415] Embodiment 20A. The method of Embodiment 19A, wherein the viscosity enhancer is ethylene glycol, polyethylene glycol, glycerol or propylene glycol, or any combination thereof.
[0416] Embodiment 21A. The method of Embodiment 18A, wherein the viscosity modifier is a viscosity reducing agent.
[0417] Embodiment 22A. The method of Embodiment 21A, wherein the viscosity reducing agent is a salt or an amino acid, or a combination thereof.
[0418] Embodiment 23A. The method of any one of Embodiments 18A to 22A, wherein the concentration of the viscosity modifier in the ASD-forming solution is 1% to 40%.
[0419] Embodiment 24A. The method of any one of Embodiments 18A to 23A, wherein the ratio of viscosity modifier to organic vehicle is 1:100 to 40:100 by volume.
[0420] Embodiment 25A. The method of any one of Embodiments 18A to 24A, wherein the amount of viscosity modifier in the mixture is based on the desired viscosity of the mixture.
[0421] Embodiment 26A. The method of any one of Embodiments 1A to 25A, wherein the organic carrier of the ASD forming solution comprises any one or more of acetone, dimethylformamide, ethanol, methanol, pentane, hexane, heptane, ethyl acetate, isopropanol, ethylene glycol, and dimethyl sulfoxide.
[0422] Embodiment 27A. The method of any one of Embodiments 1A to 26A, wherein the ASD-forming solution comprises at least 30% organic vehicle by volume.
[0423] Embodiment 28A. The method of any one of Embodiments 1A to 27A, wherein the polymer of the ASD-forming solution is suitable for forming an amorphous solid dispersion (ASD) after deposition by a droplet dispenser.
[0424] Embodiment 29A. The method of any one of Embodiments 1A to 28A, wherein the polymer is selected based on one or more characteristics of the hydrophobic agent.
[0425] Embodiment 30A. The method of any one of Embodiments 1A to 29A, wherein the polymer is selected from the group consisting of: cellulose derivatives, poly(vinyl pyrrolidone) (PVP), poly(vinyl pyrrolidone-co-vinyl acetate) (copovidone or PVPVA), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose or HPMC), and HPMC acetate succinate (hydroxypropyl methylcellulose acetate succinate or HPMC-AS), and acrylic resins, or any combination thereof.
[0426] Embodiment 31A. The method of any one of Embodiments 1A to 30A, wherein the polymer is a grade selected from the group consisting of LF, MF, HF, LMP, MMP, HMP, LG, MG, and HG.
[0427] Embodiment 32A. The method of any one of Embodiments 1A to 31A, wherein the polymer is HPMC-AS-LF.
[0428] Embodiment 33A. The method of any one of Embodiments 1A to 32A, wherein the ratio of the concentration of polymer to the concentration of drug in the ASD-forming solution is 1:20 to 20:1.
[0429] Embodiment 34A. The method of any one of Embodiments 1A to 33A, wherein the ratio of the concentration of polymer to the concentration of drug in the ASD-forming solution is 1:2 to 2:1.
[0430] Embodiment 35A. The method of any one of Embodiments 1A to 34A, wherein less than 5% of the hydrophobic agent is crystallized in a dry state after deposition by the droplet dispenser.
[0431] Embodiment 36A. The method of any one of Embodiments 1A to 35A, wherein the hydrophobic agent does not substantially crystallize in a dry state.
[0432] Embodiment 37A. The method of any one of Embodiments 1A to 36A, wherein the ASD forming solution is supersaturated with the hydrophobic agent.
[0433] Embodiment 38A. The method of any one of Embodiments 1A to 37A, wherein the hydrophobic agent is a drug.
[0434] Embodiment 39A. The method of Embodiment 38A, wherein the drug is a small molecule drug.
[0435] Embodiment 40A. The method of Embodiment 38A or 39A, wherein the pharmaceutical agent is a Biopharmaceutics Classification System (BCS) Class II or Class IV drug.
[0436] Embodiment 41A. The method of Embodiment 38A, wherein the drug is a biomolecule.
[0437] Embodiment 42A. The method of Embodiment 41A, wherein the biomolecule is a polypeptide.
[0438] Embodiment 43A. The method of any one of Embodiments 38A to 42A, wherein the drug has a narrow therapeutic index.
[0439] Embodiment 44A. The method of any one of Embodiments 38A to 43A, wherein the drug is a high potency drug.
[0440] Embodiment 45A. The method of any one of Embodiments 1A to 37A, wherein the hydrophobic agent is a diagnostic compound.
[0441] Embodiment 46A. The method of any one of Embodiments 1A to 37A, wherein the hydrophobic agent is a reagent.
[0442] Embodiment 47A. The method of any one of Embodiments 1A to 37A, wherein the hydrophobic agent is an adjuvant or excipient.
[0443] Embodiment 48A. The method of any one of Embodiments 1A to 47A, wherein the agent has a solubility in water of less than 0.1 mg / mL.
[0444] Embodiment 49A. The method of any one of Embodiments 1A to 48A, wherein the concentration of the agent in the mixture is about 5 mg / mL to about 1,000 mg / mL.
[0445] Embodiment 50A. The method of any one of Embodiments 1A to 49A, wherein the ASD-forming solution further comprises a surfactant.
[0446] Embodiment 51A. The method according to embodiment 50A, wherein the surfactant is selected from Tween80, Vit-E, TPGS or SDS, or any combination thereof.
[0447] Embodiment 52A. The method of Embodiment 50A or 51A, wherein the ASD forming solution comprises 10% to 20% surfactant by volume.
[0448] Embodiment 53A. The method of any one of Embodiments 50A to 52A, wherein the ASD forming solution comprises a ratio of surfactant to hydrophobic agent of 1:100 to 5:1.
[0449] Embodiment 54A. The method of any one of Embodiments 1A to 53A, wherein the substrate is a pharmaceutically acceptable polymer.
[0450] Embodiment 55A. The method of any one of Embodiments 1A to 54A, wherein the substrate comprises chitosan, ethylenediaminetetraacetic acid, polyvinyl pyrrolidone, polyvinyl alcohol, alginate, agar, carrageenan, guar gum, xanthan gum, polycarbophil, and polyacrylic acid derivatives, or any combination thereof.
[0451] Embodiment 56A. The method of any one of Embodiments 1A to 55A, wherein the substrate is a film substrate.
[0452] Embodiment 57A. The method of any one of Embodiments 1A to 56A, wherein at least a portion of the hydrophobic agent is within the substrate after deposition by the droplet dispenser.
[0453] Embodiment 58A. The method of any one of Embodiments 1A to 57A, wherein at least a portion of the hydrophobic agent is on top of the substrate after deposition by the droplet dispenser.
[0454] Embodiment 59A. The method of any one of Embodiments 1A to 58A, wherein the dosage form is an oral dosage form.
[0455] Embodiment 60A. The method of any one of Embodiments 1A to 58A, wherein the dosage form is a buccal dosage form.
[0456] Embodiment 61A. The method of any one of Embodiments 1A to 58A, wherein the dosage form is a transdermal dosage form.
[0457] Embodiment 62A. The method of any one of Embodiments 1A to 61A, wherein the dosage form is sterile.
[0458] Embodiment 63A. The method of any one of Embodiments 1A to 62A, wherein the ASD forming solution is a colloid.
[0459] Embodiment 64A. The method of any one of Embodiments 1A to 63A, further comprising preparing an ASD forming solution.
[0460] Embodiment 65A. An ASD forming solution comprising:
[0461] Organic carrier,
[0462] Hydrophobic agents, and
[0463] Polymer crystallization inhibitors,
[0464] The polymer inhibitor is crystallized in a dry state.
[0465] Embodiment 66A. The ASD formulation solution of Embodiment 65A, wherein the ASD forming solution has a viscosity of 0.5 cP to 3 cP.
[0466] Embodiment 67A. The ASD-forming solution of any one of Embodiments 65A to 66A, wherein the ASD-forming solution has a viscosity between 1 cP and 2 cP.
[0467] Embodiment 68A. The ASD forming solution of any one of Embodiments 65A to 67A, wherein the ASD forming solution has a viscosity of 1.2 cP to about 1.8 cP.
[0468] Embodiment 69A. The ASD-forming solution of any one of Embodiments 65A to 68A, wherein the ASD-forming solution comprises a viscosity modifier.
[0469] Embodiment 70A. The ASD forming solution of any one of Embodiments 65A to 68A, wherein the viscosity modifier is a viscosity enhancer.
[0470] Embodiment 71A. The ASD forming solution of any one of Embodiments 65A to 70A, wherein the viscosity enhancer is ethylene glycol, polyethylene glycol, glycerol, or propylene glycol, or any combination thereof.
[0471] Embodiment 72A. The ASD forming solution of any one of Embodiments 65A to 69A, wherein the viscosity modifier is a viscosity reducing agent.
[0472] Embodiment 73A. The ASD forming solution of any one of Embodiments 65A to 69A or 72A, wherein the viscosity reducing agent is a salt or an amino acid, or a combination thereof.
[0473] Embodiment 74A. The ASD-forming solution of any one of Embodiments 65A to 73A, wherein the concentration of the viscosity modifier in the ASD-forming solution is 1% to 40%.
[0474] Embodiment 75A. The ASD forming solution of any one of Embodiments 65A to 74A, wherein the ratio of viscosity modifier to organic vehicle is from 1:100 to 40:100 by volume.
[0475] Embodiment 76A. The ASD forming solution of any one of Embodiments 6A5 to 75A, wherein the amount of viscosity modifier in the mixture is based on a desired viscosity of the mixture.
[0476] Embodiment 77A. An ASD forming solution according to any one of Embodiments 65A to 76A, wherein the organic carrier of the ASD forming solution comprises any one or more of acetone, dimethylformamide, ethanol, methanol, pentane, hexane, heptane, ethyl acetate, isopropanol, ethylene glycol and dimethyl sulfoxide.
[0477] Embodiment 78A. The ASD-forming solution of any one of Embodiments 65A to 77A, wherein the ASD-forming solution comprises at least 30% organic vehicle by volume.
[0478] Embodiment 79A. The ASD forming solution of any one of Embodiments 65A to 78A, wherein the polymer is selected based on one or more characteristics of the hydrophobic agent.
[0479] Embodiment 80A. An ASD forming solution according to any one of Embodiments 65A to 79A, wherein the polymer is selected from the group consisting of: a cellulose derivative, poly(vinyl pyrrolidone) (PVP), poly(vinyl pyrrolidone-co-vinyl acetate) (copovidone or PVPVA), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose or HPMC), and HPMC acetate succinate (hydroxypropyl methylcellulose acetate succinate or HPMC-AS), and an acrylic resin, or any combination thereof.
[0480] Embodiment 81A. The ASD forming solution of any one of Embodiments 65A to 80A, wherein the polymer is a grade selected from the group consisting of LF, MF, HF, LMP, MMP, HMP, LG, MG, and HG.
[0481] Embodiment 82A. The ASD-forming solution of any one of Embodiments 65A to 81A, wherein the polymer is HPMC-AS-LF.
[0482] Embodiment 83A. The ASD-forming solution of any one of Embodiments 65A to 82A, wherein the ratio of the concentration of the polymer to the concentration of the drug in the ASD-forming solution is 1:20 to 20:1
[0483] Embodiment 84A. The ASD-forming solution of any one of Embodiments 65A to 83A, wherein the ratio of the concentration of the polymer to the concentration of the drug in the ASD-forming solution is 1:2 to 2:1.
[0484] Embodiment 85A. A dispensing cartridge comprising the ASD-forming solution of any one of Embodiments 61A to 84A.
[0485] Embodiment 86A. A dosage form comprising an amorphous solid dispersion of a hydrophobic agent deposited via droplets onto a substrate.
[0486] Embodiment 87A. A dosage form prepared by the method according to any one of Embodiments 1A to 64A.
[0487] Embodiment 88A. The dosage form of Embodiment 87A, wherein the dosage form comprises: a fixed amount of a hydrophobic agent, wherein the hydrophobic agent is a therapeutic agent; and a fixed amount of a second hydrophobic agent.
[0488] Embodiment 89A. The dosage form of Embodiment 87A, wherein the second hydrophobic agent is a therapeutic agent.
[0489] Embodiment 90A. The dosage form of Embodiment 87A, wherein the second hydrophobic agent is a pharmaceutically acceptable excipient.
[0490] Example 91A. A method for determining a ratio of a hydrophobic agent to a polymer that forms an amorphous solid dispersion, the method comprising dispensing an amount of a first precursor solution and an amount of a second precursor solution onto a substrate, the first precursor solution comprising a first organic carrier, a hydrophobic agent, and a first viscosity enhancer, the second precursor solution comprising a second organic carrier, a polymer, and a second viscosity enhancer to determine a ratio of a hydrophobic agent to a polymer that forms an amorphous solid dispersion of the hydrophobic agent and the polymer, wherein the dispensing causes the first precursor solution to contact the second precursor solution.
[0491] Embodiment 92A. The method of Embodiment 91A, wherein the dispensing mixes the first precursor solution and the second precursor solution on the substrate.
[0492] Embodiment 93A. The method of Embodiment 91A, wherein the dispensing mixes the first precursor solution and the second precursor solution prior to applying the first precursor solution and the second precursor solution to the substrate.
[0493] Embodiment 94A. The method of any one of Embodiments 91A to 93A, wherein the amount of the first precursor solution and the amount of the second precursor solution are dispensed so that a gradient ratio of agent and polymer is formed in an area on the substrate.
[0494] Embodiment 95A. The method of Embodiment 94A, wherein the amount of the first precursor solution and the amount of the second precursor solution are dispensed such that an area on the substrate has a predetermined ratio of agent and polymer.
[0495] Embodiment 96A. The method of any one of Embodiments 91A to 95A, wherein the amount of the first precursor solution is dispensed from a first sub-nanoliter droplet dispenser, and wherein the amount of the second precursor solution is dispensed from a second sub-nanoliter droplet dispenser.
[0496] Embodiment 97A. The method of any one of Embodiments 91A to 96A, further comprising crystallization of the assessment agent.
[0497] Embodiment 98A. The method of any one of Embodiments 91A to 97A, wherein the first organic carrier and the second organic carrier are the same.
[0498] Embodiment 99A. The method of any one of Embodiments 91A to 98A, wherein the first viscosity enhancing agent and the second viscosity enhancing agent are the same.
[0499] Embodiment 100A. The method of any one of Embodiments 91A to 99A, wherein the substrate is a film.
[0500] Embodiment 101A. A droplet dispenser for producing a dosage form comprising an amorphous solid dispersion of a hydrophobic agent, the dispenser comprising:
[0501] (a) a dispensing head comprising one or more nozzles;
[0502] (b) ASD forming a solution comprising an organic carrier, an agent, a polymer and a viscosity modifier,
[0503] wherein the inhibitor and the polymer are present in the mixture in a ratio such that the inhibitor crystallizes on the substrate in the dry state,
[0504] wherein the mixture cartridge is operably coupled to the dispensing head; and
[0505] (c) A control system configured to dispense the mixture via the dispensing head according to a dispensing pattern.
[0506] Embodiment 102A. The dispenser of Embodiment 101A, wherein the dispensing head comprises from about 100 to about 1000 nozzles.
[0507] Embodiment 103A. The dispenser of Embodiment 101A or 102A, wherein each nozzle has an aperture size of about 20 μm to about 120 μm.
[0508] Embodiment 104A. The dispenser of any of Embodiments 101A to 103A, wherein the dispensing head uses a thermal process to dispense the droplets.
[0509] Embodiment 105A. The dispenser of any of Embodiments 101A to 104A, wherein the dispensing head uses a piezoelectric process to dispense the droplets.
[0510] Embodiment 106A. The dispenser of any of Embodiments 101A-105A, further comprising a second dispensing head operably coupled to a second mixture cartridge, wherein the second mixture cartridge comprises a second mixture comprising a second dose.
[0511] Embodiment 107A. The dispenser of Embodiment 106A, further comprising a third dispensing head operably coupled to a third mixture cartridge, wherein the third mixture cartridge comprises a protective coating mixture.
[0512] Embodiment 108A. The dispenser of Embodiment 107A, further comprising a fourth dispensing head operably coupled to a fourth dispensing cartridge, wherein the fourth mixture cartridge comprises an edible mixture.
[0513] Example 109A. A gradient of two components on a substrate, the gradient comprising
[0514] A first component comprising a hydrophobic agent;
[0515] a second component comprising a polymer crystallization inhibitor; and
[0516] A ratio of a first component to a second component, wherein the ratio varies across a gradient.
[0517] Embodiment 110A. The gradient of Embodiment 109A, wherein the first component further comprises an organic vehicle.
[0518] Embodiment 111A. The gradient of Embodiment 109A or 110A, wherein the first component further comprises a viscosity enhancer.
[0519] Embodiment 112A. The gradient of any one of Embodiments 109A to 111A, wherein the second component further comprises an organic vehicle.
[0520] Embodiment 113A. The gradient of any one of Embodiments 109A to 112A, wherein the second component further comprises a viscosity enhancer.
[0521] Embodiment 114A. The gradient of any one of Embodiments 109A to 113A, wherein the second component is capable of inhibiting crystallization of the hydrophobic agent.
[0522] Embodiment 115A. The gradient of Embodiment 109A, wherein the first component and the second component each comprise an organic vehicle, wherein the organic vehicles are the same.
[0523] Embodiment 116A. The gradient of Embodiment 109A, wherein the first component and the second component each comprise a viscosity enhancer, wherein the viscosity enhancers are the same.
[0524] Embodiment 117A. The gradient of any one of Embodiments 109A to 116A, wherein the ratio becomes low enough at some point on the gradient to prevent crystallization of the hydrophobic agent.
[0525] Embodiment 118A. The gradient of any one of Embodiments 109A to 117A, wherein the first component and the second component are dispensed onto the substrate from a sub-nanoliter droplet dispenser.
[0526] Embodiment 119A. The gradient of any one of Embodiments 109A to 117A, wherein the first component is dispensed onto the substrate from a first sub-nanoliter droplet dispenser and the second component is dispensed onto the substrate from a second sub-nanoliter droplet dispenser.
[0527] Embodiment 120A. The gradient of any one of Embodiments 109A to 119A, wherein the ratio changes at a consistent rate across the gradient.
[0528] Examples
[0529] The following examples are included for illustrative purposes and are not intended to limit the scope of the teachings provided in this application. Unless otherwise stated, reagents and materials were obtained from commercial sources and used as received. Unless otherwise stated, loadings and concentrations are reported as weight percent (wt.%).
[0530] Example 1: Production of nanosuspension
[0531] Naproxen was used as received commercially. 45.6 grams of yttria-stabilized zirconium oxide powder grinding beads were loaded into a 20 mL glass scintillation vial. Naproxen solid (0.876 g) was weighed into a vial. In a separate 20 mL vial, water (2.628 mL) and a stock solution of 5% polyvinyl pyrrolidone (PVP, 4.380 mL) and 1% sodium dodecyl sulfate (SDS, 0.876 mL) were mixed. The aqueous solution was then transferred to the vial containing naproxen to form a slurry with a naproxen:PVP:SDS ratio of 1:0.25:0.01 and a total drug concentration of 100 mg / mL. The vial was sealed with a polytetrafluoroethylene cap and then placed on an acoustic resonance mixer for grinding at 40 G's for 2 hours.
[0532] The resulting liquid nanosuspension sample was removed from the grinding beads by extraction with a syringe equipped with a 26-gauge needle, resulting in an average yield of approximately 7 grams (80%). The resulting nanosuspension appeared as a white, opaque mixture with well-dispersed and suspended nanoparticles visible only under high magnification of an optical microscope (see Figure 1 ). The nanosuspension at a drug concentration of 100 mg / mL was diluted with an appropriate volume of water to obtain formulation samples at drug concentrations of 10 mg / mL and 1 mg / mL. Ethylene glycol was added to some formulation samples as a viscosity enhancer.
[0533] Example 2: Viscosity measurement and inkjet printing of nanosuspensions
[0534] The viscosity of the naproxen formulations was measured using a viscometer. A circulating water bath was used to maintain a temperature of 25° C. at the sample chamber. An aliquot (0.5 mL) of the formulation sample was added to the sample chamber and the viscosity was recorded after the measurement had stabilized to <0.1% deformation.
[0535] A commercial inkjet photo printer equipped with a standard thermal inkjet print head is used to print the pattern of nanosuspension. Refillable ink cartridges are used as received and are loaded with liquid preparations for printing. Nanosuspension is introduced into the barrel via the hole at the top to fill the internal reservoir. The barrel has a sponge material, which is used to help control the release rate of liquid through the macropores at the bottom of the barrel, and the liquid enters the inkjet print head at the macropores for final distribution. Adobe Photoshop is used to create a simple printing pattern using ink colors (e.g., cyan) from a single cartridge source, which consists of a circle with a diameter of 100 pixels and a resolution of 72 dots per inch (dpi). Commercial 8.5 "x 11" acetate transparent film is used as a printing substrate. Before analysis, the printed output is allowed to air dry for several hours. Between multiple printing runs, the inkjet print head is carefully washed with deionized water and acetone to remove any residual preparations. The results of four preparation samples are shown in Table 2.
[0536] 1mg / mL and 10mg / mL nanosuspension formulations were not retained in the cartridge and therefore could not be effectively printed. The 10mg / mL formulation with 10% ethylene glycol had a viscosity of about 1.5cP. This higher viscosity formulation was very suitable for printing, which was consistent with the measured results of commercial inks (which had a viscosity between about 1cP and 5cP). Further measurements were performed to determine the effect of ethylene glycol on formulation stability.
[0537] Table 1: Suitability of nanosuspension formulations of different concentrations and viscosities for inkjet printing.
[0538]
[0539] Example 3: Particle size analysis using dynamic light scattering of nanosuspensions
[0540] Determine the particle size distribution of naproxen formulations prepared as in Example 1. Take a 10 μL aliquot of each nanosuspension sample and dilute in 90 μL of water for analysis using a dynamic light scattering instrument. A 40 μL aliquot of the diluted suspension is dispensed into a low volume black polystyrene 384-well plate for analysis. The particle size of each sample is reported as the average of 10 acquisitions at 25°C, with an acquisition time of 3 seconds. The autocorrelation curve is fitted using a cumulative amount or regularization method, and the D50 radius measurement is obtained and reported. Normalized polydispersity (% Pd) is calculated as the polydispersity divided by the hydrodynamic radius estimated by the cumulative amount fit of the autocorrelation function multiplied by 100. The results of the D50 radius are shown in Table 2. Adding ethylene glycol to the formulation increases the size of the nanoparticles in the nanosuspension.
[0541] Table 2. Effect of adding ethylene glycol as a viscosity enhancer on nanoparticle size.
[0542]
[0543] Example 4: Analysis of drug concentration in printed patterns using HPLC
[0544] The printed nanosuspension patterns from Example 2 were analyzed for drug concentration using a high performance liquid chromatography (HPLC) system equipped with a quaternary pump, a photodiode array UV-Vis detector, and a reverse phase alkylsilane column (3.5 μm particle size, 50×4.6 mm size). The printed patterns from Example 2 were cut and then washed and completely dissolved with 1:1 acetonitrile: water. The resulting solution was then analyzed by HPLC for drug concentration compared to standards of known concentrations. The mobile phase of the HPLC process consisted of a solution of 0.05% trifluoroacetic acid in water and in acetonitrile. A gradient elution was used in which the acetonitrile mobile phase was increased from 2% to 65% in 6.5 min at a flow rate of 1.25 mL / min. The column was heated at 30° C. and detection was performed at 254 nm. Analysis of multiple printed patterns (n=3) indicated that microgram amounts of drug were deposited onto transparent films with high reproducibility and low variability. The results are shown in Table 3.
[0545] Table 3. Deposition analysis of printed samples of naproxen nanosuspensions at 100 mg / mL concentration and 10 mg / mL concentration
[0546]
[0547] For the naproxen nanosuspension formulation with a drug concentration of 100 mg / mL, the measured deposition was 13.19 μg / cm 2 And the target printing resolution in the pattern was 72 dpi, and the droplet size was calculated to be 16.6 picoliters. This is well within the expected range of droplet sizes dispensed by similar inkjet print heads. This also indicates that there was no major disruption to droplet formation during the printing process, nor was there significant loss or degradation of the drug formulation, consistent with the HPLC analysis results.
[0548] These results are consistent with the expectations of the inkjet printing process as a precise method for controlling droplet deposition, indicating that no significant problems occurred despite the replacement of traditional printer inks with drug formulation "inks" and the ability to produce consistent dosage forms with good content uniformity. In addition, the amount of deposited drug is proportional to the initial concentration of the nanosuspension ink. Reducing the initial concentration from 100 mg / mL to 10 mg / mL resulted in a 10-fold reduction in the amount of naproxen deposited on the transparent film. In addition, HPLC analysis showed the absence of degradation products or other impurities, indicating that despite the flash heat required for deposition, the drug remained stable throughout the inkjet printing process.
[0549] Example 5: Optical analysis and reconstruction of printed patterns
[0550] Optical microscopy analysis of the printed nanosuspension patterns from Example 2 was performed using a microscope equipped with a camera. Commercially available acetate transparencies used for inkjet printed nanosuspension formulations were directly analyzed by bright-field transmitted light microscopy at different magnifications. Figure 2 and Figure 3 Shown in.
[0551] The reconstitution of the printed nanosuspension after drying was then studied. A drop of water was placed on a transparent body containing the dried and printed nanosuspension from Example 3. The wetting and redispersion of the nanosuspension droplets were observed in real time by monitoring the advancing water line with an optical microscope (see FIG. 4A to FIG. 4C ). Upon exposure to water, the dried nanosuspension droplets immediately hydrated, releasing the drug nanoparticles into solution. The resulting reconstituted nanosuspension was recovered and analyzed by optical microscopy, showing a homogeneous, well-dispersed suspension with no significant aggregation (see FIG7 ). Dynamic light scattering analysis of the reconstituted sample showed particles consisting of 114 nm in diameter that did not show significant aggregation after drying and redispersion, confirming that nanosuspension stability was maintained during the process.
[0552] Example 6: Dispensing and depositing an organic vehicle using an inkjet printer
[0553] This example demonstrates the use of a droplet dispenser to dispense and deposit an organic vehicle that uses a thermal process to dispense droplets, enabling the dispensing of pharmaceutical agents that are prone to crystallization, such as hydrophobic agents, and polymers for producing amorphous solid dispersions containing pharmaceutical agents.
[0554] The solvent mixture was prepared according to Table 4. Refillable inkjet printer cartridges were used as received and loaded with the solvent mixture for printing. A commercial inkjet photo printer equipped with a standard thermal inkjet print head was used to dispense and deposit droplets of the solvent mixture onto the film substrate.
[0555] Table 4. Solvent mixtures and their characteristics.
[0556] Solvent mixture Viscosity(cP) Is it printable? 20% mixture of ethylene glycol in acetone 0.611 no 30% mixture of ethylene glycol in acetone 0.963 no 40% mixture of ethylene glycol in acetone 1.658 yes 50% mixture of ethylene glycol in acetone 3.085 no
[0557] It has been observed that if the solvent mixture is too fluid (low viscosity), the solvent mixture leaks in some droplet dispensers and from some dispenser cartridges. On the other hand, if the solvent mixture is too viscous, dispensing of the solvent mixture is impossible or unreliable. A mixture of 40% ethylene glycol in acetone with a viscosity of 1.659 cp was successfully dispensed and deposited on a film substrate, indicating that a high concentration organic vehicle is a suitable solution for use in a droplet dispenser.
[0558] Example 7: Production of amorphous solid dispersion using an inkjet printer
[0559] This example demonstrates the use of two precursor solutions to identify an ASD-forming solution, and the use of a droplet dispenser to generate and optimize ASDs therefrom.
[0560] A first precursor solution was prepared containing 2% griseofulvin (a fast crystallizer model drug; 20 mg / mL), an acetone organic vehicle, and ethylene glycol. Different amounts of ethylene glycol (a viscosity modifier) were evaluated, including 30%, 35%, and 40%. Only the 35% and 40% ethylene glycol precursor solutions had viscosities between 1 cP and 2 cP (1.200 and 1.702, respectively), and the 40% ethylene glycol precursor solution was used to evaluate droplet distribution.
[0561] A second precursor solution was prepared containing 2% HPMCAS-LF (polymer; 20 mg / mL) in an acetone organic vehicle, and optionally with ethylene glycol. Different amounts of ethylene glycol (a viscosity modifier) were evaluated, including 0% (pure acetone), 5%, 20%, 30%, and 40%. Only the 0% and 5% ethylene glycol precursor solutions had viscosities between 1 cP and 2 cP (1.208 and 1.365, respectively), and the 5% ethylene glycol precursor solution was used to evaluate droplet distribution. It is worth noting that the polymer HPMCAS-LF was also used to adjust the viscosity of the precursor solution.
[0562] The first precursor solution and the second precursor solution were added to separate refillable inkjet printer cartridges. A commercial inkjet photo printer equipped with a standard thermal inkjet print head was used to dispense and deposit droplets of the first precursor solution and the second precursor solution onto a substrate according to the desired ratio of griseofulvin to HPMCAS-LF and the methods described herein. Specifically, Fig. 7AAs shown, two droplet dispensers (print heads) are used to produce a gradient deposition. The amount of the first precursor solution dispensed from the first droplet dispenser and the amount of the second precursor solution dispensed from the second droplet dispenser can vary across regions, resulting in a gradient deposition. The gradient can be varied as desired, and in this example a uniform gradient is produced, wherein on the left side of the gradient deposition, the deposition includes 100% loading of griseofulvin, and on the right side of the gradient deposition, the deposition includes 100% HPMCAS-LF. An image is captured, and the image shows crystallization of griseofulvin at 100% loading of griseofulvin, and amorphous polymer at 100% loading of HPMCAS-LF. In addition, as shown Figure 7B As shown, regions (100%, 50%, 40%, 30%, 20%, 10% and 0%) with set loadings of griseofulvin were produced relative to HPMCAS-LF. The captured images of regions with 20% loading of griseofulvin and corresponding 20% griseofulvin loading on the gradient deposition prove that ASD of griseofulvin was produced using the droplet dispensing technology taught herein. ASD was produced via conventional large-scale spray drying technology with a known 20% griseofulvin loading. The results presented herein show that the droplet dispenser technology is able to reproduce known ASD properties on a miniaturized scale.
Claims
1. A method for preparing a dosage form comprising a hydrophobic agent, the method comprising: A plurality of droplets of a formulation comprising the hydrophobic agent are deposited onto a substrate using a high frequency droplet dispenser to form a dosage form, wherein the viscosity of the formulation is less than 3 cP. 2 . The method of claim 1 , wherein the high frequency droplet dispenser uses a thermal process to deposit the plurality of droplets.
3. The method of claim 1, wherein the high frequency droplet dispenser uses a piezoelectric process to deposit the plurality of droplets.
4. The method of any one of claims 1 to 3, wherein the high frequency droplet distributor comprises from about 100 to about 1000 individual nozzles. 5 . The method of claim 4 , wherein each nozzle comprises an orifice having a diameter of about 20 μm to about 120 μm.
6. The method according to any one of claims 1 to 6, wherein the high-frequency droplet dispenser is a high-frequency sub-nanoliter droplet dispenser.
7. The method of claim 6, wherein the high frequency sub-nanoliter droplet dispenser dispenses droplets at in excess of 3 kHz, as measured per nozzle.
8. The method according to any one of claims 1 to 7, wherein the high-frequency droplet dispenser dispenses droplets having a volume of 1 nanoliter or less.
9. The method of claim 8, wherein the average volume of each dispensed droplet of the plurality of droplets of the formulation is from about 1 picoliter to about 50 picoliters.
10. The method of claim 7 or 8, wherein a plurality of formulation droplets are deposited onto the substrate based on an average number of droplets per square inch.
11. The method of claim 10, wherein the average number of droplets deposited per square inch of the substrate is from about 1 droplet per square inch to about 500 droplets per square inch.
12. The method of claim 10 or 11, wherein the plurality of droplets of the formulation deposited on the substrate have an average diameter of about 5 μm to about 100 μm.
13. The method of any one of claims 1 to 12, wherein the plurality of droplets of the formulation deposited on the substrate forms a continuous layer.
14. The method according to any one of claims 1 to 13, wherein the ASD forming solution has a viscosity of 0.5 cP to 3 cP.
15. The method according to any one of claims 1 to 14, wherein the viscosity of the formulation is less than 2 cP and greater than 1 cP.
16. The method according to any one of claims 1 to 15, wherein the viscosity of the formulation is between 1.2 cP and 1.8 cP.
17. The method according to any one of claims 1 to 15, wherein the formulation further comprises a viscosity modifier.
18. The method of claim 16, wherein the viscosity modifier is a viscosity enhancer.
19. The method of claim 17, wherein the viscosity enhancer is selected from the group consisting of ethylene glycol, polyethylene glycol, glycerol, and propylene glycol.
20. The method of claim 18, wherein the viscosity modifier is a viscosity reducing agent.
21. The method of claim 20, wherein the viscosity reducing agent is a salt or an amino acid, or a combination thereof.
22. The method of any one of claims 17 to 21, wherein the amount of the viscosity modifier in the mixture is based on a desired viscosity of the mixture.
23. The method of claim 17 or 18, wherein the viscosity enhancing agent is present in the formulation at a concentration of about 1% to about 40% v / v of the formulation.
24. The method of any one of claims 17 to 20, further comprising adding the viscosity enhancing agent to the formulation to achieve a viscosity of the formulation of between about 1 cP and about 2 cP.
25. The method according to any one of claims 1 to 24, wherein the formulation is a suspension comprising: Aqueous carriers, and A plurality of nanoparticles are suspended in the aqueous carrier, wherein the nanoparticles comprise the hydrophobic agent.
26. The method according to any one of claims 1 to 25, wherein the suspension is a nanosuspension.
27. The method according to any one of claims 1 to 26, wherein the suspension is a colloidal suspension.
28. The method of any one of claims 1 to 27, wherein the aqueous carrier comprises water and an organic solvent.
29. The method of any one of claims 18 to 19, wherein the formulation has a ratio of the viscosity enhancing agent to the aqueous carrier of from about 1:1000 to about 1:2 by volume.
30. The method of any one of claims 25 to 29, wherein the hydrophobic agent is insoluble in the aqueous carrier.
31. The method of any one of claims 1 to 30, wherein the hydrophobic agent has a solubility in water of less than 1 mg / mL.
32. The method of any one of claims 25 to 31, wherein the concentration of the hydrophobic agent in the suspension is from about 5 mg / mL to about 1,000 mg / mL.
33. The method according to any one of claims 1 to 32, wherein the suspension further comprises a stabilizing component.
34. The method of claim 33, wherein the ratio of the stabilizing component of the suspension to the aqueous carrier is from about 1:500 to about 1:10 by weight.
35. A method according to claim 33 or claim 34, wherein the stabilizing component comprises PVP and / or SDS.
36. The method of claim 25, wherein the plurality of nanoparticles have an average diameter of less than about 500 nm.
37. The method of claim 25, wherein the plurality of nanoparticles have a D50 of about 100 nm to about 400 nm.
38. The method of claim 25, wherein the plurality of nanoparticles have a D90 of about 250 μm to about 50 nm.
39. The method of claim 25, wherein at least a portion of the plurality of nanoparticles are deposited within the substrate.
40. The method of claim 25, wherein at least a portion of the plurality of nanoparticles are deposited on top of the substrate.
41. The method of any one of claims 1 to 24, wherein the formulation is an amorphous solid dispersion (ASD) forming solution comprising: The hydrophobic agent; an organic carrier; and A polymer, wherein the ratio of the polymer to the hydrophobic agent inhibits crystallization of the hydrophobic agent on the substrate in a dry state.
42. The method of claim 41, wherein the ASD forming solution is a colloid.
43. The method according to claim 41 or 42, wherein the organic vehicle of the ASD forming solution comprises any one or more components selected from the group consisting of acetone, dimethylformamide, ethanol, methanol, pentane, hexane, heptane, ethyl acetate, isopropanol, ethylene glycol and dimethyl sulfoxide.
44. The method of any one of claims 41 to 43, wherein the ASD-forming solution comprises at least 30% by volume of an organic vehicle.
45. The method of any one of claims 44, wherein the ratio of the viscosity modifier to the organic vehicle is from 1:100 to 40:100 by volume.
46. The method of any one of claims 41 to 45, wherein the polymer of the ASD forming solution is suitable for forming an amorphous solid dispersion (ASD) after deposition by the droplet dispenser.
47. The method of any one of claims 41 to 46, wherein the polymer is selected based on one or more characteristics of the hydrophobic agent.
48. The method of any one of claims 41 to 47, wherein the polymer is selected from the group consisting of cellulose derivatives, poly(vinyl pyrrolidone) (PVP), poly(vinyl pyrrolidone-co-vinyl acetate) (copovidone or PVPVA), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose or HPMC), and HPMC acetate succinate (hydroxypropyl methylcellulose acetate succinate or HPMC-AS), and acrylic resins, or any combination thereof.
49. The method of any one of claims 41 to 48, wherein the polymer is a grade selected from the group consisting of LF, MF, HF, LMP, MMP, HMP, LG, MG and HG.
50. The method of any one of claims 41 to 49, wherein the polymer is HPMC-AS-LF.
51. The method of any one of claims 41 to 50, wherein the ratio of the concentration of the polymer to the concentration of the hydrophobic agent is from 1:20 to 20:
1.
52. The method of any one of claims 41 to 51, wherein the ratio of the concentration of the polymer to the concentration of the hydrophobic agent is from 1:2 to 2:
1.
53. The method of any one of claims 41 to 52, wherein the ASD forming solution further comprises a surfactant.
54. The method according to claim 53, wherein the surfactant is selected from Tween 80, Vit-E, TPGS or SDS, or any combination thereof.
55. The method of claim 53 or 54, wherein the ASD-forming solution comprises 10% to 20% by volume of the surfactant.
56. The method of any one of claims 53 to 55, wherein the ASD forming solution comprises a ratio of the surfactant to the hydrophobic agent of 1:100 to 5:
1.
57. A method according to any one of claims 41 to 56, wherein less than 5% of the hydrophobic agent is crystallized in the dry state after deposition by the droplet dispenser.
58. The method of any one of claims 41 to 57, wherein the hydrophobic agent does not substantially crystallize in a dry state.
59. The method of any one of claims 41 to 58, wherein the ASD forming solution is supersaturated with the hydrophobic agent.
60. The method of any one of claims 41 to 59, wherein the concentration of the hydrophobic agent in the mixture is from about 5 mg / mL to about 1,000 mg / mL.
61. The method of any one of claims 41 to 60, wherein at least a portion of the hydrophobic agent is within the substrate after deposition by the droplet dispenser.
62. The method of any one of claims 41 to 61, wherein at least a portion of the hydrophobic agent is on top of the substrate after deposition by the droplet dispenser.
63. The method of any one of claims 1 to 62, wherein the hydrophobic agent is a therapeutic agent.
64. The method of claim 63, wherein the therapeutic agent is a small molecule drug.
65. The method of claim 63, wherein the therapeutic agent is a biomolecule.
66. The method of claim 63, wherein the therapeutic agent is a Biopharmaceutics Classification System (BCS) Class II or Class IV agent.
67. The method of any one of claims 63 to 66, wherein the therapeutic agent has a narrow therapeutic index.
68. The method of any one of claims 63 to 67, wherein the therapeutic agent is a high potency drug.
69. The method of any one of claims 1 to 62, wherein the hydrophobic agent is an excipient or adjuvant.
70. The method of any one of claims 1 to 62, wherein the hydrophobic agent is a diagnostic compound.
71. The method of any one of claims 1 to 62, wherein the hydrophobic agent is a reagent.
72. The method of any one of claims 1 to 71, wherein the hydrophobic agent has a solubility in water of less than 0.1 mg / mL.
73. The dosage form of any one of claims 1 to 72, wherein the amount of the hydrophobic agent is less than 0.1 mg.
74. The method of any one of claims 1 to 73, wherein the substrate is a pharmaceutically acceptable polymer.
75. The method of any one of claims 1 to 74, wherein the substrate is selected from the group consisting of one or more of the following: chitosan, ethylenediaminetetraacetic acid, polyvinylpyrrolidone, polyvinyl alcohol, alginate, agar, carrageenan, guar gum, xanthan gum, polycarbophil and polyacrylic acid derivatives.
76. The method of any one of claims 1 to 75, wherein the substrate is a film substrate.
77. The method of any one of claims 1 to 76, wherein the dosage form is an oral dosage form.
78. The method of any one of claims 1 to 76, wherein the dosage form is a buccal dosage form.
79. The method of any one of claims 1 to 76, wherein the dosage form is a transdermal dosage form.
80. The method of any one of claims 1 to 79, wherein the dosage form is sterile.
81. A suspension comprising: Aqueous carrier; A plurality of nanoparticles are suspended in the aqueous carrier, the plurality of nanoparticles comprising a hydrophobic agent, wherein the viscosity of the suspension is less than 3 cP.
82. The suspension of claim 81, wherein the viscosity of the suspension is less than 2 cP and greater than 1 cP.
83. The suspension of claim 81 or 82, wherein the viscosity of the suspension is between 1.2 cP and 1.8 cP.
84. A suspension according to any one of claims 81 to 83, wherein the suspension further comprises a viscosity modifier.
85. The suspension of claim 84, wherein the viscosity modifier is a viscosity enhancer.
86. The suspension of claim 85, wherein the viscosity enhancing agent is selected from the group consisting of ethylene glycol, polyethylene glycol, glycerol, and propylene glycol.
87. The suspension of claim 85 or 86, wherein the viscosity enhancing agent is present in the suspension at a concentration of about 1% to about 40% v / v of the suspension.
88. The suspension of any one of claims 81 to 87, wherein the suspension has a ratio of the viscosity enhancing agent to the aqueous carrier of about 1:1000 to about 1:2 by volume.
89. The suspension of any one of claims 81 to 88, further comprising adding the viscosity enhancer to the suspension to achieve a viscosity of the suspension of between about 1 cP and about 2 cP.
90. A suspension according to any one of claims 81 to 89, wherein the aqueous carrier comprises water and an organic solvent.
91. A suspension according to any one of claims 81 to 90, wherein the suspension is a colloidal suspension.
92. A suspension according to any one of claims 81 to 91, wherein the suspension further comprises a stabilizing component.
93. The suspension of claim 92, wherein the ratio of the stabilizing component of the suspension to the aqueous carrier is from about 1:500 to about 1:10 by weight.
94. A suspension according to claim 92 or 93, wherein the stabilizing component comprises PVP and / or SDS.
95. A suspension according to any one of claims 81 to 94, wherein the average diameter of the plurality of nanoparticles is less than about 500 nm.
96. A suspension according to any one of claims 81 to 95, wherein the plurality of nanoparticles have a D50 of about 100 nm to about 400 nm.
97. The suspension of any one of claims 81 to 96, wherein the plurality of nanoparticles have a D90 of about 250 μm to about 50 nm.
98. A suspension according to any one of claims 81 to 97, wherein the hydrophobic agent is insoluble in the aqueous carrier.
99. The suspension of any one of claims 81 to 98, wherein the hydrophobic agent has a solubility in water of less than 1 mg / mL.
100. The suspension of any one of claims 81 to 99, wherein the hydrophobic agent is a therapeutic agent.
101. The suspension of claim 100, wherein the therapeutic agent is a small molecule drug.
102. The suspension of claim 100, wherein the therapeutic agent is a biomolecule.
103. The suspension of claim 100, wherein the hydrophobic agent is a Biopharmaceutics Classification System (BCS) Class II or Class IV agent.
104. The suspension of any one of claims 100 to 103, wherein the therapeutic agent has a narrow therapeutic index.
105. The suspension of any one of claims 100 to 104, wherein the therapeutic agent is a high potency drug.
106. A suspension according to any one of claims 81 to 99, wherein the hydrophobic agent is an excipient or adjuvant.
107. The suspension of any one of claims 81 to 106, wherein the concentration of the hydrophobic agent in the suspension is from about 5 mg / mL to about 1,000 mg / mL.
108. A suspension form according to any one of claims 81 to 107, wherein the amount of the hydrophobic agent is less than 0.1 mg.
109. An ASD forming solution comprising: Organic carrier, Hydrophobic agents, and A polymeric crystallization inhibitor, wherein the polymer inhibits crystallization of the agent in a dry state.
110. The ASD formulation solution of claim 109, wherein the ASD forming solution has a viscosity of 0.5 cP to 3 cP.
111. The ASD forming solution according to any one of claims 109 to 110, wherein the ASD forming solution has a viscosity between 1 cP and 2 cP.
112. The ASD forming solution of any one of claims 109 to 111, wherein the ASD forming solution has a viscosity of 1.2 cP to about 1.8 cP.
113. The ASD forming solution of any one of claims 109 to 112, wherein the ASD forming solution comprises a viscosity modifier.
114. The ASD forming solution of claim 113, wherein the viscosity modifier is a viscosity enhancer.
115. The ASD forming solution of claim 114, wherein the viscosity enhancing agent is ethylene glycol, polyethylene glycol, glycerol or propylene glycol, or any combination thereof.
116. The ASD forming solution of claim 113, wherein the viscosity modifier is a viscosity reducing agent.
117. The ASD forming solution of claim 116, wherein the viscosity reducing agent is a salt or an amino acid, or a combination thereof.
118. The ASD-forming solution of any one of claims 114 to 117, wherein the concentration of the viscosity modifier in the ASD-forming solution is 1% to 40%.
119. The ASD forming solution of any one of claims 114 to 118, wherein the ratio of the viscosity modifier to the organic vehicle is from 1:100 to 40:100 by volume.
120. The ASD forming solution of any one of claims 114 to 119, wherein the amount of viscosity modifier in the mixture is based on a desired viscosity of the mixture.
121. The ASD forming solution according to any one of claims 109 to 120, wherein the organic carrier of the ASD forming solution comprises a component selected from the group consisting of: acetone, dimethylformamide, ethanol, methanol, pentane, hexane, heptane, ethyl acetate, isopropanol, ethylene glycol and dimethyl sulfoxide.
122. The ASD-forming solution of any one of claims 109 to 121, wherein the ASD-forming solution comprises at least 30% organic vehicle by volume.
123. The ASD forming solution of any one of claims 109 to 122, wherein the polymer is selected based on one or more characteristics of the hydrophobic agent.
124. An ASD forming solution according to any one of claims 109 to 123, wherein the polymer is selected from the group consisting of: cellulose derivatives, poly(vinyl pyrrolidone) (PVP), poly(vinyl pyrrolidone-co-vinyl acetate) (copovidone or PVPVA), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose or HPMC), and HPMC acetate succinate (hydroxypropyl methylcellulose acetate succinate or HPMC-AS), and acrylic resins, or any combination thereof.
125. The ASD forming solution of any one of claims 109 to 123, wherein the polymer is a grade selected from the group consisting of: LF, MF, HF, LMP, MMP, HMP, LG, MG and HG.
126. The ASD forming solution of any one of claims 109 to 123, wherein the polymer is HPMC-AS-LF.
127. The ASD forming solution of any one of claims 109 to 126, wherein the ratio of the concentration of the polymer to the concentration of the drug in the ASD forming solution is 1:20 to 20:
1.
128. The ASD-forming solution of any one of claims 109 to 127, wherein the ratio of the concentration of the polymer to the concentration of the drug in the ASD-forming solution is 1:2 to 2:
1.
129. A composition comprising a dried or lyophilized suspension, wherein upon reconstitution a suspension according to any one of claims 81 to 108 is formed.
130. A dosage form prepared by the method of any one of claims 1 to 80.
131. The dosage form of claim 130, wherein the dosage form comprises: a fixed amount of the hydrophobic agent, wherein the hydrophobic agent is a therapeutic agent; and a fixed amount of a second hydrophobic agent.
132. The dosage form of claim 131, wherein the second hydrophobic agent is a therapeutic agent.
133. The dosage form of claim 131, wherein the second hydrophobic agent is a pharmaceutically acceptable excipient.
134. A plurality of dosage forms according to any one of claims 130 to 133, prepared as a batch of pharmaceutical dosage forms, wherein the amount of the hydrophobic agent in each pharmaceutical dosage form in the batch varies by no more than 5% relative to a mean value.
135. A system for producing a dosage form, the system comprising: a. A suspension comprising a hydrophobic agent, wherein the suspension comprises an aqueous carrier and a plurality of nanoparticles, wherein each of the plurality of nanoparticles comprises the hydrophobic agent, and wherein the viscosity of the suspension is less than 2 cP; as well as b. A high frequency droplet dispenser comprising from about 100 to about 1000 individual nozzles, each nozzle being configured to deposit at least one droplet of the suspension onto a substrate of the dosage form.
136. The system of claim 135, wherein each nozzle has an aperture of about 20 μm to about 120 μm.
137. The system of claim 135 or 136, wherein the suspension droplets are deposited onto the substrate using a thermal process.
138. The system of claim 135 or 136, wherein the suspension droplets are deposited onto the substrate using a piezoelectric process.
139. A system for producing a dosage form, the system comprising: an amorphous solid dispersion (ASD) comprising a hydrophobic agent, the method comprising depositing droplets of an ASD-forming solution comprising the hydrophobic agent, an organic vehicle, and a polymer onto a substrate using a droplet dispenser, wherein the ratio of the polymer to the hydrophobic agent inhibits crystallization of the hydrophobic agent on the substrate in a dry state, and wherein the viscosity of the ASD-forming solution is less than 2 cP; as well as A high frequency droplet dispenser comprising from about 100 to about 1000 individual nozzles, each nozzle being configured to deposit at least one droplet of solution onto a substrate of the dosage form.
140. The system of claim 139, wherein each nozzle has an aperture of about 20 μm to about 120 μm.
141. The system of claim 139 or 140, wherein the solution droplets are deposited onto the substrate using a thermal process.
142. The system of claim 139 or 140, wherein the solution droplets are deposited onto the substrate using a piezoelectric process.
143. A dispensing cartridge comprising an ASD forming solution according to any one of claims 109 to 128.
144. A dosage form comprising a nanosuspension of a hydrophobic agent deposited via droplets onto a substrate.
145. A dosage form comprising an amorphous solid dispersion of a hydrophobic agent deposited via droplets onto a substrate.
146. A method for determining a ratio of a hydrophobic agent to a polymer that forms an amorphous solid dispersion, the method comprising dispensing an amount of a first precursor solution and an amount of a second precursor solution onto a substrate, the first precursor solution comprising a first organic vehicle, the hydrophobic agent, and a first viscosity enhancer, and the second precursor solution comprising a second organic vehicle, a polymer, and a second viscosity enhancer to determine a ratio of the hydrophobic agent to the polymer that forms an amorphous solid dispersion of the hydrophobic agent and the polymer, wherein the dispensing causes the first precursor solution to contact the second precursor solution.
147. The method of claim 146, wherein the dispensing mixes the first precursor solution and the second precursor solution on the substrate.
148. The method of claim 146, wherein the dispensing mixes the first precursor solution and the second precursor solution prior to applying the first precursor solution and the second precursor solution to the substrate.
149. The method of any one of claims 146 to 148, wherein the amount of the first precursor solution and the amount of the second precursor solution are dispensed so as to form a gradient ratio of the agent and the polymer in a region on the substrate.
150. The method of any one of claims 146 to 148, wherein the amount of the first precursor solution and the amount of the second precursor solution are dispensed such that an area on the substrate has a predetermined ratio of the agent and the polymer.
151. The method of any one of claims 146 to 150, wherein the amount of the first precursor solution is dispensed from a first sub-nanoliter droplet dispenser, and wherein the amount of the second precursor solution is dispensed from a second sub-nanoliter droplet dispenser.
152. The method of any one of claims 146 to 151, further comprising assessing crystallization of the agent.
153. The method of any one of claims 146 to 152, wherein the first organic carrier and the second organic carrier are the same.
154. The method of any one of claims 146 to 153, wherein the first viscosity enhancing agent and the second viscosity enhancing agent are the same.
155. The method of any one of claims 143 to 154, wherein the substrate is a film.
156. A droplet dispenser for producing a dosage form comprising a nanosuspension of a hydrophobic agent, the dispenser comprising: (a) a dispensing head comprising one or more nozzles; (b) a first cartridge containing a suspension comprising: Aqueous carrier; as well as a plurality of nanoparticles suspended in the aqueous carrier, the plurality of nanoparticles comprising a hydrophobic agent, wherein the viscosity of the suspension is less than 3 cP, wherein the first cartridge is operably coupled to a first dispensing head; and (c) a control system configured to dispense the mixture via the first dispensing head according to a dispensing pattern.
157. The dispenser of claim 156, wherein the first dispensing head comprises from about 100 to about 1000 nozzles.
158. The dispenser of claim 156 or 157, wherein each nozzle has an aperture of about 20 μm to about 120 μm.
159. A dispenser according to any one of claims 156 to 158, wherein the first dispensing head dispenses droplets using a thermal process.
160. A dispenser according to any one of claims 156 to 159, wherein the first dispensing head dispenses droplets using a piezoelectric process.
161. The dispenser of any one of claims 156 to 160, further comprising a second dispensing head operably coupled to a second cartridge, wherein the second cartridge contains a second dose.
162. The dispenser of claim 161, further comprising a third dispensing head operably coupled to a third cartridge, wherein the third cartridge contains a protective coating.
163. The dispenser of claim 162, further comprising a fourth dispensing head operably coupled to a fourth cartridge, wherein the fourth cartridge contains an edible agent.
164. A droplet dispenser for producing a dosage form comprising an amorphous solid dispersion of a hydrophobic agent, the dispenser comprising: (a) a first dispensing head comprising one or more nozzles; (b) a first mixture cartridge containing an ASD forming solution comprising an organic carrier, the agent, a polymer and a viscosity modifier, wherein the agent and the polymer are present in the mixture in a ratio such that crystallization of the agent on the substrate in the dry state is inhibited, wherein the first mixture cartridge is operably coupled to the first dispensing head; and (c) a control system configured to dispense the mixture via the dispensing head according to a dispensing pattern.
165. The dispenser of claim 164, wherein the first dispensing head comprises from about 100 to about 1000 nozzles.
166. The dispenser of claim 161 or 162, wherein each nozzle has an aperture of about 20 μm to about 120 μm.
167. A dispenser according to any one of claims 164 to 166, wherein the first dispensing head dispenses droplets using a thermal process.
168. A dispenser according to any one of claims 164 to 167, wherein the first dispensing head dispenses droplets using a piezoelectric process.
169. The dispenser of any one of claims 164 to 168, further comprising a second dispensing head operably coupled to a second mixture cartridge, wherein the second mixture cartridge contains a second mixture comprising a second dose.
170. The dispenser of claim 169, further comprising a third dispensing head operably coupled to a third mixture cartridge, wherein the third mixture cartridge contains a protective coating mixture.
171. The dispenser of claim 170, further comprising a fourth dispensing head operably coupled to a fourth mixture cartridge, wherein the fourth mixture cartridge contains an edible mixture.
172. A gradient of two components on a substrate, the gradient comprising A first component comprising a hydrophobic agent; a second component comprising a polymer crystallization inhibitor; and A ratio of the first component to the second component, wherein the ratio varies across the gradient.
173. The gradient of claim 172, wherein the first component further comprises an organic carrier.
174. The gradient of claim 172 or 173, wherein the first component further comprises a viscosity enhancer.
175. The gradient of any one of claims 172 to 174, wherein the second component further comprises an organic carrier.
176. The gradient of any one of claims 172 to 175, wherein the second component further comprises a viscosity enhancer.
177. The gradient of any one of claims 172 to 176, wherein the second component is capable of inhibiting crystallization of the hydrophobic agent.
178. The gradient of any one of claims 172 to 177, wherein the first component and the second component each comprise an organic carrier, wherein the organic carriers are the same.
179. The gradient of any one of claims 172 to 178, wherein the first component and the second component each comprise a viscosity enhancer, wherein the viscosity enhancers are the same.
180. The gradient of any one of claims 172 to 179, wherein the ratio becomes sufficiently low at some point on the gradient to prevent crystallization of the hydrophobic agent.
181. The gradient of any one of claims 172 to 180, wherein the first component and the second component are dispensed onto the substrate from a sub-nanoliter droplet dispenser.
182. A gradient according to any one of claims 172 to 181, wherein the first component is dispensed onto the substrate from a first sub-nanoliter droplet dispenser and the second component is dispensed onto the substrate from a second sub-nanoliter droplet dispenser.
183. The gradient of any one of claims 172 to 182, wherein the ratio changes at a consistent rate across the gradient.
